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Abstract 
This meta-analysis investigated the difference in perceptions of health-related quality of 
life (HRQOL) among long-term early-stage breast cancer survivors (BCS).  The 
comparison was between African American and European American women.  Initial pilot 
searches suggested that enough studies existed for a meaningful meta-analysis of a BCS 
population at least 5 years post diagnosis.  Only studies using the outcome measure 
HRQOL were included in the study; this yielded an initial sample of 212 study reports, 
with 56 reports entering the coding phase of the process.  African American women were 
grossly underrepresented in this set of studies in comparison to the overall breast cancer 
population. Separate analyses of Medical Outcomes Study 36- Item Short- Form Health 
Survey, Quality of Life-Cancer Survivor and Quality of Life Index – Cancer Version III 
instruments were executed. However, no stringent comparison across instruments of the 
difference between the HRQOL of African American and European American women 
was possible. When African American women were included in the populations, 
researchers often did not report their data separately but rather included their data in an 
overall population and thus differences were masked.  The data that were available, 
including qualitative studies for African American women, suggested that there was a 
lower perception of the quality of survival in some areas for African American women. 
These differences suggest the need for greater attention to the physical components of 
African American BCS.  The results point to a need to improve African American 
participant recruitment in research and to use online databases as a results repository to 
improve data availability for analysis.  
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Chapter 1: Introduction to the Study 
Background of the Study 
Most women diagnosed today with early-stage breast cancer will survive for more 
than 5 years (American Cancer Society, 2011).  As of 2012, the 5-year relative survival 
rate amongst women diagnosed with localized breast cancer was 98.4%, with a difference 
between African American (92.7%) and European American women (99.2%) in long-
term survival (Howlander et al., 2012). The approximately 2.8 million women living with 
breast cancer in 2012 were primarily early-stage survivors from all races (American 
Cancer Society, 2010).  More than 50% of women diagnosed will be diagnosed with 
Stage I or II  breast cancer, with that number rising to over 80% if a Stage 0 (in situ) 
diagnosis is included (Ries, Eisner, & Kosary, 2001). 
The American Cancer Society (2010) estimated that around 230,000 women in 
the United States would be diagnosed with breast cancer in 2011, of whom almost 12% 
(estimate 26,840) would be African American women (Susan G. Komen Circle of 
Promise, 2009).  Extrapolating from the data presented above, a little over quarter of a 
million BCS were African American, and about 1.8 million were European American, 
with the remaining 8% of survivors made up from Asian, Native American and Hispanic 
identified women (Howlander et al., 2012).  There has been evidence of disparity in 
treatment of breast cancer (Bradley, Given, & Roberts, 2001; Dignam, 2000; Li & 
Malone, 2003). While socioeconomic status SES can account for some of these 
differences (American Cancer Society, 2011), evidence has emerged that even in 
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localized breast cancer there may be impact differences (Vin-Raviv et al., 2013) between 
African American and European American women. 
English-speaking women of European descent, in the United States or the United 
Kingdom, have constituted the majority of the population studied in post-diagnosis and 
treatment research. Women identified as African American have been less studied (Hulka 
& Moorman, 2001; Thompson et al., 2008).  The percentage of African American 
participants was lower in the 22 studies in the final stage of this analysis (8.12%) than in 
the BCS population in general.  Nine of the final papers did not report racial breakup of 
participants, and there was little reporting of data for African American and European 
American populations separately.  African American women have often been 
underrepresented in clinical trials (Cross, Harris, & Recht, 2002).  African American 
women have also been underrepresented in published psychosocial research, as have 
other women belonging to minority groups and who do not speak English (Thompson et 
al., 2008). 
Focus on Long-term Survival 
The treatments applied to cancer, even its early-stages, are powerful and 
potentially toxic (Lipscomb, Gotay, & Snyder, 2004a).  There is a growing awareness 
that impacts from treatment can develop months and even years after primary treatment 
has ended (Aziz, 2007; Hewitt, Greenfield, & Stovall, 2005).  These impacts can include 
physical symptoms such as pain (Ashing-Giwa, 1999a; Carver, Smith, Petronis, & 
Antoni, 2006), cardiotoxicity (Darby et al., 2013), distress suffered in response to the 
functional impact, and social and financial consequences related to treatment and survival 
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(Aziz, 2007; Hewitt, Herdman, & Holland, 2004; Thewes, Butow, Girgis, & Pendlebury, 
2004).  The cost of treatment and the cost of recovery increase if additional services are 
required to cope with the impact.  The focus of this study on long-term survival was a 
response to this growing awareness of consequences that occur long after treatment has 
ceased, as well as the increasing population of women who survive early-stage breast 
cancer. 
Racial Category and Survival 
European American women are more likely to receive a breast cancer diagnosis.  
African American women have a higher chance of dying from the disease than European 
American women (Hewitt et al., 2004, p. 19), with an average 5-year survival rate of 78% 
versus 90%.  Later stage detection and more aggressive tumor characteristics lead to 
poorer stage-specific survival (American Cancer Society, 2010, 2011; Hewitt et al., 
2004).  Comorbid illness and social and demographic characteristics also contribute to 
survival differences (Hewitt et al., 2004, p. 19).  For example, African American women 
have a higher chance of being diagnosed younger and at a later stage of cancer, with 55% 
diagnosed above Stage I compared to 45% of European American women (Cross et al., 
2002).  Cross et al. (2002) argued that African American women are more likely to be 
impacted by “lower educational level and income, cultural beliefs, lower insurance status, 
diet, and screening practices” (p. 1990), all of which have a potential impact on when a 
woman presents for diagnosis.  They also argued from their review of the literature that 
there may be treatment differences in the treatment given to African American women 
and that this may be due to differences in SES.  Racial identification may be used a proxy 
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for SES (Cross et al., 2002; Krieger, Williams, & Moss, 1997).  While a significant 
number of the studies reviewed by Cross et al. (2002) identified characteristics of SES as 
having predictive value of survival of the population under study, in clinical trials where 
the treatment of patients was homogeneous for women of the same disease stage, African 
American women had a worse prognosis with estrogen receptor negative cancers (Cross 
et al., 2002).  Women of other races in the United States have had a lower incidence and 
lower mortality rate than either European American or African American women 
(Howlander et al., 2012). 
This study set out to understand, from current research, if there was a perceptible 
difference in the experienced long-term survival (greater than 5 years; American Cancer 
Society, 2011) between African American women and European American women who 
survive early-stage (localized) breast cancer.  The primary comparison in this review was 
between Americans of African racial heritage, also referred to in some studies as Black 
and in this study as African American, and Americans of European heritage, or White, 
also named Caucasian or, as in this study, referred to as European American. 
A brief review of the literature on breast cancer survival follows in the next 
section.  The nature of the study, the problems under investigation, and the hypotheses 
tested follow that section in appropriately headed sections.  Both meta-analysis and 
outcomes assessment, particularly HRQOL, are discussed briefly as the theoretical base.  
The chapter concludes with the limitations, assumptions, and considerations of the study 
including the possible implications for use of the information.  
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Research Findings 
Breast cancer and its treatment have been the focus of the largest body of 
knowledge about adult cancer survivors (Aziz, 2007). Much of that research focused on 
the physical and medical aspects of surviving.  A growing focus in both medical and 
psychological research is in outcomes research, which is directed at understanding the 
results of health care practices on “final end points that matter to decision makers: 
patients, providers, private payers, government agencies and society at large” (U.S. 
National Cancer Institute, as cited in Lipscomb et al., 2004a, p.1).  Health-related quality 
of life (HRQOL) is one of these end points and was the focus of this review.  Several 
interrelated domains were of interest, with different instruments having a focus on 
different areas of survival (Ashing-Giwa, 2005b; Ferrans, 2004).  Aside from the physical 
arena, investigators usually considered mental, social, spiritual, and sometimes economic 
areas (Ferrans, 2004) with the patients’ self-assessment being the only measure (Zebrack, 
2004). 
There is a growing understanding that the quality of life can also impact physical 
survival (Montazeri, 2008).  Two reports from the Institute of Medicine of the National 
Academies consolidated much information on cancer survival in general (Hewitt et al., 
2005) and detailed issues relating to psychosocial aspects of survival in breast cancer 
(Hewitt et al., 2004).  The Susan G. Komen for the Cure (n.d.) research spending (on 
cancer control, survivorship, and outcomes) was 7% of their total research budget in 2008 
and 2009, up from 1% in the years prior to 1996.  Of the 777 research initiatives that a 
search of breast cancer on the National Institute of Health site returned (as at December 
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15, 2012), 21 were, based on their descriptions, related to survivors (National Institutes of 
Health, n.d.).   
Breast cancer research can be roughly categorized into research focused on the 
period from diagnosis to the end of treatment, research focused on the first 5 years of 
survival, and long-term survival past the 5-year transition point (Thewes et al., 2004).  
Thompson et al. (2008) pointed out that early-stage and end-stage components of the 
cancer trajectory have been well researched.  They identified that the impact of cancer as 
a chronic disease requires more research and attention, including the day-to-day issues of 
living with the symptoms as well as chronic comorbidities that may be treatment effects 
or existing conditions such as diabetes, arthritis, and weight gain (Thompson et al., 2008).  
The majority of the population who has participated in breast cancer clinical trials 
and psychosocial research has been from the United States or to a lesser extent the United 
Kingdom, of European descent, English speaking, and of moderate to high SES (Hulka & 
Moorman, 2001; Thompson et al., 2008).  Some research has been conducted with 
women who were not European and who did not speak English, focused especially at 
long-term survival and quality of life (Ashing-Giwa, Tejero, Kim, Padilla, & Hellemann, 
2007; Ashing-Giwa et al., 2010, 2004; Ashing-Giwa, Padilla, Bohórquez, Tejero, & M. 
Garcia, 2006; Chan et al., 2006; López, Eng, Randall-David, & Robinson, 2005; Lu et al., 
2009; Neyt & Albrecht, 2006).  There remains a lack understanding of how women in 
minority subgroups experience long-term survival and how it differs from their more 
studied counterparts.   
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Gaps identified in the research by narrative review include a lack of research 
about how cancer and cancer treatment burdens survivors long term (Boyle, 2007) and 
research into underserved populations that may include the elderly, those in lower 
education and income segments, in remote geographic locations, an in minority 
populations. (Aziz, 2007) 
Age and survival. Breast cancer risk increases with age.  Between 2002 and 2006 
95% of new cases of breast cancer and 97% of deaths occurred in women over 40, with 
the highest incidence rate recorded for the age group 75 to 79 (Centers for Disease 
Control and Prevention [CDC], 2010).  The median age of diagnosis was 61 years (CDC, 
2010). Older women have been underrepresented in studies (Thompson et al., 2008).  
Underrepresentation means that how older women survived breast cancer was less visible 
in the work that was available.  Authors of the studies in the current meta-analysis did not 
identify data separately for different age groups within racial designations. 
SES and survival. Researchers have pointed to a robust correlation between 
health and SES (Daly, Duncan, McDonough, & Williams, 2002; Krieger et al., 1997; 
Liberatos, Link, & Kelsey, 1988; Oakes & Rossi, 2003).  SES has also been shown to 
have correlations with the occurrence and mortality associated with breast cancer 
(Braveman et al., 2005; Kreiger, 1990) and with breast cancer survival (Krieger, 1992).  
Cross et al. (2002) found that when controlling for tumor characteristics and age, SES 
was often a better predictor of outcome than race.  Where single institutions were 
involved, with the likelihood of consistent treatment increased, race usually ceased to be 
a predictor of survival (Cross et al., 2002).  Where studies were of a heterogeneous 
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population, or where SES was inferred from living locale or other surrogates for SES 
rather than self-report, race tended to become a predictive factor (Cross et al., 2002).  
Regardless of race, women with lower SES tended to present with worse tumor 
pathologic factors, more advanced disease, and lower survival likelihood in clinical trials 
(Cross et al., 2002) and SES consistently emerged as a risk factor for breast cancer 
(Hulka & Moorman, 2001). 
Depending on the instruments used, one domain of interest in HRQOL has been 
social/socioeconomic influence (Ashing-Giwa, 2005b).  The studies in the meta-analysis 
did not report socioeconomic data. 
Problem Statement 
The population of BCS of more than 5 years since the primary treatment ceased 
has been growing (Hewitt et al., 2005; Howlander et al., 2012), along with evidence of 
late occurring medical and psychosocial impacts from both the disease and treatment 
(Hewitt et al., 2005).  Consolidating research on how women survive long-term had the 
potential to give clearer direction to future research and action to support those women. 
African American women who survive early-stage breast cancer make up about 
12% of the population of early BCS, and European American survivors make up around 
80% of the survivor population (American Cancer Society, 2010; Susan G. Komen Circle 
of Promise 2009).  There has been evidence of treatment and impact differences 
(American Cancer Society, 2011; Bradley et al., 2001; Hewitt et al., 2005; Li & Malone, 
2003; Vin-Raviv et al., 2013), some of which may be accounted for by socioeconomic 
factors (American Cancer Society, 2011).  
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There is a body of research into long-term survival from localized breast cancer 
conducted using the outcomes assessment measure HRQOL (Lipscomb et al., 2004a).  
Use of the techniques of systematic review and meta-analysis allowed a comparison of 
the different research (Cooper, Hedges, & Valentine, 2009; Lipsey & Wilson, 2001).  The 
HRQOL of long-term BCS had the potential to indicate differences that could inform 
ongoing decision making (Chalmers, 2007) about the development and provision of 
support for women of different racial backgrounds. 
The dependent variable, HRQOL, is a composite measure that is used in an 
attempt to encompass the multiple dimensions into a manageable variable that can be 
used to show how survival from a disease can be characterized and described.  While 
different instruments have been used, overall it provides a workable construct with which 
to frame the differences (Lipscomb et al., 2004a).  A more detailed understanding of the 
impact of breast cancer can be achieved by examining HRQOL within its composite 
domains (Avis, Ip, & Foley, 2006; Cella et al., 1993; Ferrans, 2004; Osoba, Aaronson, 
Zee, Sprangers, & te Velde, 1997; Ringdal & Ringdal, 1993; Schag, Ganz, & Heinrich, 
1991).  
The independent variable, race, includes the categorization of European American 
(White), African American (Black), Asian American/Pacific Islander, Hispanic/Latino, 
and American Indian/Alaskan Native, as used in the American Cancer Society (2010, p. 
4) report on cancer survival.  Researchers variously referred to European American, 
Caucasian, or White study populations, or to African American or Black study 
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populations. In this study, only the designations African American and European 
American were of interest. 
While disease stage has a significant impact on survival from breast cancer, I 
bounded the population under study to those with local or early regional disease at 
diagnosis (Stage 0, I or II).  Primary studies that included participants who had recurrent 
cancer or later stage cancers were excluded. 
Purpose of the Study 
The purpose of the study was to identify from the body of research if there were 
significant differences correlated with racial categorization in the experience of long-term 
BCS and to compare the effects specifically between African American and European 
American populations.  Understanding how current researchers have differentiated the 
experience of women in the population of interest had the potential to lead to a better 
understanding of the support and help these women need, or if the research was 
inadequate to be able to make that determination.  Understanding the adequacy of 
research had the potential to lead to further research in targeted areas, with more targeted 
populations, or the ability to focus funding where it is most required. 
Nature of the Study 
The study undertaken was a meta-analysis of the research using HRQOL as the 
outcome measure (dependent variable) of long-term survival from early-stage breast 
cancer. The focus of the study was to understand the evidence for differences in 
experience between women of African American and European American racial 
designation (independent variable).   
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It was planned to examine the instruments used to measure HRQOL in the subject 
studies as a moderator on the effect size (Borenstein, Hedges, Higgins, & Rothstein, 
2009).  If data were available from the selected studies, I had planned to analyze age, 
SES, and study characteristics. 
Research Questions and Hypotheses 
The research questions associated with this problem statement are as follows: 
1. Compare the effects of survival for more than 5 years post treatment on 
HRQOL of African American Breast cancer patients diagnosed with Stages 0-
II with those of patients of European American racial identification? 
2. Is enough data available in the population of studies to observe the impact of 
age on the effect size? 
3. Is there enough data on SES in the population of studies to identify its impact 
as a moderating variable?   
4. Can the choice of HRQOL instruments be identified as having an impact on 
the effect size seen in the research? 
5. Can subgroup analysis identify differences in components of HRQOL? 
6. The null hypothesis for the study is that the mean effect size is zero (random 
effects model; Borenstein, Hedges, Higgins, & Rothstein, 2010). 
The Standardized Mean Difference (SMD) of HRQOL is the effect size being 
measured in this meta-analysis. 
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Theoretical Base  
Meta-analysis 
Meta-analysis is “the statistical analysis of a large collection of analysis results for 
the purpose of integrating the findings” (Glass, as cited in DeCoster, 2004, p. 2).  Lipsey 
and Wilson (2001) explained that this form of analysis is another approach to survey 
research except that it is the research reports that are surveyed rather than people.   
Meta-analysis has some significant advantages when trying to synthesize and 
consolidate data across a significant body of work.  As a structured technique, it requires 
the documentation of the process used so that in theory another researcher could take the 
same body of work and reach the same conclusions (Lipsey & Wilson, 2001; Randolph, 
2009).  The use of effect sizes means that a more nuanced synthesis is possible with the 
ability to test findings that differ across research reports (Lipsey & Wilson, 2001).  Using 
a meta-analysis approach may allow relationships across studies that would not appear in 
a narrative approach, and by using the systematic coding and management approach of 
meta-analysis it is possible to consider a large number of studies (Lipsey & Wilson, 
2001). 
Outcomes Assessment 
According to Lipscomb et al. (2004a), “Outcomes research may be defined 
generally as the scientific field devoted to measuring and interpreting the impact of 
medical conditions and health care on individuals and populations” ( p. 1).  This 
relatively young field (Ferrans, 2004; Lipscomb et al., 2004a) continues to evolve, but 
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HRQOL has become a key way that the impacts of chronic disease can be monitored over 
time with some sensitivity to the experience of the individual (Lipscomb et al., 2004a). 
There are many instruments that may be used to measure different components of 
HRQOL (Erickson, 2004; Feeny, 2004; Ferrans, 2004; Zebrack, 2004).  Depending on 
the research question, the researcher may choose instruments that best suit the purpose 
(Ferrans, 2004). General instruments designed to measure people who are not ill or who 
are ill without specific reference to a particular condition (Erickson, 2004), or instruments 
specific to the type of illness or to the site of illness (for example, breast cancer; Ferrans, 
2004), or a specific instrument for measuring an outcome (for example, a standardized 
instrument for measuring depression; Zebrack, 2004) are available. 
Within the overall concept of HRQOL, there may be a focus on one or more 
domains of interest (Ashing-Giwa, 2005b; Ferrans, 2004).  The physical, mental, and 
social are those usually considered the minimum number of domains included (Ferrans, 
2004).  In some studies authors chose domains like the spiritual, socioeconomic and 
cultural components to more clearly identify the differences in minority perceptions of 
illness (Ashing-Giwa, 2005b). 
Definition of Terms  
Health-related quality of life (HRQOL): HRQOL is a patient-reported, subjective 
assessment or evaluation (Lipscomb et al., 2004a) of the experience and impact of illness 
on a person (Ashing-Giwa, 2005b) that may or may not have an overall global well-being 
assessment (Lipscomb et al., 2004a, p. 7).  The domains that were of interest in this study 
were physical, psychological/emotional, economic, spiritual, and social (Ferrans, 2004, p. 
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15; Ferrans, Zerwic, Wilbur, & Larson, 2005).  These domains can often be aggregated to 
provide an overall score if one is not part of the measure (Powe et al., 2007).  HRQOL 
may change over time (Cella, 1994).  
Long-term cancer survival: “Individuals who are5 or more years beyond the 
diagnosis of their primary disease and embody the concept of permanent survival” (Aziz, 
2007, p. 418).  
Late effects: There is recognition that long-term survivors of cancer, including 
breast cancer, may have impacts and impairments from treatment, including drugs, which 
do not appear until long after treatment is complete (Aziz, 2007). 
Long-term effects: Side effects or complication of treatment that have an impact 
on a patient’s life, either in the ability to function or in additional medical treatments for 
which some adjustment is required from the patient.  These may appear months or years 
after treatment and may persist for many years (Aziz, 2007, p. 418).   
Assumptions 
Data provided from the sources were accurate.  All processes for acquiring data 
were identified.  Sources and approaches were visible, as is required by the process of 
meta-analysis.  Accuracy of the data, statistics, and information provided in the studies 
could not be proven true and accurate, especially if data from nonpublished sources could 
be included in the study. 
Limitations 
The approach was based only on quantitative research so that studies of a 
qualitative nature could not be included (DeCoster, 2004; Lipsey & Wilson, 2001).  By 
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definition, systematic review and meta-analysis require an exhaustive search of the 
literature.  Unpublished sources may contain findings where the significance of the 
results was low and there was little support for publication.  Despite best efforts to 
include all relevant sources, it was reasonable to expect that some material that would 
change or influence the results may not be included.  Publication bias, the more likely 
publication of significant results, influenced the published data.  Searches that included 
grey literature and other non-journal resources were my attempt to overcome this. The 
process of the search appears in Chapter 3. 
The operational definition used for the outcome measure of this study was the 
effect measured by HRQOL instruments.  HRQOL measures vary, appropriately 
depending on the stage of the cancer trajectory that is being studied.  While I assumed 
that researchers would have used appropriate measures, an analysis of the differences in 
effect sizes with different instruments was planned.    
There was no attempt to review the literature focused on the validation or 
proposal of interventions, treatment options, or approaches to preventative strategies. 
Research into long-term breast cancer survivorship has primarily been focused in 
the United States.  Because of the focus on racial background in this current study, 
studies of subjects not from the United States were excluded from this work. This work is 
by its nature only generalizable within the population of BCS in the United States and 
within the defined groups of African American and European American. 
Two issues that have emerged in research into long-term and late effects of cancer 
treatment that I did not directly address in this analysis were the as follows. The first was 
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an understanding of how the BCS population differs from a matched cohort of women 
who have not had breast cancer, although where possible data were compared to 
population norms for the instrument.  The second was how the evolution of treatment 
modality has been changing the survival pattern of breast cancer (Stein, Syrjala, & 
Andrykowski, 2008).   
The second of these questions had an impact on the data that was included, as 
women in the target of the analysis may have been through many variants of standard 
treatment.  Over the last 50 years, treatment choices have changed dramatically from full 
mastectomy to lumpectomy and chemotherapy and radiation, to lumpectomy and 
radiation and longer term follow-up therapy (Reynolds, 2012).  It was likely that as 
treatment has become less toxic, so the long-term effects may be less.  Studies used as the 
basis for this analysis rarely contained the data needed to separate out and control for the 
effects of this variable.  
Delimitations 
The review focused on the research conducted and the findings that have been 
published, using HRQOL instruments as the outcome measure in long-term breast cancer 
survival.  I examined the research that has been conducted into the experience of women 
surviving breast cancer.  I specifically excluded medical components, treatment 
regimens, physical impacts, and comorbid disease, as variables in the analysis.  These can 
all contribute to the quality of life of survivors.    
The focus was on long-term survival without recurrence, so recurrent breast 
cancer and the associated trauma was excluded from the discussion.  Additionally, the 
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review focused on the population with a diagnosis of local or early regionalized stage of 
the disease as the survival rates and the possibility of living disease-free was more likely 
in that population(American Cancer Society, 2011; Hewitt et al., 2004; Howlander et al., 
2012). 
To be included in this review, a study had to focus on participants who had been 
out of active treatment for more than 3 years, or 5 years post diagnosis.  This long-term 
timeframe was specifically chosen because of the large number of women surviving 
through this period. 
There was no attempt in this study to draw causal relationships between variables 
within HRQOL and breast cancer history, experience, or demographics.   
Significance of the Study 
Interventions targeted at reducing psychosocial distress have been valuable for 
patients identified as distressed but of less value if the clients are drawn from the survivor 
population without targeting (Sheard & Maguire, 1999).  A more granular understanding 
of the differences between African American and European American BCS may allow 
for better targeting of those who need support.  
There has been significant research and integration of that research into how race, 
age, and SES impact the incidence, survival rates, and mortality associated with breast 
cancer (American Cancer Society, 2011).  While there have been several literature-based 
reviews (Bigby & Holmes, 2005; Chopra & Kamal, 2012; Gotay & Muraoka, 1998; 
Howard, Balneaves, & Bottorff, 2007; Meyerowitz, Kurita, & D’Orazio, 2008; 
Montazeri, 2008; Phillips & Bernhard, 2003; Powe et al., 2007), no meta-analysis was 
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identified in the search; while conclusions have been drawn, the size and direction (Ellis, 
2010) of the effect was at best subjective (I. Wilson, 2004). 
Identifying and integrating the research that has been conducted and 
understanding where significant differences occurred would have supported a better 
understanding of services that may be required to support this population.  It had the 
potential to differentiate different approaches to managing the impact of breast cancer in 
the long-term survivor.  The outcome of this analysis was planned to provide information 
that would allow a more tailored approach to these women by synthesizing research 
outcomes over the body of knowledge and identifying information about how these 
groups differ from current understanding.   
An improved understanding of differences in the survival experience would have 
supported more effective planning of appropriate interventions and post-treatment care 
both in content and length.  The detail of the difference was planned to provide support 
for change in lifestyle or care recommendations for long-term survivors.  These changes 
could have had the potential to impact the quality and length of survival (Aziz, 2007) and 
support positive change in managing the psychosocial aspects of breast cancer survival 
and for the women who survive. 
Summary 
The difference in the experience of breast cancer survival in women of different 
racial background has the potential to inform more effective deployment of limited 
resources.  The incorporation of research from across the survival spectrum using a meta-
analytic approach potentially would have included even small studies in scholars’ overall 
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understanding.  Meta-analysis requires exhaustive documentation and visibility of 
process so that issues, problems, and gaps are visible in the data. 
In the next chapter I discuss the literature currently available on long-term 
survival from breast cancer.  The literature on the use of HRQOL and outcomes analysis 
as well as the current state of knowledge on the use of systematic review and meta-
analysis are provided. 
20 
 
 
Chapter 2: Literature Review 
Introduction 
This review of the literature begins with an overview of BCS.  A discussion of the 
use of HRQOL as an outcome measure for survival begins a section that looks at the 
body of knowledge about breast cancer survival as informed by the domains of HRQOL.  
I discuss how researchers on long-term HRQOL have distinguished between African 
American BCS and European American BCS as well as the findings related to the 
interaction with age and SES; I also explored the distinctions made in the literature.  The 
final section of this chapter addresses the literature relating to systematic review, 
including meta-analysis that informed the methodology of this study and the issues and 
considerations associated with this approach.  
Methodology 
Literature searches were conducted using the Walden University online databases, 
using search arguments associated with breast cancer survival, including terms that relate 
to breast carcinoma and long-term survival.  The research databases of the National 
Institutes of Health were also searched, and I built a database of articles and references.  
The number of studies was reduced by limiting the focus to longer term survival and to 
Stages 0 through II of breast cancer diagnosis.  Two key reviews of breast cancer survival 
(Hewitt et al., 2005, 2004) provided a starting point for an overall view of the research 
focus and the development of a list of key researchers in the area of interest.  More 
detailed research on racial categorization and the interaction with SES and health-related 
outcomes was initiated through an Internet search.  
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HRQOL is a complex theoretical variable that researchers have often used as a 
measure of the quality of survival (Lipscomb et al., 2004a).  An Internet search was 
instituted to retrieve literature that related to the development of the concept and its 
application in survival research.  In all cases, initial retrieval of published literature was 
followed by the development of an understanding of the key researchers in the area and 
the retrieval of additional literature referenced in key articles.  When retrieving literature, 
I did not try to be exhaustive, but rather representative and informative of the state of the 
body of knowledge.  In 2004, the publication of the work of Cancer Outcomes 
Measurement Working Group commissioned in 2001 by U.S. National Cancer Institute 
provided a critical synthesis of outcomes assessment, particularly using HRQOL 
(Lipscomb et al., 2004a).  It included material from authors in the field identified from 
the literature search above and added depth to the understanding of the use of the 
construct and instruments both in overall cancer survivorship research and with the breast 
cancer population. 
The search for methodological literature on systematic reviews and meta-analysis 
started from key texts on the subject (Borenstein et al., 2009; Cooper, 2009; Cooper et al., 
2009; DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 2001; Rosenthal & DiMatteo, 2001; 
Rosenthal, 1995).  It progressed using the bibliographies and further database searches, 
and I developed the bibliography used in both the literature review and to support the 
development of the methodology in Chapter 3. 
In all subject areas, a snowball technique was used to broaden the search from 
references provided in seminal articles and publications. 
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Breast Cancer Perspective 
Each year around the world about 1.1 million women are diagnosed with breast 
cancer, accounting for more than 400,000 deaths (Montazeri, 2008).  In the United States 
in 2012 approximately 2.8 million women were living with a past diagnosis of breast 
cancer (American Cancer Society, 2011), almost a quarter of a million were African 
American (around 12%; Susan G. Komen, 2009).  BCS are “the largest group of female 
cancer survivors” (Casso, Buist, & Taplin, 2004, Background section, para 2) 
The incidence rate of breast cancer in non-Hispanic European American women 
has been higher than for African American women for all age groups except those 
younger than 40 years of age at time of diagnosis.  African American women are more 
likely to die from breast cancer regardless of age (American Cancer Society, 2011, p. 4).  
Between 1980 and 1987 the rate of occurrence of breast cancer increased, and researchers 
thought that this was due to improved screening methods that allowed smaller tumors to 
be identified.  The rate stabilized between 1987 and 1994 and then rose again to a peak in 
1999.  Between 2002 and 2003 the rate dropped by nearly 7%, likely due to a decrease in 
the use of hormone replacement (American Cancer Society, 2011).  Among African 
American, women the rate rose until 1992 and has been stable since then (American 
Cancer Society, 2011). 
The “American Cancer Society (ACS) defines cancer survivorship as beginning at 
diagnosis with cancer and continuing for the balance of life and views quality of life 
(QOL) as a key outcome” (Smith et al., 2007, p. 1).  The National Coalition of Cancer 
Survivorship has used the same definition (National Cancer Institute, 2012).  Long-term 
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survivors are patients who do not die in the 5 years after diagnosis (American Cancer 
Society, 2011).  Better capability for detection and improved treatment of breast cancer 
means that the majority of the women diagnosed will become long-term survivors (Aziz, 
2002; Ganz et al., 2002; Paskett et al., 2008).  HRQOL has become an important area of 
research in this population (Ashing-Giwa, Padilla, Tejero, & Kim, 2004).  The largest 
body of knowledge for adult cancers comes from BCS (Aziz, 2007), with much of that 
research focused on the physical and medical aspects of surviving (Ganz et al., 2002). 
Cancer is considered a chronic disease (National Center for Chronic Disease 
Prevention and Health Promotion, 2012).  As a patient continues through the trajectory, 
the stresses of treatment are often replaced with physical sequelae of treatment that may 
include ongoing side effects (Darby et al., 2013) that can have a negative impact on 
survivors’ quality of life (Chopra & Kamal, 2012; Montazeri, 2008).  Survivors may have 
to deal with the uncertainty of cancer recurrence (Deimling et al., 2006) and perhaps 
psychological distress and the disruption of social life, sometimes decades after treatment 
(Henderson, 1997).  Around 10.2% of BCS will deal with physical issues, and about 
5.9% of BCS will deal with continuing mental issues, similar to women who have not 
had breast cancer (Weaver et al., 2012).  These sequelae may become “more problematic 
with increasing age” (Chopra & Kamal, 2012, p. 13).  Most long-term survivors are more 
60 years old because the rate of incidence increases in middle age (Mishel et al., 2005). 
HRQOL 
The dependent variable in this relationship is the experience of survival as 
measured by instruments focused on HRQOL.  HRQOL is a composite concept used to 
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encompass the multiple dimensions of survival (Ferrans, 2004).  HRQOL attempts to 
distinguish those components of experience of illness that are within the impact zone of 
the health system from those that are not (Ferrans, 2004).  However, as Ferrans (2004) 
pointed out, when a woman is ill many aspects of her life, such as race, education, and 
SES, that are of interest in this study and that would otherwise not be part of the overall 
health assessment, may be influential in the outcome.  A defining aspect of an HRQOL 
assessment is that the status is patient reported and is a subjective assessment or 
evaluation (Lipscomb et al., 2004a) 
HRQOL measures are designed for specific populations and illness trajectory 
points as well as specific research requirements (Ferrans, 2004).  There are generic 
measures that are not specific to cancer and may be applied across the health spectrum 
(Lipscomb et al., 2004a), for example, the Medical Outcomes Study 36- Item Short- 
Form Health Survey (MOS SF-36; Ware, Snow, Kosinski, & Gandek, 1993).  General 
cancer measures, for example, the Functional Assessment of Cancer Therapy - General 
(FACT-G, Cella et al., 1993) or the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC QLQ C30, Aaronson et al., 1993) can 
be used regardless of cancer site (Lipscomb et al., 2004a).  Measures that are specific to a 
cancer site like the FACT- B (Breast, Brady et al., 1997) are more used to identify patient 
concerns for that site, in this case Breast Cancer (Lipscomb et al., 2004a).  Additionally 
some researchers choose standard instruments, for example, the Beck Depression 
Inventory (BDI, Beck, Steer, & Carbin, 1988) for outcomes assessment (Montazeri, 
2008; Perry, Kowalski, & Chang, 2007). 
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Outcomes Assessment Using HRQOL 
Much research into the impacts of breast cancer relies on the theoretical backdrop 
of HRQOL (Ganz, 2008).  The concept of HRQOL encompasses “complete social and 
psychological being: the individual’s performance of social roles, her mental acuity, her 
emotional state, her sense of well-being and her relationships with others” (Levine, 1987, 
p. 4).  This concept goes beyond measurable and objective health outcomes and includes 
a person’s expectations, attributions and perceptions. The measure is influenced by life 
experience, gender, and age so that the same health profile may result in very different 
HRQOL perspectives (Bloom, Petersen, & Kang, 2007).  HRQOL attempts to measure 
the experience of the individual and is, by definition, patient reported (Lipscomb et al., 
2004a).    
HRQOL is usually constructed of physical, mental and social domains and may 
be expanded to include the economic and spiritual (Ferrans, 2004).  The physical 
dimension is focused on the control or relief of symptoms, keeping function, and 
independence (Ashing-Giwa, Padilla, Tejero, & Kim, 2004; Ferrans, 2004; Powe et al., 
2007).  The psychological includes trying to deal with a life-threatening illness and 
includes emotional distress, the presence or absence of depression (Deshields, Tibbs, 
Ming-Yu Fan, & Taylor, 2006), anxiety (Powe et al., 2007), or symptoms of Post-
Traumatic Stress Disorder (PTSD) (Kornblith et al., 2003; Shelby, Golden-Kreutz, & 
Andersen, 2008; Skrzypulec, Tobor, Drosdzol, & Nowosielski, 2009).  This dimension 
may also include changes in priority, fear (Carver et al., 2006; Dow, Ferrell, Haberman, 
& Eaton, 1999; Mishel et al., 2005; Polinsky, 1994) and positive life changes (Ganz et 
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al., 2002).  Social well-being is related to dealing with relationships, family (Dow et al., 
1999; Howard et al., 2007), support (Ashing-Giwa, Tejero, Kim, Padilla, & Hellemann, 
2007; Wyatt & Friedman, 1996), and the impact of cancer in how a person relates to 
society (Carver et al., 2006).  The spiritual dimension involves hope (Dow et al., 1999), 
meaning (Ashing-Giwa & Lim, 2011), religion, belief, and spiritual practices (Ashing-
Giwa, Padilla, Tejero, & Kim, 2004; Ganz et al., 2002; Leak, Hu, & King, 2008; Wyatt & 
Friedman, 1996).  These are not independent constructs, changes in one area impact one 
or more of the other areas so that the construct of HRQOL is a complex balance across 
different aspects of life (Bloom et al., 2007; Ferrell, Grant, Funk, Otis-Green, & Garcia, 
1997). 
Ashing-Giwa (2005b) expanded the model of HRQOL previously developed 
(Ferrans et al., 2005; Wilson & Cleary, 1995) to include context with cultural and socio-
ecological variables.  Not all researchers use the same naming conventions, for example 
Zebrack (2000) proposes seven categories of quality of life: “(a) physical concerns 
(symptoms, pain), (b) functional ability (activity), (C) family well-being, (d) emotional 
well-being, (e) treatment satisfaction (including financial concerns), (f) 
sexuality/satisfaction (including body image), and (g) social functioning” (Zebrack, 2000, 
p. 1397).  In this study the Ashing-Giwa (2005b) nomenclature that includes physical, 
mental, social, and spiritual dimensions is the theoretical map used.  Not all instruments 
use all dimensions and the functioning, cultural, sexual, socioecological dimensions are 
not often included in instruments (Ashing-Giwa, 2005b, p. 299).  In the initial literature 
review findings fell primarily into the physical, psychological, spiritual and social 
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domains, with socioeconomic and socio-ecologic findings primarily being related to the 
social sphere.  Impacts on function may be reported in the physical, psychological, or 
social contexts, and the socioeconomic and socio-ecologic components like age may be 
reported in the social domain. 
HRQOL instruments are designed to capture from the patient “subjective 
perceptions and assessments of their health” (Wilson, 2004, p. 434).  These are not 
available through objective testing, and patients often perceive different components of 
the overall conceptual framework as being more important (Wilson, 2004).  For example, 
two women with the same stage and type diagnosis, and with the same treatment regime, 
may rate their overall health very differently.  For a woman who still desires to have 
children, the impact on her fertility and body image may be of paramount importance, 
whereas for a woman who is most concerned with her earning potential, how quickly and 
effectively she can return to work will most likely have the largest impact on her overall 
perception of her quality of life.  
Most researchers at least acknowledged that HRQOL is both subjective and 
unique to each person.  The salience of psychosocial variables changes with age, life 
stage and for cancer patient’s time since diagnosis and treatment.  Capturing a person’s 
score on quality of life without capturing the associated salience for that person does not 
give an accurate picture (Bloom et al., 2007; Zebrack, 2000). 
The existential, spiritual and religious aspects of life quality were often not 
included in older studies although these dimensions are seen in more modern studies by 
inclusion of instruments built for that purpose, (Zebrack, Ganz, Bernaards, Petersen, & 
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Abraham, 2006; Zebrack, Yi, Petersen, & Ganz, 2008) or with additions to already 
existing instruments (Ganz et al., 2002). 
Quality of life is a well-documented framework, and many studies have used it as 
a measure of outcome in breast cancer treatment.  Comparing the research on HRQOL is 
often difficult as a number of standard instruments are used and often as many as four or 
five different instruments may be used in a study (Bloom et al., 2007; Gotay & Muraoka, 
1998; Hewitt et al., 2004; Kornblith et al., 2003; Montazeri, 2008; Zebrack, 2000).   
Outcomes measurement and the use of HRQOL is a developing field (Lipscomb 
et al., 2004a), and researchers often vary in how the variable is constructed, measured, or 
reported (Zebrack, 2000).  As would be expected in relatively broad research area, both 
sample size and how instruments are used vary considerably across investigations.  Some 
instruments are based on normal populations that are not health impaired.  In more recent 
studies, instruments normed for specific cancer populations like BCS have been 
developed (Gotay & Muraoka, 1998; Hewitt et al., 2004).  There is however an 
acceptance that HRQOL provides a measure that gives insight into the experience of 
patients, and their consequent needs for treatment, support and recognition (Lipscomb et 
al., 2004a) 
Overall there are many aspects of breast cancer survival that have been well 
researched across the total population, including the target population of this review.  
Long-term impact on a survivor’s quality of life (Ganz et al., 2002; Gotay & Muraoka, 
1998; Zebrack et al., 2008) is now accepted. 
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Conceptual definition. HRQOL is a patient reported, subjective assessment or 
evaluation (Lipscomb et al., 2004a) of the experience and impact of illness on a person 
(Ashing-Giwa, 2005b). It may or may not have an overall global well-being assessment 
(Lipscomb et al., 2004a, p. 7).  The domains that are of interest in this study are physical, 
psychological/emotional, economic, spiritual, and social (Ferrans et al., 2005; Ferrans, 
2004, p. 15).  These domains can often be aggregated to provide an overall score if one is 
not part of the measure (Powe et al., 2007).  HRQOL may change over time (Cella, 
1994). 
Operational definition. Operationally there are many instruments that measure a 
component of the concept, and they are sometimes used in concert in a study (Ashing-
Giwa, Padilla, Tejero, Kraemer, et al., 2004; Bowen et al., 2007; Ganz et al., 2002).  A 
list of the identified instruments used in HRQOL studies of breast cancer is provided in 
Chapter 3. 
Instruments that measure the concept are often developed for a specific 
component or purpose in outcomes assessment of health care (Ferrans, 2004).  
Consequently, researchers may choose different instruments based on their research 
objectives (Ferrans, 2004), which has the consequence of making comparison across 
research studies more complex (Lipscomb et al., 2004a).  The researcher is often trying to 
choose an instrument that will be sensitive enough to the particular concerns of the 
patients and healthcare professionals in a particular combination of site and trajectory 
point (Ferrans, 2004).  For example, the spiritual and family dimension of HRQOL are 
unlikely to be strong differentiating factors of a drug’s efficacy, but are likely to be 
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important in an end of life inquiry (Ferrans, 2004).  The plan in this systematic review 
was to treat the instruments as moderator variables and compare the effect sizes from 
different instruments. 
HRQOL in Breast Cancer Survival 
HRQOL is considered an outcome measure in clinical trials, and breast cancer has 
received significant focus with of the growing number of survivors who are living longer 
disease free due to improvements in treatment and detection (American Cancer Society, 
2011).  A woman’s identity is often impacted by the changes in her body from the 
treatment.  This impact may affect family members and her ability to carry out the role 
she played prior to the cancer (Montazeri, 2008). 
In general long- term BCS report quality of life that ranges from satisfactory 
(Ashing-Giwa et al., 2007; Ashing-Giwa, 1999a) through excellent (Ganz et al., 2002; 
Giedzinska et al., 2004) with high levels of physical and emotional functioning (Casso et 
al., 2004; Polinsky, 1994).  Their overall functioning was reported as similar to disease 
free controls (Dorval, Maunsell, Deschênes, Brisson, & Mâsse, 1998; Vinokur, Threatt, 
Caplan, & Zimmerman, 1989).  Von Ah et al. (2012) found no overall differences in 
well-being between BCS and normal controls, but did identify some areas of difference in 
detailed analysis.  In an earlier review (Russell, Von Ah, Giesler, Storniolo, & Haase, 
2008) both African American and white survivors were found to have favorable HRQOL 
although BCS had a lower sense of overall health than those who had not been diagnosed 
with breast cancer.  
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Race 
There is considerable diversity in the “Black” population of the United States.  
Around 16% of the Black population is reported as foreign-born or of foreign-born 
parentage; those of West Indian heritage account for as much as 10% of the Black 
population (Williams & Jackson, 2000).  These differences in origin are likely to be 
reflected in beliefs, behavior and culture.  Some evidence that “Black” subgroups have 
different health status was reported.  West Indian and Haitian immigrants have lower 
rates of breast cancer than Black women born in the U.S. (Williams & Jackson, 2000).  
The use of race in the United States is more closely aligned with social structure than 
biology (Williams & Jackson, 2000).  Researches including African American BCS did 
not distinguish differences that may have been relevant due to the continuum described 
above. Responses to research even when the respondents were self-identified as African 
American possibly come from a spectrum of cultural influence. 
Minority subgroups are in positions of cultural, political, and socioeconomic 
disadvantage (Stratton, Nepaul, & Hynes, 2007).  The racial categories in use in the 
United States are reflections of “differences in power, status and resources” (Williams, 
1999, p. 177) and as such may underlie discrimination, and the development of 
prejudicial attitudes.  Race and ethnicity are often confused (Betancourt & López, 1993), 
or used as interchangeable concepts (Stratton et al., 2007).  Racial categories are based on 
observable characteristics, for example, skin color or geographic location (Betancourt & 
López, 1993; Stratton et al., 2007).  Ethnicity includes assumed commonality based on 
religious, linguistic, cultural, behavioral or geographic determinants that define a group 
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of people (Stratton et al., 2007).  Hispanic ethnic status is usually recorded separately 
(Winker, 2004).   
A Note on Terminology 
 Throughout the literature review when quoting from other studies or published 
material I have, where it matters, maintained the terminology used by the authors of the 
study.  Thus, African American BCS were referred to by some authors as Black, or 
women of color.  European American women were sometimes referred to as Caucasian, 
or Non-Hispanic White, or White, or varying forms of these.  Otherwise, the terminology 
of this discussion refers to African American women and European American women. 
BCS and Race  
The number of minority women in the population of BCS is increasing.  African 
American women are more often diagnosed with breast cancer than any other cancer 
(Mishel et al., 2005).  They are more likely to have been diagnosed with advanced states 
of breast cancer, and their survival chances are smaller than European American women 
(American Cancer Society, 2011; Li & Malone, 2003; Northouse et al., 1999).  The 
difference in mortality rates persist even adjusting for hormone receptor status and 
staging (Li & Malone, 2003).  African American BCS have also been more likely to have 
more aggressive surgical treatment (mastectomy versus lumpectomy) than European 
American women although at least one study found exactly the opposite (Bradley, Given, 
& Roberts, 2002).  Differences in mortality are not explained by primary treatment (Li & 
Malone, 2003).  The availability of tamoxifen and other subsequent drugs that are used in 
hormone receptor positive breast cancer is thought likely to have had a significant 
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contribution to the reduction in the mortality rate for European American women.  
African American women are less likely to have a receptor positive breast cancer, and by 
2007 the mortality rate was “41% higher in African American women than white 
women” (American Cancer Society, 2011, p. 10).  
The differences seen in incidence and treatment between different ethnic groups 
extend to HRQOL (Giedzinska et al., 2004; Paskett et al., 2008).  There are disparities 
between African American and European American BCS that include their coping 
strategies, how they were treated, and the impact it has on their lives (Ashing-Giwa, 
Padilla, Tejero, Kraemer, et al., 2004).  As well as differences in physical functioning 
(Bowen et al., 2007; Deimling, Schaefer, Kahana, Bowman, & Reardon, 2003; Paskett et 
al., 2008) there may be different predictors of physical and emotional functioning 
(Ashing-Giwa et al., 2007; Bowen et al., 2007; Giedzinska et al., 2004) and differences in 
social functioning (Bourjolly, Kerson, & Nuamah, 1999). 
Studies focusing on the survival experience of minority women have been 
published, with some focused on late effects (Ganz et al., 2002; Mishel et al., 2005; 
Northouse et al., 1999; Paskett et al., 2008; Powe et al., 2007; Russell et al., 2008; Von 
Ah et al., 2012).  However, much research was focused on European American 
(Giedzinska et al., 2004; Von Ah et al., 2012) women. Even when African American 
women were targeted, the research may have limited ability to generalize the findings 
because of the small sample sizes (Paskett et al., 2008), and because the studies don’t 
always include a normal comparison (Von Ah et al., 2012).  Race has been used as a 
proxy for variables that may be more salient contributors to the measures in cancer 
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quality of life research; for example, type and intensity of treatment, socio-economic 
status, cultural variables, and attitudes towards cancer and health in general (Ashing-
Giwa et al., 2007; Giedzinska et al., 2004).  
Ashing-Giwa and Ganz (1997) executed a qualitative study of African American 
women and breast cancer.  The study was in response to their observation that the 
numbers of minority women included in breast cancer survival studies was too small to 
be able to draw conclusions.  The study was conducted in three phases using experts in 
key informant interviews (n=12), small focus groups (n=23) and in-depth interviews of 
(n=8) women selected from a different quality of life study (Ashing-Giwa & Ganz, 1997, 
pp. 22–23).  Some of the issues that emerged from this study were particularly relevant to 
the phase of the cancer trajectory focused on diagnosis and treatment. These issues 
included knowledge about breast cancer, and the patient physician relationships (Ashing-
Giwa & Ganz, 1997, p. 32).  Other issues were relevant throughout the trajectory.  SES 
was seen as a key component of quality of life and psycho-social issues, with the authors 
commenting that "ethnicity and poverty influence women's experiences with chronic 
illness such as cancer"(Ashing-Giwa & Ganz, 1997, p. 34).  In addition, Ashing- Giwa 
and Ganz (1997, p.33) found that there was a perceived lack of social support, and an 
interaction with the socialization of African American women that teaches that they must 
be strong and independent.  The researchers found that the strong spirituality of the 
participants molded both their belief and coping systems (Ashing-Giwa & Ganz, 1997, p. 
25). 
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Bradley et al. (2002, p. 490) reported “race was not statistically significantly 
associated with unfavorable breast cancer outcomes.”  Analyzing data collected from 
1996-7 study of a cohort from a single metropolitan center, the researchers found that 
“socioeconomic status was associated with late-stage at diagnosis, treatment received and 
death” (Bradley et al., 2002, p. 490).  In this study, the  categorization by race was only 
into either White (81%) or African American (19%), and the African American women 
were less likely to receive adjuvant radiation, less likely to receive surgery and more 
likely to have died from cancer.  
Bradley et al., (2002) also noted that when data were adjusted for income, the 
effect of race diagnostic stage was “greatly reduced” (Bradley et al., 2002, p. 490).  Both 
lower economic conditions and lack of health insurance were associated with lower 
survival.  A woman who lives in a lower income area has a lower five-year survival rate 
than women who live in a high income area regardless of the stage of cancer diagnosis 
(American Cancer Society, 2011).  Bradley et al., (2002, p. 493) found that "Controlled 
for age, race, marital status, cancer stage, Medicaid status, and census tract poverty level” 
stage at diagnosis and rate of death did not show a significant difference between African 
American and European American women.  In this study, 13% of white women were 
considered to live within high poverty areas, and 84% of African American women lived 
within high poverty areas (Bradley et al., 2002, p. 495). 
Small differences that were termed “clinically meaningful” (Paskett et al., 2008, 
p. 3223) in overall general health were found between African American and European 
American BCS (Paskett et al., 2008; Ye, Shim, Garrett, & Daniels, 2012) although some 
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studies found no significant differences (Carver et al., 2006; Casso et al., 2004).  African 
American BCS had lower general health assessment that African American women who 
had not been diagnosed (Paskett et al., 2008).  A finding that was consistent with African 
Americans in the general cancer survivorship population (Powe et al., 2007), but 
inconsistent with an earlier finding that African American BCS, who were 3 years from 
diagnosis had a higher HRQOL than age matched women who had not had breast cancer 
(Northouse et al., 1999).  European American BCS also had lower general health 
assessments than European American women who did not have cancer, although these 
too were small distinctions (Paskett et al., 2008). 
Age in Breast Cancer 
Increasing age in BCS tended to coexist with more comorbid conditions which 
impacted the physical dimension of HRQOL even while better mental health and 
wellbeing were reported (Vinokur et al., 1989).  Cimprich, Ronis, & Martinez-Ramos 
(2002) in a study of 105 long-term BCS using the Quality of Life-Cancer Survivor (QOL-
CS) instrument found that age at diagnosis was a key influencer of HRQOL.  Giedzinska 
et al., (2004) in a larger more ethnically diverse study of 621 BCS who were within 5 
years of diagnosis, including African Americans, European Americans, Latinas and 
Asian Americans, reported that age and income were predictors of overall HRQOL for 
both African American and European American BCS. In African American survivors 
they were also predictive of worse physical well-being (Giedzinska et al., 2004).  
In their study of 215 relatively young (40-49 year olds) who were between 5 and 
10 years from diagnosis Casso et al.(2004) found that younger BCS report HRQOL that 
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was like women who were never diagnosed with breast cancer.  They do report that there 
was an indication of lower emotional well–being in younger women (Casso et al., 2004), 
a finding that was echoed in other studies (Ganz et al., 2002; Vinokur et al., 1989).  
At the highest level differences between African American and European 
American women BCS were small if identified at all, and were more likely associated 
with differences in socioeconomic variables than ethnic or racial ones. 
Dimensions of HRQOL 
HRQOL varies across the cancer trajectory, individually, and, in populations, 
when trends across survivors were examined (Chopra & Kamal, 2012).  Investigators 
generally agreed that proximity in time to the diagnosis will negatively impact HRQOL 
(Ellman & Thomas, 1995; Holzner et al., 2001; Vinokur et al., 1989).  Holzner et al. 
(2001) reported that 5 years post diagnosis there was a decrease in HRQOL, but Casso et 
al., (2004) found no link between proximity to diagnosis and decrease in HRQOL 
Many authors in this area have mentioned the importance of not only looking at 
overall HRQOL but also of understanding how the underlying domains are distinguished 
(Avis et al., 2006; Cella et al., 1993; Osoba et al., 1997; Ringdal & Ringdal, 1993; Schag 
et al., 1991).  Wherever possible, in this analysis, the studies were examined at the lower 
level of physical, psychological, social and spiritual domains. 
Physical Dimension 
The physical and physical functioning components (Ashing-Giwa, 2005b) of the 
breast cancer survival trajectory change after diagnosis and treatment, but remain a potent 
component of long-term survival. An example of this is the growing awareness of heart 
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attack risk for women who had undergone adjuvant treatment (Darby et al., 2013).  This 
area of HRQOL includes physical concerns resulting from disease and treatment, 
including symptoms (Dow et al., 1999; Polinsky, 1994), pain, fatigue (Ashing-Giwa, 
Padilla, Tejero, & Kim, 2004), perceived, and observed bodily functions, or upset of the 
functions (Powe et al., 2007, p. 436).  Additionally the ability to function in a normal way 
(Ashing-Giwa, 2005b) is considered as part of the physical domain. 
Physical issues in breast cancer persist for long-term survivors and impact their 
measured HRQOL (Ashing-Giwa, 1999a; Ashing-Giwa, Padilla, Tejero, Kraemer, et al., 
2004; Dorval et al., 1998; Polinsky, 1994). At least one study reviewed did not find 
physical issues to be a strong component of HRQOL impact (Wyatt & Friedman, 1996) 
possibly because the population being studied was of a broader cancer population rather 
than only restricted to BCS.  Cardiotoxicity and other late treatment sequelae (Carver et 
al., 2006), and general long-term physical impairments (Russell et al., 2008) are reported 
in the research, with impact on HRQOL.  Surgical arm lymphedema is reported in a 
significant minority of BCS (Beaulac, McNair, Scott, LaMorte, & Kavanah, 2002; Dorval 
et al., 1998; Kornblith et al., 2003; S. H. Lee, Min, Park, & Jung, 2012).  Numbness at 
the surgical site that may be related to adjuvant therapy was also reported and impacts 
measures of HRQOL (Kornblith et al., 2003; Polinsky, 1994).   
Post treatment fatigue and pain (Dow et al., 1999) can be ongoing for many years 
(Ashing-Giwa, 1999a; Carver et al., 2006; Chopra & Kamal, 2012; Polinsky, 1994).  The 
impact on HRQOL was seen to be reduced in those BCS who had a domestic partner 
(Carver et al., 2006; Ganz et al., 2002; Helgeson & Tomich, 2005), and mitigated by 
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higher levels of education in BCS (Carver et al., 2006).  Von Ah et al. (2012) found 
fatigue to be the strongest predictor of overall HRQOL in their study of 62 long-term 
African American BCS compared to 78 normal controls.  
Reported fatigue impacts HRQOL (Northouse et al., 1999) and African American 
BCS report more fatigue than other survivors (Leak et al., 2008; Von Ah et al., 2012).  
They also report more impact from hot flashes (Von Ah et al., 2012), and more pain than 
African Americans without a breast cancer diagnosis (Leak et al., 2008; Paskett et al., 
2008), both of which lower reported HRQOL.  Sleep issues (Dow et al., 1999; Northouse 
et al., 1999), breast related symptoms that persist into survival (Casso et al., 2004), and 
general distress over symptoms (Northouse et al., 1999) that may impact a woman’s 
ability to function in what she considers a normal way (Russell et al., 2008), were 
identified as having impacts on HRQOL. 
While all physical components might be seen as sequelae of disease and 
treatment, there were some associations that were clearly drawn in the research.  BCS 
were found to have more comorbid conditions and take more medications, both of which 
were associated with lower HRQOL (Vinokur et al., 1989). While this review was 
restricted to early-stage breast cancer, Vinokur et al. (1989) also found that the severity of 
the diagnosis a woman was given impacts negatively on HRQOL.  Only a few studies 
reviewed found that mastectomy had a negative impact on HRQOL (Casso et al., 2004; 
Skrzypulec et al., 2009).  In a large study of 763 disease free BCS, an average of 6.3 
years post treatment, Ganz et al. (2002) found no correlation between type of surgery and 
HRQOL. 
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Adjuvant therapy, which includes chemotherapy and hormonal therapy including 
tamoxifen, aromatase inhibitors and drugs that impact hormone balance, has significant 
long-term effects (Casso et al., 2004) on women and their reporting of HRQOL (Ganz et 
al., 2002).  The impact was not only seen in physical functioning (Ahles et al., 2005; 
Ganz et al., 2002) but also in general health perceptions (Ganz et al., 2002) and overall 
symptom distress (Giedzinska et al., 2004).  Bowen et al. (2007) found a strong 
association between adjuvant therapy and fatigue and depression and associations have 
also been shown with lower social and psychological components of HRQOL (Carver et 
al., 2006; Casso et al., 2004). 
Race has an impact in the physical dimension of well-being (Russell et al., 2008).  
However, while both African American and European American BCS reported more 
physical symptoms than women who had not had breast cancer, according to Von Ah et 
al. (2012), there was no difference in their reported ability to function on a physical level. 
Giedzinska et al. (2004) found worse functioning for African American BCS and Paskett 
et al., (2008) found that both African American and European American BCS had lower 
physical functioning than non-BCS, although the effect was small.  Overall African 
American BCS had a worse physical HRQOL than European American BCS (Giedzinska 
et al., 2004) at a small but clinically useful level (Paskett et al., 2008).  African American 
BCS reported slightly higher physical limitations on their ability to perform normally in 
their role (Paskett et al., 2008; Russell et al., 2008).  Both African American and 
European American BCS reported a slightly lower level of vitality than women who had 
never been diagnosed (Paskett et al., 2008).  African American BCS reported more sleep 
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disturbance that African American women who had no breast cancer diagnosis (Leak et 
al., 2008; Paskett et al., 2008; Von Ah et al., 2012) and poorer HRQOL (Von Ah et al., 
2012). 
Older BCS (>65 years of age) tended to have worse physical HRQOL (Cimprich 
et al., 2002), have more comorbid disease (Sammarco, 2003), and experience more 
physical difficulties (Vinokur et al., 1989).  In African American survivors no 
relationship was found between overall HRQOL and age at diagnosis (Leak et al., 2008). 
The timing of physical issues has an impact on HRQOL.  During treatment 
physical problems often have a patient’s attention (Northouse et al., 1999) but the 
development of morbidity later in the trajectory was linked to poorer HRQOL as well 
(Rietman et al., 2003).  The impact of these late effects is important in evaluating the full 
impact of cancer treatment (Mols, Vingerhoets, Coebergh, & van de Poll-Franse, 2005).   
Psychological, Emotional, Mental Dimension 
Ashing-Giwa, Padilla, Tejero, and Kim (2004) defined this dimension in the 
following way “Psychological functioning is measured by the presence or absence, as 
well as levels, of depression, anxiety, and general emotional well-being” (p. 451).  
Included in this dimension are impacts like mood swings, fear, distress from various 
causes, and body image issues.  This dimension also includes both positive and negative 
aspects of the experience (Powe et al., 2007, p. 436). 
Long-term BCS may suffer psychosocial distress (Russell et al., 2008), with more 
psychological issues and HRQOL deficits seen the psychological functioning component 
of their profile (Ashing-Giwa, 1999a; Meyer & Aspegren, 1989; Russell et al., 2008).  On 
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the positive side, some BCS report a deeper maturity that translates into an improved 
HRQOL (Halttunen, Hietanen, Jallinoja, & Lönnqvist, 1992) 
Ahles et al. (2005) found no association with having had adjuvant therapy and the 
psychological component of HRQOL, but cognitive impairment has been shown with 
adjuvant therapies in long-term BCS (Brezden, Phillips, Abdolell, Bunston, & Tannock, 
2000; Carver et al., 2006; Phillips & Bernhard, 2003; Russell et al., 2008).  Association 
between breast conserving surgery and reduced psychological HRQOL was not found 
(Meyer & Aspegren, 1989; Omne-Pontén, Holmberg, & Sjödén, 1994). 
Depression and anxiety were negatively associated with HRQOL in breast cancer 
patients during treatment (Longman, Braden, & Mishel, 1999).  Both depression and 
anxiety have been associated with lower HRQOL in long-term BCS (Ashing-Giwa & 
Lim, 2011; Tomich & Helgeson, 2002; Weitzner, Meyers, Stuebing, & Saleeba, 1997).  
Perkins et al. (2007) found better psychological resources were correlated with lower 
levels of depression and better general health perception as well as improved HRQOL.  
Ellman & Thomas (1995) in a study of 290 matched pairs of BCS between 50 and 78 
years old found less anxiety and depression in BCS than in controls.  However, Weitzner 
et al. (1997) in a smaller study of BCS (n=60) versus a breast screening group (n=93) 
found higher incidence of mild to moderate depression symptoms and trait anxiety in the 
BCS group, with a lower HRQOL for those women with depression scores in the 
symptomatic range.  
African-American survivors were less depressed, and displayed less anxiety than 
European American survivors and were less likely to have worries about cancer 
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(Deimling et al., 2006).  African-American survivors, according to Deimling et al. 
(2003), experience less psychosocial impact than European American BCS.  The 
explanation for this was “it is possible that this and other cultural groups express their 
distress differently and that the distress measures used in this study do not capture the 
nature of their distress" (Deimling et al., 2006, p. 157). 
Post-Traumatic Stress Disorder symptoms were identified in a small number of 
long-term BCS with an impact on HRQOL (Kornblith et al., 2003; Skrzypulec et al., 
2009).  Long-term survivors, with emotional distress and PTSD symptoms, demonstrated 
lower HRQOL that was mainly associated with chemotherapy and a later stage diagnosis 
(Amir & Ramati, 2002).  Emotional impacts of breast cancer were found to stabilize for 
most BCS after about two years (Ashing-Giwa & Lim, 2011; Neyt & Albrecht, 2006). 
Some emotional issues continue long-term (Ashing-Giwa & Lim, 2011) with the level of 
impact being reduced and less negative thoughts reported by women with partners 
(Carver et al., 2006; Ganz et al., 2002; Helgeson, Snyder, & Seltman, 2004). 
"Years later, concerns about recurrence are likely to be most prominent along 
with the distress associated with continued monitoring and testing (Deimling et al., 2006, 
p. 144).” Worries about the future and recurrence continue for BCS into long-term 
survival (Halttunen et al., 1992; Meyer & Aspegren, 1989). Medical checkups and 
mammograms make the worries prominent (Polinsky, 1994), often bringing concerns 
about another cancer (Deimling et al., 2006), or uncertainty about the future (Dow et al., 
1999; Mishel et al., 2005) into immediate attention.  African American BCS reported 
fears of recurrence that impact HRQOL (Northouse et al., 1999). 
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The strongest associations with poor HRQOL in the area of body image and 
appearance issues were medical variables (Carver et al., 2006).  A mastectomy 
(Giedzinska et al., 2004; Omne-Pontén et al., 1994), a chemotherapy regime (Carver et 
al., 2006), a younger age at diagnosis, and having a lower income (Giedzinska et al., 
2004) meant a survivor was more likely to report body image issues.  Being a BCS was 
enough to have a higher risk of body image problems (Ashing-Giwa, Padilla, Tejero, 
Kraemer, et al., 2004; Carver et al., 2006).  African American women report more body 
image issues, but when demographic and medical variables were controlled this 
difference becomes insignificant (Giedzinska et al., 2004).  
Racial identification predicts “psychological distress, anxiety, depression and 
cancer related worries, with African-Americans exhibiting lower levels of distress than 
whites” (Deimling et al., 2006, p. 143).  African American BCS reported more optimistic 
outlook (Northouse et al., 1999) and more positive mental health impact (Ganz et al., 
2002). 
Older BCS suffer more depression (Perkins et al., 2007) and a negative 
correlation between their level of perceived uncertainty and their reported HRQOL 
(Sammarco, 2003). 
Social and Socioeconomic Dimension 
The social dimension focusses on engagement in social activities (Ashing-Giwa, 
Padilla, Tejero, & Kim, 2004).  It includes support, leisure activities, family, and 
sexuality (Powe et al., 2007).  Functional well-being is also gauged by the ability to 
engage in self-care and perform family and work responsibilities (Ashing-Giwa, Padilla, 
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Tejero, & Kim, 2004), the ability to perform tasks, work towards goals, or perform social 
roles (Powe et al., 2007). 
Typically SES is used as an explanatory variable in health research, or it is used 
as a control for other health correlates (Oakes & Rossi, 2003).  Krieger et al. (1997) 
identify two major components - economic indicators and indicators that were more 
related to social position.  Overall these indicators were considered to be a measure of the 
ability to access resources or the prestige and social power that an individual can 
command (Braveman et al., 2005).  Measures associated with resources include income, 
wealth, education or the inadequate resources associated with poverty, whereas prestige 
based measures were associated with rank or status in the social hierarchy (Krieger et al., 
1997).  SES is related to the social dimension of HRQOL (Ferrans, 2004). 
Different measures of SES may have different meanings for different groups in 
the population (Braveman et al., 2005).  Minorities including racial/ethnic groups, 
women and older populations who do not participate in the regular economy or who may 
be paid less than a white male for the same work may be categorized incorrectly 
(Berkman & Macintyre, 1997).  The age of the cohort under investigation can change the 
impact of different educational levels.  Not as many people went to college in the earlier 
part of the twentieth century as did in the 1990s, so the level of education attained has a 
different meaning for different age cohorts (Braveman et al., 2005).  Thus, considerations 
in the measurement of SES require that care is taken in any interpretations of association 
between SES and HRQOL, especially where the group under consideration is female, 
minority and older. 
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There is not a straight-line relationship between changes in SES and health status 
(Daly et al., 2002). Depending on the measure used for SES and the component of health 
being measured the relationship changes across social groups (Abramson, Gofin, Habib, 
Pridan, & Gofin, 1982; Braveman et al., 2005; Daly et al., 2002).  The level used to 
measure health, for example, symptoms rather than overall diagnosis can change the 
pattern of relationships between SES and health (Betancourt & López, 1993) as can the 
time in when SES is measured (Krieger et al., 1997).  
There is a significant body of knowledge that supports the interaction between 
race and SES in correlations with health.  Differences in race often become apparent 
where SES is considered “equivalent” (Williams, 1999).  Williams (1999) suggests that 
while SES does account for much of the racial difference in health status, at every level 
of SES, African Americans, and other minority group members, have lower life 
expectancy that their white counterparts (Williams, 1999).  The same levels of income 
across racial/ethnic groups don’t mean the same access to resources.  If wealth rather than 
income is measured the levels were different for minorities and whites and even when 
income health insurance and clinical status were held constant, the white population is 
likely to get better treatment (Williams, 1999).  Bias in medical care (Williams, 1999) is 
observed in the differences in care received by minority groups, and in access to health 
care (Williams, Lavizzo-Mourey, & Warren, 1994; Winker, 2004).  SES may measure 
different concepts in different cultures, ethnic and demographic groups (Berkman & 
Macintyre, 1997).  
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Ye, Shim, Garrett, & Daniels (2012) found "race had a significant impact on 
quality of life for all the cancer patients” (p. 302). For breast cancer patients the 
relationship was not as clear, and reports were more likely to associate ethnic minority 
status with other socioeconomic characteristics when discussing the impact on overall 
HRQOL (Ashing-Giwa et al., 2007; Giedzinska et al., 2004).  In their multi-ethnic 
sample, Ashing-Giwa et al., (2007) noted that both African Americans and European 
Americans had a favorable SES. They proposed that there may be a more diversified 
impact on overall HRQOL in a population sample that had a more diversified SES 
profile.  In an early study, Ashing-Giwa (1999a), reported no link between racial 
categorization and overall HRQOL.  
Family distress (Dow, Ferrell, Leigh, Ly, & Gulasekaram, 1996), while reported 
as less of an issue if the patient has a partner (Ganz et al., 2002; Helgeson et al., 2004), 
was none the less still an issue for BCS in the social domain of HRQOL.  Worries about 
the burden on the family from the impact of breast cancer were reported (Ashing-Giwa, 
Padilla, Tejero, Kraemer, et al., 2004; Carver et al., 2006; Dow et al., 1996).  Having 
higher education was associated with less distress about the family, and lower scores on 
psychological variables indicated more concerns about the family (Carver et al., 2006).  
Marital adjustment issues (Meyer & Aspegren, 1989) and a feeling of lack of social 
support (Moore, 2001, p. 200; Wyatt & Friedman, 1996) both were associated with a 
lower HRQOL in the social domain.  Other factors that were associated with lower 
HRQOL in the social domain included chemotherapy (Ahles et al., 2005) and lower 
scores on psychological variables (Carver et al., 2006). 
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Sexual issues were more often reported in BCS (Chopra & Kamal, 2012; Dorval 
et al., 1998; Ganz et al., 2002; Kornblith et al., 2003).  There is often a physical and 
psychological component as well as social dysfunction in sexual health assessments.  
General concerns with sexuality (Dow et al., 1999; Ganz et al., 2002), acknowledged 
sexual problems (Ashing-Giwa, 1999a; Ashing-Giwa, Padilla, Tejero, Kraemer, et al., 
2004; Carver et al., 2006; Chopra & Kamal, 2012; Kornblith et al., 2003), and issues with 
sexual satisfaction (Dorval et al., 1998) were reported as impacting HRQOL.  Casso et al. 
(2004) identified a mild impairment using the sexual scale of the CARES (Cancer 
Rehabilitation Evaluation System) instrument.  In at least one study, psychological 
variables more consistently impacted the measures of sexual disruption than physical 
issues (Carver et al., 2006).  African American BCS report less sexual issues than 
European American BCS (Giedzinska et al., 2004). 
Financial issues while less for those with higher educational attainment (Carver et 
al., 2006; Kornblith et al., 2003) were reported by some BCS.  Some report difficulties in 
functioning financially (Helgeson et al., 2004), some report concerns about health 
insurance coverage in the future (Ashing-Giwa, Padilla, Tejero, Kraemer, et al., 2004; 
Polinsky, 1994).  Carver et al. (2006) found that medical variables like cancer stage and 
treatment were correlated with financial concerns, although chemotherapy was not 
associated with a lower social domain score (Ahles et al., 2005). 
Lower SES was associated with poorer HRQOL, especially in the area of 
emotional health (Ashing-Giwa & Lim, 2011; Hewitt et al., 2004).  Lower income had a 
negative impact on HRQOL (Casso et al., 2004) and emotional health (Ashing-Giwa & 
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Lim, 2011) as did lower levels of education and being a non-English speaker (Ashing-
Giwa & Lim, 2011).  A higher level of attained education was associated with better 
HRQOL (Carver et al., 2006).  A lower level of attained education was associated with a 
lower HRQOL (Northouse et al., 1999) for African American BCS. 
For both African American and European American women social support was 
influential in HRQOL (Ashing-Giwa et al., 2007; Northouse et al., 1999).  African 
American BCS report higher levels of social support than normal controls (Von Ah et al., 
2012), and higher levels than European American BCS (Giedzinska et al., 2004).  African 
American BCS report feeling support from their family (Howard et al., 2007) but a lower 
level of family well- being (Von Ah et al., 2012). 
While lower life stress had a positive effect on HRQOL for African American 
BCS (Ashing-Giwa et al., 2007), many African American BCS report life stress as a 
significant issue (Russell et al., 2008).  Psychosocial functioning varies in African 
American BCS (Russell et al., 2008) but even after controlling for demographics and 
comorbidities social functioning was lower for African American BCS (Ye et al., 2012). 
There was a positive relationship with HRQOL and a perception of better social 
support for older BCS (Sammarco, 2003).  Younger (<44 years) BCS showed both more 
social issues (Casso et al., 2004) and worse social HRQOL (Cimprich et al., 2002). 
Spiritual 
Spirituality, independent of religion, is concerned with the way people find 
meaning and purpose in their lives and perhaps death.  It does not necessarily require 
belief in a higher power, or an organized religious group although it is possible for 
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spirituality to manifest in that way (Davison & Jhangri, 2010).  In the Ashing-Giwa 
(2005b) model both the spiritual and existential components of experience are included in 
this dimension. 
Studies have provided insight into the positive nature of changes that impact the 
spiritual dimension of HRQOL.  Increased hope, better defined life purpose and positive 
emotional changes (Dow et al., 1996) were noted in long-term BCS.  Long-term BCS 
also reported positive spiritual growth (Ganz et al., 2002) positive emotional outcomes, 
an optimistic change in outlook and finding meaning in life (Ashing-Giwa & Lim, 2011; 
Bower et al., 2005; Meyerowitz et al., 2008).  
While spirituality was not included in all studies, when it was, African American 
women assessed that higher HRQOL was a reflection and response to their spiritual 
beliefs (Chopra & Kamal, 2012).  Several studies have linked coping and spirituality for 
African American BCS (Russell et al., 2008).  They reported higher levels of spirituality 
(Ashing-Giwa et al., 2004) that supports their ability to cope with the sequelae of breast 
cancer (Von Ah et al., 2012).  In a comparison of African American BCS and those who 
have not had the disease, Von Ah et al. (2012) found that spirituality was high in all 
African American women in their sample, and found no difference in spirituality amongst 
either the BCS or non-BCS groups of either racial categorization  
African American women tend to report a religion based spirituality (Ashing-
Giwa, Padilla, Tejero, Kraemer, et al., 2004) and increasing levels of spirituality were 
associated with higher HRQOL (Leak et al., 2008).  European American women may 
report other forms of spiritual practice or belief not associated with religiosity (Ashing-
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Giwa, Padilla, Tejero, Kraemer, et al., 2004).  African American BCS report more 
positive growth and appreciation for life (Von Ah et al., 2012), and they report more 
found meaning in the cancer experience than European Americans (Giedzinska et al., 
2004; Von Ah et al., 2012). 
Systematic Reviews 
Several terms are used relatively interchangeably in the literature to refer to the 
process of attempting to integrate primary research to create a generalized view of a body 
of knowledge.  Research synthesis, research review and systematic review have slightly 
different connotations (Cooper et al., 2009, p. 6).  Meta-analysis can be used to refer to 
the whole process or to  “A statistical analysis of results from separate studies, examining 
sources of differences in results among studies, and leading to a quantitative summary of 
the results if the results are judged sufficiently similar to support such synthesis” (Porta, 
2008, p. 154).  Lipsey & Wilson (2001) explain that this form of analysis is another 
approach to survey research except that the research reports are surveyed rather than 
people.  In its purest form meta-analysis is distinguished from the traditional “narrative 
review” reports of synthesized primary research, by bringing the same rigorous 
methodological approaches that are required from experimental research (DeCoster, 
2004). 
Following the example of  Chalmers (2007) and the Dictionary of Epidemiology 
(Porta, 2008) this study referred to the overall process of defining the problem, collecting 
the research evidence, selecting and coding the studies, analyzing and integrating the 
evidence, interpreting the cumulative evidence and presenting the results (Cooper et al., 
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2009) as a systematic review and the included process of statistical integration and 
summary as meta-analysis (Borenstein et al., 2009; Cooper et al., 2009). 
Some authors (DeCoster, 2004; Lipsey & Wilson, 2001) refer to the whole 
process as meta-analysis.  The distinction that the systematic review is designed to “limit 
bias in the assembly, critical appraisal, and synthesis of all relevant studies on a specific 
topic” (Porta, 2008) is an important aspect of the newer use of the terminology that is 
reflective of the rigorous process that has developed with the increasing attention to the 
value of the synthesis of prior studies (Chalmers, 2007; Cooper et al., 2009). 
Rationale for Consolidating and Integrating Research 
Chalmers's (2007) eloquent exposition of the value of the systematic review is 
summarized in the following: “those who say that systematic review and meta-analyses 
are not ‘proper research’ are wrong: it is clinical trials done in the absence of such 
reviews and meta-analyses that are improper scientifically and ethically” (Chalmers, 
2007, p. 53). 
Chalmers (2007) reasons to conduct reviews included developing an 
understanding of the state of knowledge in a specific area, potential research avenues 
(Borenstein et al., 2009; Chalmers, 2007; Cooper et al., 2009), and the earlier detection of 
an effect.  He uses the example of Sudden Infant Death Syndrome (SIDS), where the 
knowledge existed in the effects found in research studies of back sleeping 15 years 
before it was found in the early 1990s.  If a review had been done many lives would have 
been saved (Chalmers, 2007, pp. 46–47).  Chalmers (2007) identified that evaluation of 
planned research for potential value prior to incurring the costs of the projects, in for 
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example, large drug trials (pp. 43–46), and the possibility of providing information that is 
more tailored to the needs of clinicians and patients by examining relevant research, 
rather funding and conducting undirected research studies (pp. 49–52) were benefits of 
meta-analysis in a purely practical perspective.  
This study was planned consolidate data from quantitative studies (Randolph, 
2009) and provide an understanding not only of the direction of the effect seen but an 
estimation of its size (Ellis, 2010).  While there have been a significant number of studies 
done in the general area of long-term survival from breast cancer, many of them focused 
on a literature review rather than including meta-analysis.  The question is complex, with 
multiple contributing factors.  Many of the studies focus on different aspects of the 
HRQOL construct but do not operationally define their variables the same way.  
Significantly while some researchers have included the dimension of race in their work 
(Ashing-Giwa, Tejero, Kim, Padilla, & Hellemann, 2007; Ashing-Giwa, Padilla, Tejero, 
& Kim, 2004; Ashing-Giwa et al., 2010; Aziz & Rowland, 2002; Betancourt & López, 
1993; Bradley, Given, & Roberts, 2002; Buki et al., 2008; Eversley et al., 2005; 
Freedman et al., 2011; Giedzinska, et al., 2004; Gordon, 2003; Newman et al., 2002), 
many have not reported on this variable in their results.  
Several studies have integrated parts of the considerable body of knowledge 
related to breast cancer survivorship.  Hewitt, Herdman, & Holland (2004b) surveyed the 
interventions for psychosocial needs of BCS.  Several meta-analyses have been produced 
focused on the issues of survivorship in cancer generally, including quality of life for 
African American cancer survivors (Powe et al., 2007), the link between cancer survival 
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and being unemployed (de Boer, Taskila, Ojajärvi, van Dijk, & Verbeek, 2009) and the 
effects of psychosocial interventions on survival time (Chow, Tsao, & Harth, 2004).  In 
breast cancer specifically meta-analyses have been published on impacts of hormone 
replacement therapy (Meurer & Lena, 2002), pregnancy following breast cancer 
diagnosis (Azim et al., 2011), how psychosocial factors may influence the development 
of breast cancer (McKenna, Zevon, Corn, & Rounds, 1999), the impact of exercise 
(McNeely et al., 2006), mortality and SES in African American BCS (Newman et al., 
2002), and the effect of radiation on early-stage breast cancer (Reynolds, 2006).  The use 
of meta-analysis has tended to be more for the understanding of treatment associated 
effects, while the narrative review was used more for psychosocial questions including 
reviews that support the development of research agendas for specific groups (Berger, 
2011; Girgis & Butow, 2009). 
The use of meta-analysis in this area of research allows for an understanding of 
the size of the effect seen across dimensions of the HRQOL construct (Ellis, 2010), and it 
was planned to determine if an impact from the type of instruments used to collect data 
(Borenstein et al., 2009; Lipsey & Wilson, 2001)could be observed.  The coding process 
as well as the statistical analysis was planned to allow for an assessment of the gaps in 
the current body of research (Ellis, 2010), and was expected to provide support of an 
assessment of the kinds of interventions most likely to be needed.  The use of this 
methodology was chosen to inform and support further understanding and research in this 
area. 
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The Process of the Systematic Review 
The systematic review including meta-analysis provides a set of procedures to 
“systematically review the research examining a particular effect” (Ellis, 2010, p. 95) 
from a set of previously conducted research projects (Chalmers, Hedges, & Cooper, 
2002; Chalmers, 2007; Cooper et al., 2009).  In the social sciences, large scale randomly 
controlled trials that may provide definitive answers are rare (Ellis, 2010), rather 
understanding advances in small often contradictory steps, and achieving a clear picture 
of the state of knowledge requires a concerted effort to review and consolidate data from 
many different research studies (Ellis, 2010; Lipsey & Wilson, 2001).  Meta- analysis 
allows contradictory results in research using different statistics to be combined and the 
overall trend and size of the effect identified (Borenstein et al., 2009; Cooper et al., 2009; 
Ellis, 2010).  Meta-analysis also allows for an understanding of the impact of variables in 
the research that impact the result (Ellis, 2010; Lipsey & Wilson, 2001). 
There has been a growth in the number of systematic reviews, research reviews, 
research synthesis and meta-analysis studies, and in the percentage of citations that are 
associated with those methodologies.  In the Science Citation Index Expanded and the 
Social Sciences Citation Index there was a growth from less than 1000 citations per year 
in 1995 to more than 3500 or more than 25% of citations in 2005 (Cooper et al., 2009, p. 
10).  There was a sometimes passionate championing (Chalmers, 2007) of the cause of 
consolidating research, even gold standard research like randomized controlled trials in 
medical research as a precursor to further investigation.   
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Systematic review including meta-analysis has some significant advantages when 
trying to synthesize and consolidate data across a significant body of work.  As a 
structured technique, it requires the documentation of the process used so that 
theoretically another researcher could take the same body of work and reach the same 
conclusions (Lipsey & Wilson, 2001; Randolph, 2009).  The use of the effect- sizes 
means that a more nuanced synthesis is possible with the ability to test findings that differ 
across research reports (Borenstein et al., 2009; Cooper et al., 2009; Ellis, 2010; Lipsey 
& Wilson, 2001).  Using meta-analysis may allow relationships across studies that would 
not appear in a narrative approach and by using the systematic coding and management 
approach of meta-analysis the inclusion of a large number of studies is possible (Lipsey 
& Wilson, 2001). 
A meta-analytic review includes articles based on more than the author’s 
subjective thinking because the search and inclusion criteria are publicly shared as part of 
the process of the study (DeCoster, 2004).  The subjectivity of the author can mean that 
the conclusions of one reviewer can vary significantly from another on the same body of 
work (Randolph, 2009).  Narrative reviews, when comparing results are dependent on 
statistical significance for evaluation and are at the mercy of sample size much more than 
the meta-analytic approach (DeCoster, 2004; Randolph, 2009).  There is little option in 
the narrative review in being able to reach conclusions about how differences in 
methodology influence the outcome or any provision of the classification rules for 
methodological differences (DeCoster, 2004; Jacobsen, 2009). 
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The systematic review is not perfect and has some significant criticisms that are 
leveled against the process.  Not the least of these criticisms include the amount of effort 
involved (Lipsey & Wilson, 2001), and the challenge that the process is mechanistic 
(Lipsey & Wilson, 2001). The impact of publication bias and lack of objectivity on the 
part of the researcher must be considered when attempting a meta-analysis (Cooper et al., 
2009; DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 2001).  The increasing use of the 
methodology of the systematic review (Chalmers, 2007; Cooper et al., 2009) has led to 
refinements and improvements in technique (Chalmers et al., 2002) that are focused on 
making the process transparent while acknowledging that there are subjective 
components to the execution of the process (Borenstein et al., 2009). 
Using this methodology is neither a quick nor easy approach to integrating data 
(Lipsey & Wilson, 2001).  The process is labor intensive in developing and documenting 
the search and inclusion criteria, in acquiring both published and unpublished studies, 
developing the coding schema, reading and coding the studies, developing the database to 
hold the information, acquiring the specialized statistical knowledge to select and execute 
the appropriate effect sizes and finally interpreting and publishing the outcome 
(DeCoster, 2004; Lipsey & Wilson, 2001).   
The criticism that this approach is mechanistic is not necessarily a negative when 
viewed in the light of research rigor (Lipsey & Wilson, 2001; Randolph, 2009).  
However, the associated charge that this approach to the data may lead to a lack of 
sensitivity to important issues is valid (Lipsey & Wilson, 2001).  The use of the coding 
approach of meta-analysis is analogous to the use of a survey questionnaire that uses 
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closed ended questions (Lipsey & Wilson, 2001).  Slavin (1995) in his approach of “best 
evidence” synthesis suggests a combination of meta-analytic and qualitative review so 
that key issues that are not visible in the meta-analysis can nevertheless be made visible 
as part of the interpretation of the data (Randolph, 2009).  The systematic review and 
meta-analysis should be considered as a “shared subjectivity” rather than an “objective” 
methodology (DeCoster, 2004, p. 4).  It is the overt documentation of the “subjective 
decisions” that is one of the key strength of meta-analysis as an approach (DeCoster, 
2004; Lipsey & Wilson, 2001). 
As one increases the breadth of the area of knowledge under consideration, there 
is an increasing criticism that meta-analysis tries to “add together apples and oranges” 
(DeCoster, 2004, p. 3).  Overgeneralization can occur in meta-analysis just as it can occur 
in a narrative review (DeCoster, 2004; Lipsey & Wilson, 2001).  The approach to meta-
analysis that identifies different categories within the data for calculation and reporting of 
the related statistics by category allows for the comparison of different categories.  
Additionally being able to test if there is more variation in the different studies than 
would be expected from sampling error alone allows for the testing of the assumption that 
data is comparable (Borenstein et al., 2009; Ellis, 2010; Lipsey & Wilson, 2001).  This 
focus on the variation in effect size rather than trying to develop one grand mean is a 
more subtle and focused way of understanding the data and its implications (Ellis, 2010). 
One long-standing issue in trying to aggregate the information from many 
researchers and studies is dealing with the differences in methodological quality across 
the body of knowledge (Cooper et al., 2009).  Excluding studies of questionable quality is 
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one approach and the previously mentioned best evidence synthesis (Slavin, 1995).  Clear 
rules for methodological quality are not black and white, and many of the studies of 
questionable methodological quality may contain important knowledge (Cooper et al., 
2009; Lipsey & Wilson, 2001).  In the process of the systematic review, the conditions of 
what is acceptable methodological quality are documented and coding of the research 
studies is based on that framework.  Studies can then be compared to understand if there 
is any difference between good and bad studies.  Then a decision is made, as part of the 
process, to include or exclude specific studies (Borenstein et al., 2009; DeCoster, 2004; 
Lipsey & Wilson, 2001).  The qualitative differences between studies become subject to 
the coding schema of the analysis, and the impact they have on the overall outcome can 
be identified (DeCoster, 2004; Lipsey & Wilson, 2001). 
The results of the systematic review are only as good as the process used 
(DeCoster, 2004, p. 3).  It is possible to do a bad meta-analysis (Ellis, 2010).  The 
visibility of the process, what was included and excluded, why those decisions were 
made and how the information was coded and processed should always be presented.  
The overt visibility of the process supports a much easier detection of a poor analysis 
than with other forms of aggregation (Cooper et al., 2009; Cooper, 2009; Lipsey & 
Wilson, 2001) 
The overstatement of the outcome because of the bias to publish significant 
findings (DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 2001) continues to be an issue 
for the systematic review even though there is a significant and systematic attempt to 
include relevant unpublished work.  Even an exhaustive type of search that is part of the 
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methodology of the systematic review (Cooper et al., 2009; DeCoster, 2004; Ellis, 2010; 
Lipsey & Wilson, 2001) is unlikely to achieve one hundred percent accuracy in search 
results and so the meta-analysis should always be considered to have some publication 
bias. 
Summary 
There was evidence from the literature that the experience of surviving breast 
cancer may be different for African American and European American women.  Some of 
the findings from studies of long-term survivors were inconsistent.  Using meta-analysis 
to understand the size and direction of effects from the primary research into HRQOL 
was designed allow a deeper understanding of what had been reported. 
In Chapter 3 I defined the plan and process of the study.  Meta-analysis requires 
that all steps in the study be fully documented (Lipsey & Wilson, 2001; I. Wilson, 2004).  
The methodology chapter provides documentation of the process used and the coding 
schema (S. J. Wilson, 2011).  The coding approach for data is defined, the code pages 
documented (Cooper et al., 2009), and the database organization is described. The effect 
sizes and related statistics were then computed (D. B. Wilson, 2010a), and the outcome of 
that process examined, interpreted and reported (DeCoster, 2004; Lipsey & Wilson, 
2001; Randolph, 2009; Slavin, 1995).  
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Chapter 3: Research Method 
Introduction 
This chapter provides a description of the design of the systematic review and 
meta- analysis (Cooper & Hedges, 2009) and the rationale for its use in this study.  The 
methodology design was based on the approach endorsed by the Cochrane Collaboration 
(Higgins & Green, 2011) and the Campbell Collaboration (2009).  
The chapter begins with the problem definition, which includes the eligibility 
requirements for a research study to be included in the review, and the associated 
implications for the four other major sections of the methodology (The Campbell 
Collaboration, 2011; Cooper, 2009; Cooper & Hedges, 2009; Higgins & Green, 2011).  
The process continues with the search for and collection of data, the coding of 
information from the included studies, the analysis of data (including the meta-analysis), 
and the interpretation and reporting of findings (Higgins & Green, 2011; The Campbell 
Collaboration, 2011).  The process and methods for collecting, storing, and managing the 
data were described, and the sample code pages for the database were provided.   
The process of the study and methodology of the analysis of the included studies 
were described, and a description of the approach to documentation is provided based on 
the PRISMA documentation standards for systematic reviews (Moher et al., 2009).  
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Research Design and Approach 
Process of Meta-analysis 
 
 
Figure 1. Key tasks in the process of meta-analysis.. 
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Problem Specification and Study Retrieval Approach 
The research questions associated with this problem statement are as follows: 
1. Compare the effects of survival for more than 5 years post treatment on 
HRQOL of African American Breast cancer patients diagnosed with Stages 0-
II with those of patients of European American racial identification? 
2. Is enough data available in the population of studies to observe the impact of 
age on the effect size? 
3. Is there enough data on SES in the population of studies to identify its impact 
as a moderating variable?   
4. Can the choice of HRQOL instruments be identified as having an impact on 
the effect size seen in the research? 
5. Can subgroup analysis identify differences in components of HRQOL? 
6. The null hypothesis for the study is that the mean effect size is zero (random 
effects model; Borenstein, et al., 2010). 
The SMD of HRQOL is the effect size being measured in this meta-analysis. 
Identification and Definition of the Variables 
HRQOL. The dependent variable in this relationship was the psychosocial 
experience of survival as measured by HRQOL.  This composite concept is used in an 
attempt to encompass the multiple dimensions of survival and to show how survival from 
chronic disease can be characterized and described (Ashing-Giwa, 2005b; CDC, 2011; 
Ferrans, Zerwic, Wilbur, & Larson, 2005).   
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Researchers have used HRQOL to assess the impact of illness on a person 
(Ashing-Giwa, 2005b).  It is a construct composed of physical, functional, psychological, 
social, spiritual, and sexual well-being (Ferrans et al., 2005).  According to the CDC 
(2011), HRQOL is a valid indicator of resource and service needs and may be a “more 
powerful predictor of mortality and morbidity than many objective measures of health” 
(What is health-related quality of life? section, para 3). 
Researchers have also perceived different components of this overall measure as 
more important or relevant than others.  They chose their measurement instruments based 
on the qualities they were choosing to measure (Wilson, 2004).   
Scholars consider HRQOL a viable construct (Fryback, 2010) even though there 
has been debate about the measures and the need for standardization (Fryback, 2010); 
several studies provided comparisons of those most used in breast cancer research (Ganz 
& Goodwin, 2004; Montazeri, 2008).  Most of the studies retrieved in the pilot search 
that used HRQOL did not break the data down into the constituent components but rather 
reported the overall measure.  (Note: Chapter 2 has a more detailed discussion of 
HRQOL in research for breast cancer.) 
For this study I planned to use the overall measure of HRQOL and code the 
different instruments used as part of the overall data collected from the studies.  Where 
data were available in the studies, the different dimensions of the construct were coded, 
and a separate meta-analysis to identify impact was planned and to some degree 
executed.  During the analysis phase, an assessment was planned of the impact of the 
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different instruments on overall effects size to see if there was any impact that should be 
considered in the interpretation of results. 
Race. The American Cancer Society (2010, p. 4) used the racial categorization of 
White, African American, Asian American/Pacific Islander, Hispanic/Latino, and 
American Indian/Alaskan Native. In this study only the African American and European 
American (White, per American Cancer Society, 2010) categorizations were of interest.  
Operationally to be included for consideration a study had to have had at least one of 
those two racial categories as part of its population. 
The categorization of race in the United States has a history of political, cultural, 
and historical implications that include discrimination at the individual, societal, 
institutional, and structural level (Betancourt & López, 1993; Krieger, Williams, & Moss, 
1997; Stratton, Nepaul, & Hynes, 2007; Thompson et al., 2008).  The variable is 
intimately confounded with SES and the related concept of social class with the 
implications of access to resources, prestige, and power (Williams, 1999; Williams & 
Jackson, 2000; Williams, Lavizzo-Mourey, & Warren, 1994).  
Race and ethnicity are often confused (Betancourt & López, 1993) or used 
interchangeably (Stratton et al., 2007).  In this study only the designations used by the 
study authors were considered, and the complexity of the interaction between race and 
ethnicity (Betancourt & López, 1993; Stratton et al., 2007) was outside the study scope. 
In at least one study where SES was distinguished from race in breast cancer 
experience (Bradley et al., 2002), African American women were shown not to be 
statistically significantly different than European American women for stage at diagnosis, 
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treatment and survival.  However, this finding was not sustained by research that focused 
on identifying if SES and race can be separated in looking for causal factors in breast 
cancer.  When looking at stage of diagnosis in breast cancer and how it relates to race and 
SES Lantz et al. (2006) found race was still a significant differentiation factor.  These 
studies were based on an earlier part of the breast cancer journey than my study, but I 
planned to examine the relationship between SES and HRQOL however data were not 
available to support that work. 
Age. Age was planned to be coded for the selected studies.  Studies retrieved did 
not have consistent age identification. Sufficient data was not available to do a secondary 
assessment of the impact of age. 
Diagnostic categories. The variable disease stage, which can have a profound 
effect on survival quality and mortality, was limited in this study to those with local or 
early regional disease at diagnosis (Stage0, I, or II).  Treatment characteristics can also 
influence survival quality (Casso et al., 2004; Ganz et al., 2002; Giedzinska et al., 2004; 
Northouse et al., 1999) but were not included in survivor research often enough to 
analyze as moderator variables. 
PICOS and SAMPLE assessment. The Cochrane and Campbell collaborations 
use a methodology of assessing the viability of the research question in a systematic 
review.  The PICOS (Higgins & Green, 2011) approach was a way to ensure that there 
were effective operational definitions for the key constructs of the review.  The following 
is the PICOS assessment for this review: 
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Table 1 
PICOS Assessment of Research Question (Higgins & Green, 2011) 
Category Description 
Participants/people 
Women who have survived breast cancer having been diagnosed with Stage 0-2 of 
the disease 
Intervention At least5 years elapsed since cessation of primary treatment 
Comparison 
Differences between African American and other racial categorizations. If data 
available impact of age on that comparison 
Outcome Measure of HRQOL as measured by an instrument.  
Study 
characteristics 
Quantitative studies where enough data were provided or can be retrieved. The 
racial definitions must be close enough to be substantively the same as those used 
in this study.  Age and SES were not essential data for the inclusion of a study. 
 
Table 2  
SAMPLE Assessment of Research Problem  
 
Note: Adapted from The Campbell Collaboration (Producer) (2011) Problem 
formulation, Jeffrey C. Valentine [Video]. Material presented in video. 
Question Answer 
Is it Specific? The PICOS process shows that operational definitions for the primary variables 
were developed, and inclusion and exclusion criteria can be stated Ad Hoc. 
Is it Answerable? The question was answerable given that the research studies can be retrieved and 
the data published.  See section on literature retrieval for a discussion on bias in 
publication.  
Are there 
measurable 
constructs? 
The construct of HRQOL is measureable.  The unknown question was how much 
data was available on the variables age and SES.  Race is a categorical variable 
that is not always measured in the same categories.  One of the inclusion criteria 
for studies was that the definition of race should be close enough to that of the 
American Cancer Society(American Cancer Society, 2010) 
Is it Practical?  
i.e. relevant for 
policy/practice. 
If we could know the differences between women then changes in treatment and 
support could be identified.  An overview of research provided a more viable view 
than a single study. 
Is it logical? Health outcomes in other areas can be seen to vary by racial categorization 
(Williams, 1999).  It was logical to investigate if breast cancer survival was 
different across racial categories. 
Is it empirical? 
Can we obtain 
answers using 
observable 
evidence? 
If the data were available to be observed then the questions were answerable.        
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The SAMPLE assessment (The Campbell Collaboration, 2011), tests the viability 
of the research question in the light of the effort and focus (Cooper, 2009) required to 
complete the review.  
Setting and Sample 
Systematic reviews, whether they include meta-analysis or not, have a similar 
action path to most other empirical research that deals with people, the primary difference 
is that the sample is a population of studies that are surveyed not a population of people 
(Cooper & Hedges, 2009; The Campbell Collaboration, 2011).  This section of the 
chapter deals with the identification, and retrieval of the population of studies to be used 
in the review. 
Collecting the Source Studies 
In part the value of meta-analysis lies in the inclusion of all relevant research 
(Ellis, 2010; Lipsey & Wilson, 2001).  Ideally this is all research where the effect of 
interest is the focus of research, and there is a statistically equivalent form of the findings 
(Ellis, 2010).  Ideally, all languages, and both published and unpublished research would 
be included (Ellis, 2010; Lipsey & Wilson, 2001). 
The search process attempted to include all relevant research (Ellis, 2010; Lipsey 
& Wilson, 2001). Several factors can be identified as having an impact on the 
completeness of the research. Only research that had been published in some form that 
was accessible through search engines was able to be included in the search, and because 
the research was focused on African American and European American women, it 
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primarily was focused on research in English and published in North America (Ellis, 
2010; Lipsey & Wilson, 2001). 
The ability to retrieve and examine all research in the possible population of 
studies is often limited by both time and availability of the studies (Lipsey & 
Wilson, 2001).  This limitation, and the tendency for published studies to have a 
statistically significant result, known as publication bias (Ellis, 2010), can severely 
limit the population that is included in the meta-analysis.  The process for sourcing 
the data included an attempt to identify research that was not published, however it 
must be accepted that the population of studies included was not exhaustive.  Time 
to complete the search was a limiting factor although an assessment of how many 
additional studies might have been included cannot be made (Lipsey & Wilson, 
2001). All studies that were identified as potentially relevant were able to be 
accessed in full text (Lipsey & Wilson, 2001). 
There is debate in the meta-analysis literature (DeCoster, 2004; Ellis, 2010; 
Lipsey & Wilson, 2001) relative to defining the quality of the research that is included.  
While it is possible that badly designed research may provide bad data (Ellis, 2010) until 
the coding is underway, and the quality of the studies could be assessed, no studies could 
be excluded from retrieval on the grounds of methodological inadequacy.  At the time of 
sourcing of the studies, those that were methodologically or statistically suspect were 
identified for examination and decision about inclusion.  However, because of the 
scarcity of data that were available, rejection of studies on methodological grounds 
wasn’t relevant. 
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Study Eligibility Criteria 
The framework for identifying key criteria for inclusion of studies in the meta-
analysis was adapted from the approach used by the Cochrane and Campbell 
Collaborations (Hammerstrøm, Wade, & Jørgensen, 2010; Lefebvre, Manheimer, & 
Glanville, 2011) and from Lipsey & Wilson, 2001(pp. 16–23). 
Distinguishing features. The outcome or dependent variable was a measure of 
HRQOL.  The identified HRQOL measures commonly used in Breast Cancer survival 
research are listed in Table 3.  No additional instruments were identified during study 
retrieval, so the code page was not updated.  These were primarily sourced from five key 
systematic reviews of HRQOL in breast cancer (Ganz & Goodwin, 2004; Goodwin, 
Black, Bordeleau, & Ganz, 2003; Mols et al., 2005; Montazeri, 2008; Perry et al., 2007).  
Table 3 lists the instruments used in the group of studies included in the analysis. 
Research respondents. Research respondents were on the primarily female 
although some studies had a small number of male breast cancer patients. Where research 
included male breast cancer patients and their data was not reported separately the study 
could not be included in the analysis.  
All respondents had a diagnosis and were treated for early-stage breast cancer.  
All research was for populations that had an average survival time greater than 5 years 
post diagnosis. It should be noted that some researchers included survivors who were less 
than 5 years and did not report the results separately. These studies (n=5) where the mean 
survival was greater than 5 years have been included in the study population. 
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Table 3 
HRQOL Instruments Used in the Studies Included in Analysis 
 
Research methods. This study was designed to include a meta-analysis as part of 
the systematic review so only quantitative studies were included, effects had to be 
reported in a statistic that could be transformed into SMD and the subject population had 
to be clearly identified (Ellis, 2010; Lipsey & Wilson, 2001).  Study methodology was 
not restricted to Randomized Control Trials (RCT) or Clinical trials (CT) as Quality of 
Instrument 
abbreviation Instrument name Category Date Number of studies 
CARES- SF Cancer Rehabilitation Evaluations System- 
Short Form 
Cancer 1991 2 
EORTC 
QLQ-C30 
European Organization for Research and 
Treatment of Cancer Quality of Life 
Questionnaire - 30 Item 
Cancer 1993 4 
FACT - B Functional Assessment of Cancer Therapy- 
Breast  
Breast 1997 5 
LoL Ladder of life General 1965 1 
POMS(PMS) Profile of mood states Psycholo
gical 
1981 2 
QLIC(F&P) Ferrans and powers Quality of life index-
Cancer 
General 1990 9 
QOL-CS Quality of Life Cancer Survivors  General 1996 4 
SF-36 Medical Outcomes Study Short Form 36 
(MOS-SF36) 
General 1993 31 
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life studies outside of the timeframe of primary treatment can often only be conducted on 
a convenience sample (Ganz & Goodwin, 2004) 
Timeframe. Research was included where it was relevant to the topic and 
included studies from 1998 through 2012. 
Publication type. Searches of materials were constructed to “include published 
journal articles, books, dissertations, technical reports, unpublished manuscripts, 
conference presentations” (Lipsey & Wilson, 2001, p. 19) and potentially online 
publications, as well as more traditional methods.  Availability of all types of material 
was variable so type of publication was identified.  Sources of research and efforts to 
retrieve studies were documented. 
Journal articles and dissertations were the final publication types included in the 
study. Other types of publications were retrieved but none met criteria for inclusion 
(Lipsey & Wilson, 2001, p. 19). Some publications were only online publications.  
During planning of the research it was expected that unpublished research would be 
difficult to locate (DeCoster, 2004; Lipsey & Wilson, 2001), this proved to be the case 
and no additional unpublished research was identified. 
Methodological quality. Lipsey and Wilson (2001) point out that the 
methodological criteria that are important in any given meta-analysis are likely to be 
specific to that analysis.  In a review of HRQOL in Breast Cancer that focused on how 
HRQOL could support decision making in breast cancer treatment Goodwin et al. (2003) 
used only Randomized Clinical Trials (RCT). This focus was relevant because of the 
nature of decision making during treatment, and the ability to use the findings as an 
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outcome measure in already existing research into the impact of different treatment 
options.  In studying the population that was more than 5 years post treatment, and 
especially with a focus on racial or SES characteristics, this study was not looking at the 
outcome of an intervention but rather at the combination of uncontrollable factors in 
lives.  Consequently, it was methodologically irrelevant that the studies be RCT but still 
important that they be quantitative in nature to allow for statistical analysis of results over 
multiple studies.  
Observer bias can be seen as a significant issue in judging methodological quality 
(Lipsey & Wilson, 2001). In an attempt to reduce this, the decisions about the rules for 
methodological inclusion were made in advance of surveying the data.  
The following methodological criteria were the minimum requirements: 
 Study must be quantitative in nature 
 Statistical findings must include sufficient information to transform to the 
effect size SMD.  
 Data of statistical outcomes must be available for at least a racial 
categorization of African American and European American or synonyms of 
those categorizations. 
 Racial classification must be that used by the American Cancer Society (2010, 
p. 4) or understandable in that context. 
 Study must use one or more HRQOL instruments that were identified in this 
section or whose validity and reliability can be independently validated. 
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 Population must be clearly identified, and preferably participant numbers 
identified. 
 Study must be in English. 
 Peer review was not a necessary criterion as it is possible that the “gray” 
literature including dissertations or government reports may have relevant 
study information.  If a report was not peer reviewed, it must be published 
under some authoritative body supervision. 
 Where studies that met all other criteria for inclusion but had insufficient data 
resulted in a largely unsuccessful attempt to retrieve the needed data from the 
author before rejecting the study. 
 The more restrictive the methodological criteria, the more likely, that data would 
not be included in the analysis (Lipsey & Wilson, 2001).  The methodological 
characteristics of the research studies were collected during coding with the plan of 
enabling a moderator analysis of different methodological characteristics to be performed 
so that their impact on the mean effect size could be identified.  This was not possible 
with the limited number of reports that could be included in the study. 
One way of assessing if  studies were “good” or “bad” research (Ellis, 2010; 
Lipsey & Wilson, 2001) is to assess the statistical power of the studies being combined so 
that we know if each study has the power to “detect an effect size equivalent to the 
weighted mean” (Ellis, 2010, p. 127) of all studies.  In this analysis, all studies that met 
the inclusion criteria were included in the analysis.  An assessment of the difference in 
75 
 
 
the mean of the effect sizes based on the exclusion of insufficiently powered studies was 
planned, but not relevant in the size of the population. 
Retrieval Strategy 
Retrieval of documents for possible inclusion into the database began with the 
exhaustive documentation of the approach and continued through all actions taken to 
find, sort, and include or reject studies (DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 
2001).  It was expected that studies relevant to this review would be in different databases 
and categorized in different ways (Hammerstrøm et al., 2010).  In order to reduce bias in 
the search and retrieval of studies a strategy of high sensitivity was pursued even though 
relatively low precision (many irrelevant studies) in the initial recovery (Hammerstrøm et 
al., 2010) was the result.  
There are five major groups of strategies that can be used in systematic literature 
retrieval (Hammerstrøm et al., 2010; Higgins & Green, 2011; White, McAuley, 
Estabrooks, & Courneya, 2009).  These were searches in subject indexes and computer 
bibliographic databases, searching citation indexes, “snowballing” (also called pearl 
growing, or footnote chasing), browsing or hand searching, and consultation. 
Bibliographic databases and subject indices and citation indices. Initial 
searches using the Walden Library Database of journals and internet search engines (e.g. 
Google) were used to retrieve published bibliographies in the area and review articles 
(DeCoster, 2004).  The results from this initial search were used to build both the 
keyword search list and to find an initial list of the key authors in the field (DeCoster, 
2004; Lipsey & Wilson, 2001), as well as candidate studies. An initial keyword search 
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list was built from published bibliographies and review articles (DeCoster, 2004). Table 4 
lists the keywords and search arguments. 
In all 18 databases or families of Databases were searched for reports of studies 
that met the criteria, a list of these available in Table 5.  Web searching is considered a 
good secondary search strategy (Hammerstrøm et al., 2010). It was used as part of the 
retrieval process for those reports that were retrieved in full text and to broaden the 
search. The search engines in the database proved remarkably efficient in identifying 
reports that could be considered. While conference proceedings were identified using 
internet search engines, no new usable reports were added to the database (DeCoster, 
2004). 
Additionally a strategy of searches was followed using the PICO assessment 
developed in section related to the research question.  The PICO was used as a 
framework to generate synonyms for keyword searching as in Table 4.  A keyword 
search was performed against the target databases (see Table 5) (Hammerstrøm et al., 
2010; Lefebvre et al., 2011), with results entered into the bibliographic spreadsheet 
(Lipsey &Wilson, 2001). In addition to keywords generated from synonyms, each 
database had a specific set of search terms and indexing strategies that were added to the 
keyword search sequences.  Web searching is considered a good secondary search 
strategy (Hammerstrøm et al., 2010) which provides a possibility of published an 
unpublished studies not otherwise found.  This strategy allows for the generation of data 
about conferences where still unpublished but potentially usable studies were likely to 
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have been presented (DeCoster, 2004).  Web searching was used in addition to the 
searching of databases and results were added to the bibliographic data base. 
 
Table 4 
Search Arguments Used 
 
argument rel argument rel argument rel argument 
breast cancer and HRQOL and 
African 
American and survivor 
breast cancer and HRQOL and early-stage and survivor 
breast cancer and HRQOL and survival n full text 
breast cancer and HRQOL and survivor n full text 
breast cancer  and HRQOL and black n full text 
breast cancer  and HRQOL and minority n full text 
breast cancer  and QOL and survivor n full text 
breast cancer  and QOL and survivor and long term 
Breast carcinoma  and HRQOL and survivor n full text 
Breast carcinoma  and QOL and survivor n full text 
women and breast cancer and >5 years and HRQOL 
breast cancer   HRQOL     n full text 
breast cancer and QOL and Survival n full text 
breast cancer and HRQOL and 
African 
American and survival 
breast cancer  and QOL and black     
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Table 5 
Databases Used in Search 
Database Name Source 
Academic Search Complete Walden Library 
Cochrane central register of controlled trials Walden Library 
Cochrane collection plus Walden Library 
Cochrane database of systematic reviews Walden Library 
Database of abstracts of reviews of effects (DARE) Walden Library 
Dissertations and theses Walden Library 
Dissertations and theses at Walden University Walden Library 
ERIC Walden Library 
Expanded Academic ASAP Walden Library 
Fdsys Walden Library 
MEDLINE with full text Walden Library 
OVID Nursing Journals Walden Library 
PROQUEST Central Walden Library 
PROQUEST Health and medical Complete Walden Library 
PROQUEST Nursing and allied Health source Walden Library 
PSYCARTICLES Walden Library 
PSYCINFO Walden Library 
PubMed Walden Library 
SAGE Premier Walden Library 
Science Direct Walden Library 
Science Journals Walden Library 
Soc INDEX with Full Text Walden Library 
The Evidence Network 
http://www.kcl.ac.uk/schools/sspp/inte
rdisciplinary/evidence 
The Health Inter Network Access to Research Initiative (HINARI) www.who.int/hinari/en/ 
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Database Name Source 
CITATIONS   
Web of Science Citations Walden Library 
Grey Literature   
SIGLE opensigle.inist.fr/ 
National technical information service NTIS Walden Library 
PSYCHEXTRA Walden Library 
Social Care Online 
www.scie-
socialcareonline.org.uk/search.asp 
 
Snowballing. Also called branching, is an approach which improves the 
likelihood of finding other potentially relevant studies by searching the reference lists 
from retrieved studies (Hammerstrøm et al., 2010).  In addition to allowing for the 
retrieval of other studies, new keywords for searches were added by examining the 
indexes used for useful retrieved studies and examining the reference lists of studies and 
reviews (Hammerstrøm et al., 2010; Lefebvre et al., 2011). 
Browsing or hand searching. While it was possible that studies would be found 
by searching in hardcopies of journals, the process is time consuming, and most benefit 
can be achieved by scanning the Table of Contents for journals where other studies have 
been found (Hammerstrøm et al., 2010).  Hand searching was very limited as search 
criteria had begun to return duplicates consistently before hand searching was begun.   
Consultation. Authors who have published more than one article in the field may 
have other studies that were unpublished (DeCoster, 2004).  After research approval, 
email requests were sent to authors asking if they have unpublished studies that they 
would allow to be included in the meta-analysis. No responses were received. 
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As expected there were many studies that would have met all criteria and allowed 
for the execution of a meta-analysis if the data on African American BCS had been 
presented separately to that of European American BCS. To attempt to overcome this 
issue, I sent emails to all primary researchers where an email address could be identified. 
In total 47 emails were sent. Two researchers answered the email but neither was able to 
provide data. 
Processing and managing the studies. Once studies were identified, the list was 
examined and any duplication was removed. A manual accept or reject decision was 
made based on the criteria identified above (Lipsey & Wilson, 2001). The reason for 
sorting a study into the “reject”, “accept” or “needs further work” based on the title and 
abstract was noted in the database. If there was a need to read the full article to make the 
decision, initial coding of the study was done at the same time, to reduce the amount of 
rework. Only one study was identified that met all criteria. 
It was possible that a study that should have been included was rejected.  This 
rejection was one of the areas where the subjectivity of the researcher may have impacted 
the results (Lipsey & Wilson, 2001). To ensure that this can be evaluated by another 
researcher in the future, the reasons for exclusion of any retrieved studies were included 
in the documentation.  
As this is a subjective process (Lipsey & Wilson, 2001), all data were listed in the 
retrieved database. Rejection reasons were identified. These data are available separately 
on request and contain the database used to manage research studies Lipsey & Wilson 
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(2001). Microsoft Excel 2010 was used to manage the acquisition of the study data. The 
data layouts and code pages are available in the Appendix  
A journal of actions and decisions was maintained in an Excel spreadsheet during 
the process.  This journal includes the search parameters, a summary of results, and the 
actions taken that were then documented in the bibliographic spreadsheet and the Zotero 
Database (D. Cohen & Takats, 2010). 
Lipsey & Wilson (2001) recommend the setting up of a database to manage the 
research studies.  Microsoft Excel was used as the data collection database because of its 
flexibility and ease of dissemination.  A database to keep a “meticulous accounting” 
(Lipsey & Wilson, 2001, p. 23) of the search and collection of research studies for 
analysis was kept.  Keeping this accounting required that all potentially eligible studies 
that were retrieved were entered into the database.  The documentation of this process in 
Excel spreadsheets is available on request, but is not included with the dissertation. 
 
 
Figure 2. Process diagram setup steps for the search. 
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Figure 3. Process diagram including the steps for search and recording. 
 
Table 6 below contains the definition of the columns used in the excel Database to 
record the initial retrieval of studies.  Columns marked with an asterisk were required for 
all entries.   
Once the study was retrieved and entered into the excel database it is also added 
to the Zotero DB for the content articles.  A separate Zotero DB is maintained for all 
other material used in this dissertation.  All studies saved to the hard drive and a copy 
added to the Zotero DB that is maintained on the internet.  An additional back up is 
maintained on network drive.  
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Table 6 
Initial Data Coded at Retrieval of Study 
Column heading in DB 
Coding  
Required 
 (*) Definition 
Study ID * 
Unique number assigned to every study included in the analysis.  This is the 
database identifier, the file identifier and is physically on the paper copy. 
Sequential number assignment starts at 1000 
Title * Study title 
Initial Author * First Author 
Date Published * Publication date 
document status * 
1= returned in search, 2= relevant to study , 3= background information, 4= 
possible study for inclusion, 5= study for coding, 6= coded, 7= invalid or 
withdrawn, 8 = examined, not included 
In bib software * Yes/ No 
Full text * Yes/ No 
Full text retrieval date   Date of retrieval of full data 
Journal  * Source Journal name 
Volume * Volume of journal 
Issue * Issue of journal 
Page Begin * Page start of article 
Additional Authors * Additional authors 
Abstract * Usually the author summary of the content of the study 
Search sequence * 
Reference search control.  Sequence number is made of combination of 
search arguments and search retrieval source. 
Search date * Date the initial search was complete 
SourceDataBase * category of codes for source database, see data code page 
Notes   Free hand information that should be carried about the study 
Reason for not including   
Description of the reason for not including the study.  Where a study did not 
meet the criteria, enter that in criteria field 
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Note. At least items marked with asterisk must be coded even for articles rejected on 
initial pass.  Full bibliographic code page is in Appendix B. 
 
Process Pilot Data.  For the purposes of illustration and testing of the process a 
small sample of potential studies was retrieved.  A MEDLINE with full text search using 
the search parameters “breast cancer” and “survivor” and “HRQOL” retrieved three 
studies, all of which passed initial scrutiny.  Additional records from previous test 
searches were chosen at random to process.  This step was a taken to test if there 
appeared to be enough data available to conduct the study.  The only study where and 
SMD could be calculated overall was retrieved during the pilot.  The pilot suggested that 
there would be sufficient data available. 
Column heading in DB 
Coding  
Required 
 (*) Definition 
Code for exclusion   
1= not relevant population, 2= full text could not be retrieved, 3 = did not 
meet exclusion criteria, 4= Multiple reports of the same study,  
Criteria not met   
1 = Study must be quantitative in nature 2 = Statistical findings must include 
sufficient information to transform the effect size SMD. Reference table of 
possible statistics in Section Coding, Effect size calculations. 3=Data of 
statistical outcomes must be available for at least a racial categorization of 
African American and European American or synonyms of those 
categorizations.4= Racial classification must be that used by the American 
Cancer Society (2010, p. 4) or understandable in that context, 5= Study must 
use one or more HRQOL instruments that were identified in this section or 
whose validity and reliability can be independently validated.6=  Population 
must be clearly identified and preferably participant numbers identified.7=  
Study must be in English. 
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Documentation of the Results.  In addition to maintaining an ongoing log and 
bibliographic database file.  The search was documented using the Preferred Reporting 
Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines (Moher et al., 
2009). 
Reasons for rejection of reports from the processing steps during retrieval are in 
Tables 7 and 8 below. 
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Table 7 
Reasons for Rejection of Reports on Review of Title and Abstract 
Rejection categories in title and abstract review 
 # of 
studies 
Not related to breast cancer but had quality of life 
component 10 
Met most criteria but data not presented 29 
Related to instruments but without data that could be used 107 
Not English 27 
Meta-analysis or systematic review 67 
Breast cancer related but not quality of life outcome 106 
Related to prevention of breast cancer 75 
Population not in scope, e.g. Latina 7 
Research conducted in Qualitative paradigm 139 
Editorial or not study report 15 
Data related to an early-stage of the trajectory or stage was 
not identifiable 356 
Related to treatment of breast cancer or its sequelae without 
usable quality of life data 1159 
Identified as non US and not in other categories 10 
Useful background information but not usable for study 219 
Other cancers, other conditions 1641 
                               Total   3967 
 
87 
 
 
Table 8 
Reasons for Rejection of Reports on Review of Full Text 
Rejected from study on full text examination 
  # of 
studies 
not Breast cancer 3 
Not > 5 years mean 129 
duplicates of reports 11 
instrument testing not usable 4 
could not be retrieved 8 
not quantitative 5 
wrong population 5 
Measure not quality of life 66 
not a study report 74 
wrong stage of cancer 7 
treatment related 1 
not US population 15 
                                                             Total 328 
 
Coding Process 
The purpose of coding the studies retrieved in meta-analysis is to obtain 
information using a process that is designed to minimize bias (Cooper, 2009).  
Information was retrieved from the published reports, processes to handle missing data 
(Pigott, 2009) were executed, and if a study had multiple reports, or multiple effect sizes 
reported which study or effect size to include was identified (Cooper, 2009; Lipsey & 
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Wilson, 2001; D. B. Wilson, 2011a).  Processes and documents that identified what to 
code (Cooper, 2009; Lipsey & Wilson, 2001), how to code (Cooper & Hedges, 2009; 
Lipsey & Wilson, 2001; S. J. Wilson, 2011), and how to manage the data (Lipsey & 
Wilson, 2001) were prepared so that anyone involved in the coding could be trained 
(Cooper, 2009) to execute the process in as similar way as possible (Cooper, 2009). This 
documentation also allowed another researcher to duplicate the process if desired 
(Cooper, 2009).   
Studies were eliminated during the process of coding.  The process was designed 
so that minimal work was lost if a study did not meet the criteria.  After the decision to 
eliminate a study was made, no more data were recorded about that study.  All reports 
had initial bibliographic data retrieved, but it was not until the report of a study was 
accepted into the review that the major coding was executed. 
Studies that entered coding had the article full text retrieved and stored locally, 
and the bibliographic data were entered or updated (S. J. Wilson, 2011).  Study date and 
population were checked against the database to ensure that this was not a multiple report 
of the same study (this was dealt with as a separate process for all studies that had 
multiple reports) (S. J. Wilson, 2011).  If it was a single report of a study, data from the 
study were coded as per the coding template (Cooper, 2009; Lipsey & Wilson, 2001; S. J. 
Wilson, 2011), and the effect size statistic or statistics were calculated (Borenstein et al., 
2009; Lipsey & Wilson, 2001; D. B. Wilson, 2011a; S. J. Wilson, 2011).  If the study had 
relevant population and outcome measures, but the required data were not provided, the 
study was moved to a separate process that required manual attempts to retrieve the 
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needed data, for example contacting the authors (Hammerstrøm et al., 2010).  All studies 
for which data could not be retrieved for inclusion were recorded and excluded from the 
analysis (Hammerstrøm et al., 2010; S. J. Wilson, 2011).   
 
 
Figure 4. Steps to complete the coding process.  
 
Code and Record Study Reference Data 
Once a full text version of the study was retrieved the bibliographic entry was 
updated if needed and the study passed into coding.  At this point the data recorded about 
a study were the same as recorded in Table 6, with the exception that the code for full 
text article retrieved was updated to “yes” and the retrieval date entered.  Attempts 
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continued during the coding process to retrieve all articles where the title or abstract 
suggested the study was relevant.  When all attempts at retrieval failed the study was 
discarded, and the reason recorded to ensure transparency of actions (Lipsey & Wilson, 
2001; S. J. Wilson, 2011). 
Pass Exclusion Criteria.  The exclusion criteria set out in Table 9 were the 
operational definition of the studies that form the population analyzed in this review. 
Table 9 
Exclusion Criteria for the Study 
The formulas for the calculation of the SMD are listed in Table 11.  If a report of 
a study did not have sufficient information to calculate the effect size, an attempt was 
made to contact the author and obtain the relevant information.  When that failed, the 
 Criteria 
1 Study must be quantitative in nature 
2 
Statistical findings must include sufficient information to transform the effect size SMD. 
Reference table of possible statistics in Section Coding, Effect size calculations.  
3 
Data of statistical outcomes must be available for at least a racial categorization of African 
American and European American or synonyms of those categorizations. 
4 
 Racial classification must be that used by the American Cancer Society (2010, p. 4) or 
understandable in that context. 
5 
 Study must use one or more HRQOL instruments that were identified in Table 4 or whose 
validity and reliability can be independently validated. 
6  Population must be clearly identified and preferably participant numbers identified. 
7 Study must be in English. 
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study was excluded from the review.  If a study failed to meet any other criteria, it was 
removed from the study, and the reason noted.   
It was planned that any doubt about a study’s inclusion or exclusion would 
require a second coder to assess it without being aware of the original decision.  If their 
assessment was different from the first, then a discussion was planned to take place until 
both coders were in agreement.  No studies required this process. 
Multiple Reports of a Single Study.  It is possible that multiple reports were 
published reporting a single study (Cooper, 2009; Lipsey & Wilson, 2001; D. B. Wilson, 
2011b).  A process to handle studies with multiple reports (DeCoster, 2004; Ellis, 2010) 
was required.  From the multiple reports, a single representative report should be chosen 
(Cooper, 2009; Ellis, 2010; Lipsey & Wilson, 2001; D. B. Wilson, 2011b). Studies that 
had multiple published reports, or where multiple effect sizes were reported required a 
decision on which effect size would be used.  In this study, separate analysis were 
conducted for different instruments, and only one study required the inclusion of two 
reports as data required was spread over both (Ashing-Giwa, Ganz, & Petersen, 1999; 
Ashing-Giwa, 1999a).  
Where there were multiple effects that were drawn from the same data a decision 
was made in each circumstance of the most appropriate way to handle the study, either to 
record all effects separately or to calculate the average effect size (Ellis, 2010). 
 The following were the decision guidance rules for multiple reports of the same 
study: 
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1. The report where the reported population most closely matches this review 
was the first choice. 
2. The report where the statistics allowed the best calculation of effect size 
3. Where the reports were consistent or where taken together the reports form a 
whole view of the study then the effects were averaged. 
4. If decision was not clear cut.  The plan was to include the earliest published 
study.   
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Table 10 
Reports Rejected During Coding 
Study title First Author Pub. date 
Data includes non-Breast Cancer population 
Disparities in HRQOL of cancer survivors and non-cancer managed care 
enrollees 
Clauser 2008 
Non-standard measures of quality of life used or insufficient studies in group for analysis 
Health-related quality of life in breast cancer survivors of different sexual 
orientations. 
Boehmer 2012 
Personality, coping, and quality of life in early stage breast cancer survivors Caloudas 2006 
Benefits from an uncertainty management intervention for African–American 
and Caucasian older long-term breast cancer survivors. 
Mishel 2005 
Individual differences in well-being after breast cancer survivorship in older 
women 
Perkins 2007 
Predicting Negative Mood State and Personal Growth in African American 
and White Long-Term Breast Cancer Survivors. 
Porter 2006 
Cognitive Dysfunction and Its Relationship to Quality of Life in Breast 
Cancer Survivors. 
Von Ah 2009 
Fear of breast cancer recurrence Ziner 2008 
Includes recurrent Breast cancer, or > 20 % > stage 3 or unknown 
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years 
after adjuvant chemotherapy 
Kornblith 2003 
Depressive Symptoms and Health-Related Quality of Life in Breast Cancer 
Survivors. 
Reyes-Gibby 2012 
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Study title First Author Pub. date 
Majority non US participants 
Invariance Testing of the SF-36 Health Survey in Women Breast Cancer 
Survivors: Do Personal and Cancer-related Variables Influence the Meaning 
of Quality of Life Items? 
Mosewich 2013 
Efficacy, toxicity, and quality of life in older women with early-stage breast 
cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC 
CTG intergroup trial MA.17. 
Muss 2008 
All’s Well That Ends Well? Quality of Life and Physical Symptom Clusters 
in Long-Term Cancer Survivors Across Cancer Types. 
Zucca 2012 
Population mean < 5 years, undefined or > 20% < 5 years. 
Frequent Search for Sense by Long-Term Breast Cancer Survivors Associated 
with Reduced HRQOL. 
Andersen 2008 
A cross-cultural validation of patient-reported outcomes measures: a study of 
breast cancers survivors. 
Ashing-Giwa 2012 
Association between current lifestyle behaviors and health-related quality of 
life in breast, colorectal and prostate cancer survivors. 
Blanchard 2004 
Quality of life and lymphedema following breast cancer. Heiney 2007 
Breast cancer survivorship: Contributing factors for special populations Jabson 2010 
Functional status of long-term breast cancer survivors: demonstrating 
chronicity 
Polinsky 1994 
The Quality of life of African American women with breast cancer Northouse 1999 
Worry of recurrence in breast cancer survivors Rothrock 2003 
Breast cancer in African American women:  Validation of a quality of life 
instrument. 
Rowley 2001 
Quality of life among older survivors of breast cancer.  Sammarco 2003 
Quality of life of breast cancer survivors: a comparative study of age cohorts Sammarco 2009 
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Study title First Author Pub. date 
Exercise in breast cancer survivors: Predicting quality of life with the 
cognitive-appraisal model of stress and coping. 
Wagner 2006 
Relationship between quality of life and mood in long-term survivors of 
breast cancer treated with mastectomy 
Weitzner 1997 
Data provided was incomplete, adjusted using unknown formulae, or non-standard. 
Lymphedema and quality of life in breast cancer survivors: the Iowa Women's 
Health Study. 
Ahmed 2008 
Then and now: quality of life of young breast cancer survivors. Bloom 2004 
Fatigue in long-term breast carcinoma survivors - A longitudinal investigation Bower 2006 
Quality of life for women diagnosed with breast carcinoma in situ Claus 2006 
Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a 
Follow-up Study. 
Ganz 2002 
The roles of herbal remedies in survival and quality of life among long-term 
breast cancer survivors - results of a prospective study. 
Ma 2011 
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole 
after 5 years of tamoxifen in postmenopausal women with early stage breast 
cancer 
Moy 2006 
Breast cancer survivors' health-related quality of life: racial differences and 
comparisons with non cancer controls. 
Paskett 2008 
 Five years later: a cross-sectional comparison of breast cancer survivors with 
healthy women 
Tomich 2002 
An Exploratory Analysis of Fear of Recurrence among African-American 
Breast Cancer Survivors. 
Taylor 2012 
Health-related quality of life of African American breast cancer survivors 
compared with healthy African American women. 
Von Ah 2012 
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Coding the Study 
Once a report of a study was accepted for the review it was coded.  It was planned 
that if multiple coders were used that they would use the same code pages. No additional 
coders were required as the number of studies that could be used was so small.  As 
expected, the design of the process required some modification as coding proceeded 
(Cooper, 2009; DeCoster, 2004; Ellis, 2010; S. J. Wilson, 2011).  Accurate 
documentation of changes was kept so that the path of the study can be followed by 
another researcher if needed (DeCoster, 2004).  
The records for each were linked by the Study ID.  Multiple sets of data were 
collected about the study and stored separately linked to the main bibliographic record by 
the study ID. 
The process was tested by a small number of studies in development, and a pilot 
10% of the study population chosen randomly was used initially to test the coding 
definitions for clarity and relevance.  In fact iterative coding of the studies proved a more 
effective way of developing modifications to the code pages as the numbers were so 
small (DeCoster, 2004).  
With such a small sample size, no sampling for secondary coding was possible to 
assess the validity of the coding definitions and process (DeCoster, 2004; Ellis, 2010; 
Lipsey & Wilson, 2001).  It was planned that at least 10% of the selected studies would 
be coded by another researcher.  As the number of studies available was so limited no 
additional researchers were involved in this step.  No additional training was required.   
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Information about the Studies.  Once the study was accepted into the review for 
coding, Information about the report characteristics, the study setting, the participants and 
the outcomes was collected.  Code pages for the collection of data are in Appendix B.  
Report characteristics. This section identifies the kind of publication, any 
associated organization and funding source related to the study (Cooper, 2009).  These 
data were collected to assist in identifying studies where there was multiple reporting. 
Study methodology data. Data on the instruments used and the settings in which 
they were completed, as well as an assessment of the independence of the groups 
identified in the study were recorded.  The actual study date was also collected, where it 
was available, as this may be different from the publication date and may also assist in 
identifying multiple reports of the same study (Cooper, 2009). 
Participant data. The data collected on participants (Cooper, 2009) were planned 
to identify the classifications of interest in the review, including race, SES and age.  It 
was hoped that data would be available focused on differences between African 
American and European American groups, but capturing other data would have allowed 
for a planned moderator analysis. 
Participant outcome data as captured by the HRQOL instruments used were 
captured in the statistics reported from the study.  These data became the effects that were 
reported and were the basis of the meta-analysis.  As only one effect can be incorporated 
into a meta-analysis (D. B. Wilson, 2011a), where the data cannot be reported in a single 
effect size, multiple meta-analyses were executed. 
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Reported statistics and calculated effect sizes. This data sheet was planned to 
allow the recording of multiple groups, with the associated statistics. It included the 
calculation of the effect size for the two groups of interest to the review (Lipsey & 
Wilson, 2001), using the racial categorization of African America/Black and 
European/Caucasian American/White. 
Study methodology. Cooper (2009) identifies two categories of methodological 
question that require consideration when considering if a study should be included in a 
review; were the concepts measured in the study consistent and relevant in the review, 
and if the implementation used supports the level of inference that was planned.  The first 
of these questions was operationally answered by including only studies that used 
HRQOL measures that were identified prior to data collection.  It was planned that if a 
study was identified that otherwise met the inclusion criteria that used an instrument that 
was not on that list, a case by case assessment would be made. As no overall meta-
analysis was possible, a study that used a one of a kind instrument could not be included.  
All analysis was done where there were at least two studies that used an instrument. 
As this study was about the correlation between naturally occurring categories of 
subjects and outcomes based on a naturally occurring event, methodologies that would 
not be acceptable in trying to make a causal inference were perfectly acceptable in this 
review (Cooper, 2009).  The review did not attempt to make any causal inferences about 
a particular event or intervention, so methodological questions that were related to 
interventions (Cooper, 2009), or particular events other than the occurrence of early-stage 
breast cancer were not relevant. 
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Methodological questions that were related to the ability generalize from the 
findings (Cooper, 2009) were dealt with in the exclusion criteria.  By limiting studies to 
those that included at least women of either African American or European American 
racial identification, and who were survivors of early-stage breast cancer, clearly 
identifies the population to whom the inferences can be generalized.  Likewise, the 
adequacy of the reporting of the statistical tests (Cooper, 2009) was identified in the 
exclusion criteria as a necessary condition for the inclusion of the study. 
It was planned to capture study characteristics in coding (Lipsey & Wilson, 2001) 
that had possible impact on the outcome, for example if the instrument was completed 
under supervision or not, or the time interval since the end of treatment.  The very small 
sample did not allow for more detailed analysis that was planned. 
Calculating the Effect Size 
The plan was to use the SMD as the effect size.  This effect size compares two 
independent groups on the mean of a continuous measure (HRQOL in this review) that is 
not operationally defined in the same way, across studies (Lipsey & Wilson, 2001).  This 
effect size measure is also used where the groups are not experimentally defined (Lipsey 
& Wilson, 2001) as in this review where race was the definition of group.  This measure 
is known as d or Cohen’s d.  The primary formula for the calculation of the most precise 
estimate (Hedges & Olkin, 1985) of S M D is: 
 
 
 
100 
 
 
 (1) 
 
 
 
 
(Borenstein et al., 2009; Hedges & Olkin, 1985; Lipsey & Wilson, 2001, pp. 47–
49) 
Where x̄1, x̄2 are the respective means n1, n2, are the sample sizes of the two 
groups and S1,S2 are the standard distributions of the scores of the two groups.  In all 
cases in this study Group 1 refers to African American identified participants and Group 
2 to European American participants.   
Hedges provided a correction for the bias this effect size shows on small sample 
sizes making the corrected formula: 
 (2) 
 
 
(Borenstein et al., 2009; Hedges & Olkin, 1985; Lipsey & Wilson, 2001; 
Rosenthal, Rosnow, & Rubin, 1999) 
 N is the total sample size for both groups. 
The associated Standard Error is: 
(3) 
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The Inverse variance weight formula is: 
(4) 
 
(Lipsey & Wilson, 2001) 
It is not uncommon in the reporting of studies that information that would be used 
in the above formulas is not reported directly (Cooper, 2009; Lipsey & Wilson, 2001; 
Pigott, 2009).  There are a number of alternative formulae available to convert alternate 
reporting of study results to an estimated SMD.  Table 11 lists the data required to 
calculate the effect size for different reporting data types and the appropriate formula.  
An effect size calculator based on these formulae is available on the George Mason 
University website (D. B. Wilson, 2010c) or on the Campbell Collaboration website (D. 
B. Wilson, 2010a) and was used to facilitate calculation of appropriate effect sizes.   
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Table 11 
Formulae for Additional Transformation to SMD 
Transform for 
SMD 
data required Formula 
ref Lipsey 
and 
Wilson, 
(2001) 
Means and 
Standard 
Deviations 
Mean, Standard Deviation, 
Sample Size 
 
p.198 
T-Test, 
Unequal 
Sample Sizes 
Sample Size (n) Treatment and 
control, t-value 
 
p.198 
T-Test, Equal 
Sample Sizes 
Total Sample Size, t-
value(assumes equal sample 
sizes for groups) 
p.198 
F-Test, 2-
Group, 
Unequal 
Sample Sizes 
Treatment group sample size 
(n),Control group sample size 
(n),F-test (2 group, one way) 
 
p.199 
F-Test, 2-
Group, Equal 
Sample Sizes 
Total Sample Size(assumes 
equal sample sizes for 
groups),F-test (2 groups, one 
way) 
 
p.199 
T-Test P-
Value, Equal 
Sample Sizes 
Sample Size (n) ( assumes equal 
groups), p-value of t-test 
From tables  e.g. Lipsey & Wilson (2001, p. 203) determine 
t from p and df then use t-test 
p.199 
T-Test P-
Value, 
Unequal 
Sample Sizes 
Treatment group sample size 
(n),Control group sample size 
(n),p-value of t-test 
From tables  e.g. Lipsey & Wilson (2001, p. 203) determine 
t from p and df then use t-test 
p.199 
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Transform for 
SMD 
data required Formula 
ref Lipsey 
and 
Wilson, 
(2001) 
Means and 
Standard 
Errors 
Mean, Standard Error, Sample 
(n) for treatment and control 
groups 
 
p.200 
2 by 2 
Frequency 
Table 
Outcome frequency of yes/no 
for treatment and control.  
Decide method Logit, Cox Logit 
or Probit. 
 
Wilson, 
2011 
Binary 
Proportions 
Proportion with event and 
sample size for both treatment 
and control 
 
            probit transformation of p Lipsey & Wilson (2001, p. 205) 
 
p.200 
Point-Biserial 
Correlation 
Sample size (n) (treatment and 
control), Point-Biserial r 
 
 
 
rpb is correlation coefficient 
p is proportion of  subjects in group 1 
p. 68 
Point-Biserial 
Correlation 
Equal groups 
Total Sample size( assume 
n1=n2), p-value Point-Biserial r 
 
p. 178 
Point-Biserial 
Correlation P-
Value, Equal 
Ns 
Total Sample size( assume 
n1=n2), p-value Point-Biserial r 
Transformation available in calculator, Equation not 
available.   
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Transform for 
SMD 
data required Formula 
ref Lipsey 
and 
Wilson, 
(2001) 
Point-Biserial 
Correlation P-
Value, 
Unequal Ns 
Sample size (n) (treatment and 
control), p-value Point-Biserial r 
Transformation available in calculator, Equation not 
available.   
Phi-
Coefficient 
Phi-Coefficient (r from 2x2), 
sample size (Note: use 2x2 
frequencies or binary 
proportions if available) 
 
p.200 
Phi-
Coefficient P-
Value 
p-value (Phi-Coefficient   (r 
from 2x2)), sample size (Note: 
use 2x2 frequencies or binary 
proportions if available) 
Transformation available in calculator, Equation not 
available. Low likelihood of use  
Chi-Square 
Chi squared from 2x2, sample 
size (Note: use 2x2 frequencies 
or binary proportions if 
available) 
 
p.200 
Chi-Square P-
Value 
p- value of Chi squared from 
2x2, sample size (Note: use 2x2 
frequencies or binary 
proportions if available) 
Transformation available in calculator, Equation not 
available. Low likelihood of use  
Frequency 
Distribution 
Each group's frequencies on an 
ordinal or better scale 
 
(f) frequency counts(i) each level (x) variable 
p.199 
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According to Lipsey and Wilson (2001, p. 50) there is a degree of approximation 
as the data provided ranges from complete descriptive data through t-tests, and the 
statistics associated with a one way ANOVA.  However, even though these are all 
estimates they do allow comparison across studies (Borenstein et al., 2009; Cooper, 2009; 
Lipsey & Wilson, 2001). 
Where there was not sufficient data to calculate an effect size, the report entered 
the missing data process and attempts were made to contact the author and retrieve 
sufficient data.  If the data was not retrieved, the report was discarded and cause 
recorded. 
Transform for 
SMD 
data required Formula 
ref Lipsey 
and 
Wilson, 
(2001) 
Means and 
Full Sample 
Standard 
Deviation 
Full sample SD, Mean, 
N(treatment and control) 
 
p.199 
F-Test, 3 or 
More Groups 
F-value(one way), Type of 
group(treatment, control, other) 
Mean, N. 
(k) groups, F-ratio (F), mean for each group ( ), sample 
size(n), for each group (j) 
 
 p. 200 
Means and 
ANCOVA 
MS error, Correlation (covariate 
with DV), Mean, N 
(treatment/control) 
 
p.200 
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Documenting the Process 
Initial code pages. The code pages are provided in the Appendix A.  As 
expected, these code pages were updated and modified during coding of the pilot studies. 
Coding database. Excel was used as the data repository for both coding and 
logging of process steps.  The analysis and reporting was done with Excel extensions 
(Neyeloff et al., 2012).  The design for the coding database was completed during the 
initial coding pilot. This spreadsheet is available on request and is not included with this 
report. 
Bibliographic database. The bibliographic database is the repository of the links 
to the studies and contains identifying information, the assignment of the tracking Study 
ID, and the include/exclude decision information.  Zotero was be used for citation and 
access management. Documents of the coding process and the database of studies 
sampled are available on request. 
Process log. As part of the overall level of documentation required for the meta-
analysis, a log of processing was kept in an excel Database. Appendix A contains 
supporting documentation for the search, coding and analysis processes.  The working 
excel spreadsheets are available on request but could not be attached to this report. 
Analysis 
The process of meta-analysis to this point has been to select studies that can be 
compared meaningfully at a conceptual level (Lipsey & Wilson, 2001, p. 2) and that have 
statistics that can be standardized for comparison (Borenstein et al., 2009; Lipsey & 
Wilson, 2001).  The purpose of the Analysis phase of the meta-analysis is to take all of 
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the coded data from the different studies and prepare the results for interpretation.  It is 
this standardization of the study findings into a quantitative form that allows 
interpretation consistently across the studies (Lipsey & Wilson, 2001, p. 4). 
Random or Fixed Effect Model 
The fixed effect model assumes that the difference observed in the sample of 
effect sizes is entirely due to sampling error (Borenstein et al., 2009; DeCoster, 2004).  In 
the random effects model there are considered to be two sources of variation, the 
sampling error in the studies and the random variation that occurs because the effect sizes 
are drawn from a population of effect sizes (Borenstein et al., 2009; Hedges, 2009; D. B. 
Wilson, 2011b).  If inferences outside of the set of studies in the model are required, then 
a random effect model is used (DeCoster, 2004; Ellis, 2010).  In this meta-analysis the 
random effects model was selected, as many different instruments are used to measure 
the construct, and therefore a population of effect sizes would be expected to exist.  The 
random effects model is appropriate in most meta-analysis (Ellis, 2010, p. 129) and was 
the appropriate choice for this review.   
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Figure 5. Meta-analysis (inverse variance weighted) processes.  
 
Preparation of Data 
Meta-analysis assumes the independence of data (Lipsey & Wilson, 2001) which 
has the consequence that only one effect size for a study can be used in a meta-analysis 
(Lipsey & Wilson, 2001).  The first part of the preparation of data was to identify the 
effect size that was used from each study (D. B. Wilson, 2011b).   
All effect sizes available during coding had the bias correction for small sample 
sizes applied, and the calculation of the standard error and the inverse variance calculated 
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(Lipsey & Wilson, 2001).  The inverse variance weight was used during the analysis to 
ensure that studies that had larger sample sizes had a greater contribution to the outcome 
than those with small sample sizes (Borenstein et al., 2009; Lipsey & Wilson, 2001). 
Describing the Distribution of the Effect Size 
Once an independent subset of effect sizes (Borenstein et al., 2009; D. B. Wilson, 
2011b) has been compiled and the unbiased preparatory calculations are done (Borenstein 
et al., 2009; Cooper, 2009; Lipsey & Wilson, 2001; D. B. Wilson, 2010a), the description 
of the distribution of the effect sizes is calculated.  The mean of the effects is calculated, 
and the precision measures of standard error, confidence intervals, and the z-score and 
associated p-value (Borenstein et al., 2009; Cooper, 2009; Lipsey & Wilson, 2001).  In 
practice, the calculations were done using Excel with extensions (Neyeloff et al., 2012).  
But the calculations are possible without a computer using the following formulae. 
Using the Random effects model requires the computation an estimate of the 
random effects variance component T
2
 (Borenstein et al., 2009; Lipsey & Wilson, 2001) 
which is an estimate from the observed effects of τ2, the variance of the true effect sizes 
(Borenstein et al., 2009).  The following formulas are used to calculate T
2
: 
(5) 
 
(6) 
Where df = k – 1    
(7) 
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This allows the recalculation of the weights to be used in the meta-analytic 
computations. 
(8) 
 
The statistics that describe the distribution can now be calculated using the 
random effect model (Borenstein et al., 2009; Lipsey & Wilson, 2001) 
(9) 
 
Where MES is the meta-analytic mean effect 
wi  is the inverse variance with an estimate of the random effects variance 
ESi is the effect size of the study 
k is the number of studies 
i is each study 
The standard error of the mean effect size is: 
(10) 
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The confidence interval at the .05 significance level can be calculated by: 
(11) 
 
The z-score to test the null hypotheses that the mean effect is zero can be 
calculated using: 
(12) 
 
The associated p values are available in tabular form but can also be calculated in 
Excel using the =NORMSDIST(Z*) formula.  For this analysis Excel with extensions 
(Neyeloff et al., 2012) was used for calculations. 
Finding the True Effect Size of the Analysis  
The random effects model for the meta-analysis was chosen because the studies 
could not be assumed to be “functionally equivalent” (Borenstein et al., 2009, p. 83), and 
that the assumption that the studies were all representative of the same population and 
that the effect sizes was homogenous, was false (Lipsey & Wilson, 2001).  Using the 
random effects model was based on the assumption that the observed effect sizes in the 
studies would include both the true variance in the effect sizes and random error 
(Borenstein et al., 2009).  The term “heterogeneity” was used following Borenstein et al. 
(2009) to refer to the distribution in the true effect variance component only.  To allow 
interpretation of the results of the meta-analysis it is necessary to describe the evidence of 
112 
 
 
heterogeneity in true effect sizes and the variance. The meaning of the dispersion in the 
context of the study, as well as how much of the effect size seen is real rather than what 
can be attributed to random error (Borenstein et al., 2009), can be described.  
To interpret the outcome of the meta-analysis using the random effect model, the 
true-between-studies variation was required not the observed variation.  This required 
finding the total study to study variation.  Then I made an estimate of what the study to 
study variation would be assuming there was no difference in the real effects.  The 
difference between the two indicates the real variance or heterogeneity (Borenstein et al., 
2009).  
This first step in the process was to test the assumption that the effect sizes were 
estimating the population mean (Lipsey & Wilson, 2001) and to gain insight into the 
dispersion of the observations (Borenstein et al., 2009).  When homogeneity was rejected 
I could assume that there were real differences between the studies that were not 
explained by sampling error, and that they were drawing from different populations 
(Lipsey & Wilson, 2001).  The statistic Q was used to test homogeneity calculated as 
follows: 
(13) 
 
In essence the difference of each effect size from the mean was calculated, 
squared and weighted by the inverse variance for the study.  These values were summed 
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over all studies to give a weighted sum of squares or Q, a standardized measure that is not 
impacted by the metric used for the effect size (Borenstein et al., 2009).  The Q statistic is 
not an estimation of the size of the true differences amongst the effect sizes but rather an 
estimation of the study to study variation (Borenstein et al., 2009).   
The expected value of Q if there is no difference in the true effect size from study 
to study is the degrees of freedom of the study 
(14) 
df = k – 1 
and the component of the variation that can be attributed to variances in the true 
effects is: 
(15) 
 
(Borenstein et al., 2009, p. 110) 
Because Q follows a central Chi-squared distribution with degrees of freedom 
equal to k-1 (where k is the number of effect sizes) the p- value of Q can be reported 
(Borenstein et al., 2009).  Alpha was set at 0.05 for this review, and a p-value less than 
alpha caused a rejection of the null hypothesis and an assessment that the studies do not 
share a common population (Borenstein et al., 2009; Lipsey & Wilson, 2001).  Where 
there are a small number of studies included and small sample sizes in the study the Q 
statistic is underpowered and may cause an invalid failure to reject the null hypothesis 
(D. B. Wilson, 2011b).  
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The true effect sizes cannot be observed, so the variance cannot be directly 
computed, however an estimate T
2
 can be made where  
(16) 
 
and the dispersion can be understood in the same scale as the effect size by 
calculating the estimated standard deviation T (Borenstein et al., 2009).  If Q< df then T
2
 
is set to 0 as it is not possible to have a negative variance (D. B. Wilson, 2011b), and if 
Q> df the T
2
 is positive and  
(17) 
 
In a similar way to the standard deviation in primary research, T can be used to 
describe the distribution of the effect sizes about the mean (Borenstein et al., 2009).  T 
gives a greater understanding of the range of the true effects about the mean.  If T is 
small there is a relatively limited range of values for the true mean, if T is larger the 
range of values within which the true mean falls is much larger.  
To facilitate understanding and interpretation of results, and to overcome the 
known Q bias of poor detection of heterogeneity in an analysis where there is a small 
number of studies, and a bias towards excessive power with large numbers of studies, 
Higgins I
2
 is calculated (Higgins, Thompson, Deeks, & Altman, 2003).  The Higgins I
2
 
statistic “quantifies the effect of heterogeneity, providing a measure of the degree of 
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inconsistency in the studies’ results” (Higgins et al., 2003).  The I2 statistic helps to see 
what part of the variance observed is the real difference in effects size providing a view 
of how much of the total variance is the true difference.  The I
2
 statistic is a descriptive 
statistic (Borenstein et al., 2009) that is an indication of the level of inconsistency 
between the studies and not a measure of the real variation (Borenstein et al., 2009).  It 
can be used to indicate if there is a need to explain the variance.  If I
2
 is small then it is 
reasonable to assume that the variation is an artifact of the analysis. If I
2
 is medium to 
large (>50-75%) (Higgins & Thompson, 2002; D. B. Wilson, 2011b) then additional 
analysis is appropriate.  For example, where there is a large inconsistency it would be 
appropriate to break the studies into subgroups to try to assess where the inconsistency 
lies.  In this study, it was expected that one of the subgroups would be the different 
instruments that were used, and in fact the most productive analysis was at this level.  I
2
 
is calculated with the following formula: 
(18) 
 
Or alternatively if required in the effect size metric rather than standardized form. 
(19) 
 
While formulae exist for the calculation of confidence intervals for I
2
, the 
recommendation is to use I
2
 as a descriptive statistic to supplement Q as the sampling 
116 
 
 
distribution is derived from the sampling distribution of Q and therefore the power 
characteristics will be the same as Q (Shadish & Haddock, 2009, p. 263).  Negative 
values of I
2
 are set to zero, with possible values ranging from 0-100%. 
Graphical Methods 
There are several graphical methods of displaying results from a meta-analysis 
that can assist in the interpretation as well as the presentation of the findings.  The 
L'Abbé plot is used in meta-analysis to show variations in observed results that are 
plotted with the event rate in the treatment group on the vertical axis and that in the 
control group in the horizontal axis (Song, 1999).  This study was not a meta-analysis of 
clinical trials but rather of survey type studies so there was no reason to use a L'Abbé 
plot.  A scatter plot of the studies referred to as a funnel plot of sample size is plotted on 
the vertical axis and the standardized effect size is plotted on the horizontal axis (Higgins 
& Green, 2011).  This provides another alternative way of looking at the different studies, 
but again because of the size of the sample was not realistic for this study.  The forest 
plot is “the new standard for the presentation of meta-analytical findings” (Borman & 
Grigg, 2009, p. 505), although it is less used in the social sciences.  The Campbell 
Collaboration often includes the forest plot, but it is not universal (Borman & Grigg, 
2009).  The forest plot uses text and graphics to display the sample size, the effect size, 
and the confidence intervals of the studies included in the analysis, and to present a 
summary effect size for the whole analysis.   
As with primary studies, in the random effects model for meta-analysis, both the 
mean effect size and the distribution of the true effects about that mean (Borenstein et al., 
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2009) are important.  The confidence interval is the quantification of the accuracy of the 
mean. 
When produced on a forest plot like the example below, the horizontal line though 
each point is the confidence interval associated with that study, the solid vertical line with 
a diamond represents the mean of the analysis. In this example the mean for comparable 
population norms is also plotted (in a dotted vertical line) for comparison.  In this 
analysis the meta-analysis and forest plots in the results section and in Appendix A were 
developed using Microsoft excel extensions (Neyeloff et al., 2012) 
 
 
Figure 6. Example of a forest plot   
 
Note: showing the effect and confidence intervals for studies included and the summary 
effect for a subscale of data from SF-36 data Calculated using the excel extensions in 
Neyeloff et al., 2012, p. 4 which is licensed under a Creative Common license Attribution 
3.0 Unported (CC BY 3.0) 
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Moderator Analysis 
Moderator or subgroup analysis allows for a greater understanding of the 
variation in the mean effects seen in the studies that makeup the meta-analysis.  The first 
step in understanding the variance is to compare the mean effects for studies that fall into 
different subgroups (this is like using an analysis of variance in primary research) 
(Borenstein et al., 2009).  When this comparison is done it can be followed by assessing 
the relationship between the covariates from study to study in a process analogous to 
multiple regression in primary studies (Borenstein et al., 2009; Cooper, 2009).  This 
assessment is done in an attempt to gain an understanding of the variability in the 
distribution of effect size estimates (Ellis, 2010).   
Multiple moderator analyses were planned. The first analysis that was planned 
was of the categorical moderator of the measurement instrument.  An analogue if the 
ANOVA procedures using code for SPSS (D. B. Wilson, 2010b) was planned to be used 
to perform the moderator analyses as all were categorical variables.  Looking at the 
variance in effects from one instrument to another would have allowed for an indication 
if the instruments impact the effect size.  For example, does measuring HRQOL using a 
FACT – B, instrument have a significantly different mean effect than if the EORTC 
QLQ-C30- BR-23 were used?  Looking at the studies grouped by those that used multiple 
instruments and those that used more comprehensive instruments to see if there was a 
significant difference in mean effects also had the potential to shed light on the impact of 
the instrument.  Unfortunately, the number of studies available meant that the moderator 
analysis was not possible, and the comparison across instruments severely limited.  
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It was planned that if during coding of studies data on SES and age were 
sufficiently reported in the studies a moderator analysis would also be executed.  For 
example, if age were coded in enough studies to allow subgroups of studies and effect to 
be identified, the analysis may have shown differences in HRQOL for women of different 
ages.  Variables associated with study methodology, location and approach, and 
recruitment and administration approach were also slated to undergo moderator analysis 
to understand if methodological questions had a significant effect on the findings.  For 
example did studies that were done in single facilities show a difference in HRQOL mean 
effect to those that were population based.  Finally, a subgrouping of studies by HRQOL 
component was planned, to try to add dimension to the outcome of the overall analysis by 
finding if there were differences at the component level of the studies.  None of these 
analyses was possible during the study because of insufficient data. 
Understanding the Quality of the Meta-analysis 
There is a bias towards statistically significant studies in published research (Ellis, 
2010; Lipsey & Wilson, 2001). This bias means that a “fail safe” N, or the number of 
studies that have conflicting evidence that would need to be included to overturn the 
result (Ellis, 2010), should be calculated to understand how likely it is that there is a false 
positive in the meta- analysis. This calculation was not performed as the population size 
was too small to complete the meta-analysis. 
Calculating the power of the analysis. The statistical power of the random 
effects model approach to meta-analysis is impacted by both the within studies and 
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between studies variance (Borenstein et al., 2010).  To facilitate interpretation the 
calculation of the statistical power of the study was planned. 
An analysis of the impact of removing all studies where there was a power level 
less than .50 was planned to see the impact that low powered individual studies had on 
the overall analysis (Ellis, 2010, p. 127), but proved unnecessary. 
Presenting the results of the analysis. The PRISMA guidelines (Moher et al., 
2009) were used as guidance in the presentation of the material with modifications to 
comply with the required Walden template.  This format supports the presentation of how 
the effects were distributed (Cooper, 2009; DeCoster, 2004), why moderator analysis was 
done and what was found, and the correlations between moderators and regression 
models used (DeCoster, 2004). 
Information about the included studies and the outcome of the meta-analysis was 
presented in the form of a forest plot (Borenstein et al., 2009; Cooper, 2009; DeCoster, 
2004; Ellis, 2010; Lipsey & Wilson, 2001), with a discussion of outliers and the possible 
underlying dispersion (DeCoster, 2004).  Information on the total number of participants 
(DeCoster, 2004), and the number of participants in the different race/ethnic categories 
(DeCoster, 2004; Lipsey & Wilson, 2001) was provided for the different analyses 
performed.  The mean weighted effect sizes with their confidence intervals from the 
different studies were presented in the forest plots, (Lipsey & Wilson, 2001, p. 144), and 
the corresponding heterogeneity results are noted (DeCoster, 2004). 
At the very least in this study, a subgroup analysis of the different instruments 
used was planned to be conducted and presented.  Multiple Regression is used in primary 
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studies to allow the assessment of the relationship between “one or more covariates 
(moderators) and the dependent variable” (Borenstein et al., 2009).  An analogous 
process is available for meta-analysis that allows for the assessment of the relationship of 
the study level moderators and the study level effect sizes (Borenstein et al., 2009).  
Software used to do this must be specifically designed for Meta-regression to ensure that 
the study weights and meta- analysis model can be correctly assigned (D. B. Wilson, 
2011a).  On the completion of coding, it was understood that there was not sufficient data 
to complete moderator analysis so a meta- regression was not required. 
Interpretation of the results. In published journals there is a growing 
requirement for the interpretation of results of a meta-analysis to contribute to a greater 
depth of understanding of theory (DeCoster, 2004; Ellis, 2010), or ensure that the 
findings are reported in plain language, driven according to Ellis (2010) by journal 
editors requiring that a deeper level of interpretation be provided.  Interpretations should 
take the bare statistics and provide a practical statement of what the findings mean in 
relation to who may be affected, and any consequences of the more comprehensive 
knowledge that is provided by the analysis (Ellis, 2010; Lipsey & Wilson, 2001)  
The interpretation section should also deal with any issues with the study, and any 
implications for future research (DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 2001).  
There are a number of criticisms of the process of meta-analysis that must be 
incorporated in the interpretation and discussion of results.  One of the criticisms of meta-
analysis is that when the studies are combined, especially when they are not simply 
replications of each other, it is like trying to combine apples and oranges (Borenstein et 
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al., 2009; Lipsey & Wilson, 2001).  Rosenthal said that “combining apples and oranges 
makes sense if your goal is to produce fruit salad” (Rosenthal in Borenstein et al., 2009, 
p. 357).  Part of the goal of the interpretation section is to make sense of the “fruit salad” 
that is the outcome of a meta-analysis, and to be able to explain why logically the studies 
that were put together make sense. 
Often the goal of a meta-analysis, as it was in this study, is to broaden 
understanding by looking at research with a different lens (Borenstein et al., 2009).  The 
interpretation of the findings is not necessarily that a common significant effect has been 
found, but rather an understanding of the dispersion in effects and what that can tell us 
about the body of knowledge is also important.  While the meta-analytic approach was 
criticized early for using a single number to describe the body of knowledge under study 
(Borenstein et al., 2009), the interpretation of the outcome of the meta-analysis requires 
more than a single answer.  If there is a dispersion of effects, how big is that dispersion 
and where is it noted is just as important in the conclusions that are reached about the 
analysis.   
This methodology assumes the likely hood of publication bias (Borenstein et al., 
2009; Cooper, 2009) where studies that had null or negative findings might not have been 
reported or published, and that important studies might have been missed (Lipsey & 
Wilson, 2001).  The assumption can be made that not all studies that were relevant were 
uncovered, and it is not possible to even know what has been missed.  Thoughtful 
consideration and open process and documentation at least allow for transparency of the 
approach and interpretation (Borenstein et al., 2009; DeCoster, 2004; Lipsey & Wilson, 
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2001).  Not all studies that are included in a meta-analysis are perfect. However, studies 
that are methodologically suspect, or that are of low power may still have value in the 
overall understanding of the question.  Identifying why studies were included and 
excluded for all reasons in this study was an attempt to overcome the “garbage in- 
garbage out” (DeCoster, 2004, p. 3) criticism that has been leveled at meta-analysis 
(Ellis, 2010).   
The visibility of the process is a component of the interpretation and is part of the 
presentation of the research in an attempt to make finding a poor analysis easier that with 
other forms of aggregation (Cooper et al., 2009; Cooper, 2009; Lipsey & Wilson, 2001).  
The interpretation of the findings will always be impacted by the inability to include all 
possible studies, by the decisions made during the data collection and coding, and by 
research questions that began the process.  An open and meticulously documented 
process that provides clear and open access to decisions made is the best way of ensuring 
that the interpretations of the data can be openly checked and tested. 
Ellis (2010, p. 3) asked the question “So what? Why do this study?”  Meta-
analysis requires the investment of significant effort (Lipsey & Wilson, 2001); within the 
interpretation of the findings is where context and language that is meaningful to non-
researchers is used.  Chapter 5 of this report is where the context of what I found is 
discussed. 
Documentation 
Part of the value of meta-analysis lies in the openness with which the process is 
documented and the thoroughness with which records of the analysis are kept (Borenstein 
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et al., 2009; Cooper, 2009; DeCoster, 2004; Ellis, 2010; Lipsey & Wilson, 2001).  This 
thorough recording inevitably leads to a large volume of documentation.  The 
organization of the data and the meticulous keeping of records require the use of 
electronic storage.  Unless specifically required, no hardcopy of the documentation is 
planned.  Excel spreadsheet documentation of this process, while not included with the 
text of this dissertation, is available and will be retained for a minimum of 5 years. 
Electronic storage has some important advantages for storage of documents.  It is 
easier to disseminate even large documents, and storing multiple copies in various 
locations means that it is easier to protect against total loss of the document.  However, 
there are some negative characteristics of electronic storage that must be addressed.   
The ease with which an electronic document can be destroyed by accident or on 
purpose is an important consideration.  Fortunately, a good backup plan with data stored 
in multiple physical and virtual locations can alleviate that problem.  This document will 
be stored with a multiple stage backup on a personal computer, a network server, in 
physical offsite storage, and in an online storage vault.  Because magnetic media can 
degrade over time, the media will be refreshed at least annually for5 years, at which time 
an evaluation will be made of the need to continue that practice. 
Documents stored electronically are much more malleable than hard copy 
documents if stored in a form that is easily updatable.  There is a trade off in being able to 
copy parts of a document and in keeping it pristine.  The documents associated with this 
study will be stored in Portable Data Format (PDF) a fixed form stable content document 
version that is difficult to change. As spreadsheets cannot be easily stored as PDF, a 
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password protected form of the spreadsheets will also be saved.  All documents will be 
stored with a digital signature to increase the protection.  A backup of the malleable form 
of the document will be kept, password protected, should the PDF ever have to be 
recreated, and should the creating program be upgraded before the decision is made to 
discard the malleable form, the document will be upgraded to readable by the new 
version. 
One of the issues with electronic storage is finding the document.  The PDF form 
and password protected form will be stored with keyword and citation metadata to 
facilitate retrieval and file naming conventions that include author, date and key content 
information will be used.   
There are three concerns when one is using electronic document storage. These 
concerns are related to making sure that the content is adequately preserved, making sure 
that the storage media is robust enough to maintain integrity, and ensuring that metadata 
is stored with the document so that the context of the document and its sources are easily 
searchable.  The storage and backup plans for this document address all of those 
concerns.   
Protection of Human Participants  
As this study was a meta-analysis, there were no human participants in the study. 
Dissemination of Findings  
The final report of the study will be presented for evaluation by the committee 
members.  Publication of findings will be evaluated at the time it is accepted. 
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Summary 
The design for this study was for a meta-analysis based on the SMD effect size 
planned to be calculated between the data for African American survivors and European 
American survivors.  HRQOL as measured by standard instruments was the dependent 
variable, and it was planned that covariates of the instrument used, and if data were 
available socio-economic status and age.  A search of electronic databases was planned 
and executed and the candidate studies processed through coding and analysis.  
Chapter 4 presents the results of the process beginning with a summary of what 
was found and providing detail of key components of the outcome.  More detail of results 
is available in Appendix A.  
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Chapter 4: Results 
Overview 
After conducting an electronic search for articles that included studies where the 
population studied was of women who had been diagnosed with early-stage breast cancer 
more than 5 years previously, and where the HRQOL was a dependent variable, 56 peer-
reviewed articles, dissertations, or reports were entered in the initial coding phase of the 
study.  
The coding phase of the study included articles that examined HRQOL measured 
on standard instruments, where more than one study used an instrument and where 
enough data were provided for either the calculation of SMD or where mean and standard 
deviation were provided.  Only reports that were based on a U.S. population and included 
participants of either African American or European American racial identification were 
included, resulting in the inclusion of 22 reports in the final meta and comparative 
analysis.  Following the research method of strict meta-analysis, one study allowed for 
the calculation of an effect size of the difference between African American and 
European American population HRQOL.  The percentage of African American 
participants was lower in the 22 studies in the analysis phase than in the BCS population 
in general.  Nine studies did not report racial breakup of participants and few reported the 
data for African American and European American populations separately.  
African Americans, when compared to European Americans, showed a negative 
SMD effect size.  There was not enough data to calculate the effect size as in other meta-
analyses.   
128 
 
 
I then turned to the question of HRQOL as operationalized in the MOS SF-36 
(also referred to as SF-36).  The SF-36 instrument has been used in both healthy and 
clinical populations and in both cross sectional and longitudinal studies (Zebrack, 2004).  
It is a standardized, general measure of health status with normative data available from 
the United States population, but not for different racial backgrounds, and is used in 
oncology populations including breast cancer (Zebrack, 2004).  It includes the HRQOL 
dimensions of physical, mental, and social quality of life and is the most evaluated 
HRQOL measure across numerous patient populations (Garratt, Schmidt, Mackintosh, & 
Fitzpatrick, 2002). 
I conducted an analysis of the results from 13 studies that used the SF-36 to 
measure HRQOL.  SMD no greater than 0.07 (i.e. no greater probability than chance) 
were found between the total population of long-term breast cancer patients (including 
both African American and European American participants) and SF-36 population 
norms (1990) for the summary scales of this instrument (Physical Component Scale 
[PCS] and Mental Component Scale [MCS]), and in the subscales of the instruments that 
report on the separate dimensions of HRQOL.  
Insufficient data meant that it was not possible to draw conclusion as to the 
impact of race on the scoring across the subscales.  One study (Chen, 2005) was the only 
study that reported subscale data using the SF-36 for African American (n = 101) and 
European American women (n = 3,150) separately.  Chen’s (2005) dissertation was a 
study of women 5 years post breast cancer from registry data, and it included both 
Canadian and U.S. participants, but only the U.S. data were analyzed for my study in 
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keeping with the criteria set for inclusion.  African American women scored lower on all 
subscales, with an effect size in the low to moderate range.   
The small number of studies that used either the QOL-CS or the Quality of Life 
Index – Cancer Version III (QLI-CVIII) instruments, as well as the lack of population 
norms available for those instruments, meant that few conclusions could be drawn about 
the usefulness of those instruments in this study.   
Research Questions 
1. Compare the effects of survival for more than 5 years post treatment on 
HRQOL of African American breast cancer patients diagnosed with Stages 
0-II with those of patients of European American racial identification. 
Three studies contained a direct comparison of data from African American and 
European American participants.  While a meta-analysis theoretically only requires a 
minimum of two studies (Lipsey & Wilson, 2001), only one study had data that were at 
an overall HRQOL level, and two of the studies provided data on different categories and 
subscales.  Some data analysis was possible to suggest direction and size of effect. 
2. Is enough data available in the population of studies to observe the impact of 
age on the effect size? 
The moderator variable of age could not be assessed due to insufficient data to 
calculate effect size. 
3. Is there enough data on SES in the population of studies to identify its impact 
as a moderating variable?   
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The moderator variable of SES could not be assessed due to insufficient data to 
calculate the effect size. 
4. Can the choice of HRQOL instruments be identified as having an impact on 
the effect size seen in the research? 
Separate analysis was done of the data from the different instruments identified in 
the studies and those data are presented. 
5. Can subgroup analysis identify differences in components of HRQOL? 
Component parts of HRQOL could not be assessed in the population because 
there was not enough data to evaluate the effect size.  For the SF-36 instruments, subscale 
comparisons to population norms were conducted. 
6. The null hypothesis for the study is that the mean effect size is zero (random 
effects model; Borenstein et al., 2010). 
A full meta-analysis could not be performed, so the null hypothesis was neither 
supported nor unsupported. 
The primary result of this study was that I was unable to complete the meta-
analysis as originally planned.  As a consequence, neither the secondary or tertiary 
questions could be answered.  A summary of the data available was completed for those 
studies where an indirect comparison could be made. 
This status was identified at the completion of the search phase of the study.  
Studies that met all criteria except those needed to make the comparison were coded and 
an analysis performed to identify if there was a difference in studies to attempt to answer 
the fourth research question.  It was possible to do a subscale analysis of the most used of 
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the HRQOL instruments (SF-36) and some indication of overall comparison to 
population norms was possible, so the fifth question could be partially answered. 
Process 
 As part of the search for and acquisition of copies of the studies, exclusion 
criteria were applied.  At that point, it was identified that only one study included enough 
data.  The decision was made to continue to code the studies to enable comparison of the 
instruments and an analysis of the data on participation in the studies.  At the completion 
of coding, ad hoc analysis of the sources was conducted.  In keeping with the process of 
meta-analysis, a meticulous accounting of the processes was kept and is available in soft 
copy.  Appendix A includes addition information from the process. 
Study Eligibility Criteria 
Using an adaption from the Cochrane and Campbell Collaborations approach 
(Hammerstrøm et al., 2010; Lefebvre et al., 2011) and from Lipsey & Wilson, 2001(pp. 
16–23) the study eligibility criteria used were set up before the search was initiated.  
During the search process, an additional criterion that excluded studies that had 
multinational populations but that failed to report their data separately was added to the 
eligibility criteria.  The criteria in Table 12 were identified as a minimum for inclusion in 
a meta-analysis. 
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Table 12 
Inclusion Criteria Used in Identifying Studies 
Criterion Status 
Study must be quantitative in nature  All studies were quantitative in nature 
Statistical findings must include sufficient 
information to transform to the effect size SMD 
As mentioned in the introduction only one study 
provided data separately for African American 
and European American women.  The calculation 
of SMD was not possible on more than one study 
so the meta-analysis failed. 
Data of statistical outcomes must be available for 
at least a racial categorization of African 
American and European American or synonyms 
of those categorizations 
While the racial categorization of African 
American and European American was used or 
identifiable in all studies statistical reporting was 
inadequate. 
Racial classification must be that used by the 
American Cancer Society (2010, p. 4) or 
understandable in that context 
All studies had appropriate racial classification. 
Study must use one or more HRQOL instruments 
that were identified in this section or whose 
validity and reliability can be independently 
validated 
Studies used HRQOL instruments identified in 
Table 13.  Two studies were excluded from the 
final total because they were unique in their use 
of instrument. 
Population must be clearly identified and 
preferably participant numbers identified 
This criterion was met 
Study must be in English This criterion was met 
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Criterion Status 
Peer review is not a necessary criterion as it is 
possible that the “gray” literature including 
dissertations or government reports may have 
relevant study information.  If a report is not peer 
reviewed it must be published under some 
authoritative body supervision 
Dissertations were included in the final total.  No 
government reports met the criteria. 
Should a study meet all other criteria for 
inclusion but data is insufficient an attempt was 
be made to retrieve the needed data from the 
author before rejecting the study 
For all study reports that otherwise met the 
criteria and where an author could be identified.  
Communication was attempted to recover the 
data to allow for the analysis.  47 authors were 
emailed.  Two replied, neither has provided the 
data, although both expressed a willingness to do 
so.  One of those authors proved to have a 
primarily non US participant base. 
 
Two hundred and twelve studies were examined in full text using the criteria 
above.  Of these 59 studies that appeared to meet the participant requirements and used 
standard identified quality of life measures, entered the coding phase.  The following 
diagram (Fig 4.1) documents the search using the Preferred Reporting Items for 
Systematic reviews and Meta-Analysis (PRISMA) guidelines (Moher et al., 2009). 
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Figure 7. Search for reports of studies. Numbers returned from process steps and numbers excluded.  
 
Note: Adapted from “Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement,” by D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, 
and The PRISMA Group. (2009), PLoS Med, 6(7), e1000097.  
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Coding Process 
Of the 59 reports of studies that entered coding, 3 studies that used non-
standardized measures were eliminated before entering coding and 34 were excluded 
during the process.  Categories for the reason for exclusion were documented in Table 10.  
In some cases, multiple reasons applied but only the primary exclusion reason was 
documented. 
Eleven studies were excluded based on study characteristics. Four studies did not 
fall within the population boundaries. Three of those were non-USA populations 
(Mosewich, Hadd, Crocker, & Zumbo, 2013; Muss et al., 2008; Zucca, Boyes, Linden, & 
Girgis, 2012). One (Clauser et al., 2008), was for a general cancer population that 
included Breast Cancer patients, but did not provide separate data for the BCS.  Seven of 
the reports used non-standard HRQOL measures or were the only report to use a common 
measure (Boehmer, Glickman, Milton, & Winter, 2012; Caloudas, 2011; Mishel et al., 
2005; Perkins et al., 2007; Porter et al., 2006; Von Ah, Russell, Storniolo, & Carpenter, 
2009; Ziner, 2008) 
Two studies were rejected based on the stage of cancer.  Kornblith et al., (2003) 
did not delineate disease stage but identifies 22% of the sample experienced recurrence.  
In the other study rejected because stage was unclear (Reyes-Gibby, Anderson, Morrow, 
Shete, & Hassan, 2012), while only 13 of the 246 participants were identified as having 
Stage III Breast cancer, 5% were identified as having metastasis, 10% as having 
recurrence and 10% as having a new primary breast cancer.  It was not clear from the 
report if those percentages were additive or refer to the same participants.  
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Thirteen of the reports of studies either had a mean years since diagnosis of less 
than 5 years or a large percentage (>20%) of the participants were less than5 years.  In 
some cases, a few very long-term participants pulled the mean up to over 5 years but the 
majority of the participants were much closer to their diagnosis.  Time since diagnosis 
has been shown to have an impact on HRQOL (Bloom, Stewart, Chang, & Banks, 2004; 
Ganz et al., 1996; Kessler, 2002).  Setting the criteria to 5 years of disease free survival 
agrees with the commonly accepted time of transition into long-term survival (American 
Cancer Society, 2011). Reports that did not include a specification of time since 
diagnosis or where the time since diagnosis was biased towards those who had passed 
less than 5 years since diagnosis had potential to bias the results. 
The final 11 reports that were rejected did not provide data that were usable in 
even the modified analysis that was executed.  These reports fell into two major 
categories.  The first category was where only results where significant statistical analysis 
were reported, or where the reporting was incomplete (Bloom et al., 2004; Bower et al., 
2006; Paskett et al., 2008; Taylor et al., 2012).  These may have been sufficient to 
support the study, but the data were not suitable for meta-analysis.  The second category 
was more numerous and was where the author preprocessed data, adjusting them for age, 
time since diagnosis or for other variables that were the subject of that study (Ahmed, 
Prizment, Lazovich, Schmitz, & Folsom, 2008; Claus, Petruzella, Carter, & Kasl, 2006; 
Ganz et al., 2002; Ma, Carpenter, Sullivan-Halley, & Bernstein, 2011; Moy et al., 2006; 
Tomich & Helgeson, 2002; Von Ah et al., 2012).  While the reporting described in these 
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reports supported the purposes of the studies, the reports were unusable for a meta-
analytic study because there was not a clear indication of the transformation of the data. 
Race as a Variable in Reports Rejected 
Three of the reports that were primarily non-USA participants and were 
disregarded from any participant racial analysis (Mosewich et al., 2013; Muss et al., 
2008; Zucca et al., 2012).  Of the other rejected reports one (Moy et al., 2006; Tomich & 
Helgeson, 2002) reported only “Caucasian” participants, another only that there were n = 
351 “minority” participants and n = 4708 Caucasian participants (Moy et al., 2006).  This 
second was a report of the impact of a post breast cancer drug Letrozole on long-term 
quality of life and Disease Free Survival (DFS).  The category identified as minority 
women did not see any change in disease free survival even thought there was a 
significant improvement for Caucasian women.  In discussing the findings, the authors 
hypothesized that the “Large ethnic variations in allele frequencies and types in the 
aromatase gene between Caucasian Americans, African Americans, Han-Chinese and 
Mexican Americans” (Moy et al., 2006, p. 1640) could be contributing to variations in 
drug action observed.  Moy goes on to point out treatment inequality, and overall cancer 
care may differ by patient race (Moy et al., 2006, p. 1641).  While these comments were 
directed primarily toward drug action and treatment conditions, more granular reporting 
of HRQOL data would have been informative to the questions asked in this dissertation.  
HRQOL data changes were reported only at the level of Minority and Caucasian and then 
only in graph form.  
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Four of the rejected reports (Northouse et al., 1999; Rowley, 2000; Taylor et al., 
2012; Von Ah et al., 2012) only had African American participants (total participants n = 
307), and two reports (Ahmed et al., 2008; Bower et al., 2006) gave no breakdown of the  
participants in the studies.  Several had either no identification of different minority 
participants or no African American participants (Heiney et al., 2013; Ma et al., 2011; 
Polinsky, 1994; Reyes-Gibby et al., 2012; Sammarco, 2009; Tomich & Helgeson, 2002).  
The total number of participants that could be identified in the rejected studies was n = 
19,124 of who n = 17,359 had identification as African American, European American or 
other.  Approximately n = 2268 of those identified were African American (13%), n = 
14,044 (80 %) were European American, and n = 729 (6.3%) were identified as other 
minorities.  These data were approximate as the reporting of actual racial statistics was 
not universal.  Six instruments were used in the rejected studies as reported in Appendix 
A, Table A.4. 
Summary Findings 
The key question of the meta-analysis could not be answered. However, by using 
all of the data available and calculating SMD effect sizes for comparisons between 
African American and European American populations of studies, it was possible to 
develop and overview of the research.   
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Summary of effect sizes for African American and European American long term BCS studies
Study
Sample 
Size
Effect size SMD 
(95% CI)
QLI 326 -0.82(-1.06,-0.59)
Ashing Giwa, 1999 278 -1.46(-1.75,-1.17)
Summary 604 -1.14 (-1.73,-0.54)
Studies differentiated by color of marker
-2.00 -1.50 -1.00 -0.50 0.00 0.50 1.00
 
 
Figure 8. Summary of available effect sizes comparing African American and European American Long-
term Breast Cancer patients using calculated SMD. 
 
This forest plot summarizes the comparison of data derived from four different 
studies all of which used the same instrument the QLI-CV III. This included n = 124 
African American participants (Huff, 2013; Leak et al., 2008) M= 22.75 SD= 5.07 and n 
= 202 primarily European American participants (Keating, 2007; Lee, 1997) was M= 
27.25 SD=5.68.  Giving a SMD of d = -0.8247 with 95% Confidence Interval (CI) of -
1.0571 to -0.5923 v = 0.0141.  This SMD would be considered a large effect size (Cohen, 
1988) and would be expected to be observable in any of the social, economic or clinical 
contexts.  The sample size of this comparison was small and alone would not be 
particularly useful as an overview of the impact.  Q was significant for the fixed effect 
model, so the Random effect model was used.  I
2
 was of a moderate heterogeneity as 
expected when different measures were used. 
 While this was not a traditional way to achieve a SMD, combining studies that 
used the same instrument and therefore the same operational definition of HRQOL at 
least allows for an indication of differences that might be expected between long-term 
survivors of different ethnic backgrounds.  The second component of this comparison 
was the one study where it was possible to estimate the SMD (Ashing-Giwa, 1999a; 
Ashing-Giwa, Ganz, & Petersen, 1999).  The effect size was calculated from the 
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correlation coefficient and accounts for n = 117 African American participants and n = 
161 European America participants with an effect size of –1.4615. 
The total number of African American participants in this group was n = 241, and 
the total number of European American participants was n = 363.  While the numbers of 
participants was relatively modest the ratio of African American to European American 
participants was high compared to the studies that entered into the coding phase.  The 
reports that entered analysis had an African American Component of 8.1%, a European 
American component of 87.7% and other minority component of 4.8%.  Nine reports did 
not identify racial breakdown of participants. 
Additional indications of the direction of the difference between African 
American and European American long-term BCS can be seen in the study where no 
overall score on the SF-36 was available but where the information on the Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores was 
included (Trimble, 1997). The study was conducted with n = 21 African American 
participants and n = 205 European American participants and resulting in a negative PCS 
SMD effect size of -0.017 and MCS of - 0.322.  The second would be considered a small 
effect size (Cohen, 1988) (both indicate that the African American participants scored 
lower than the European participants).  The final study on which differences can be 
calculated (Chen, 2005), had a very large European American sample between n = 3115 
and n = 3159 participants depending on the subscale of the SF-36 being reported and 
between n = 100 and n = 110 African American participants.  The effect size for this 
study comparing African American to European American participants ranges from -0 .5 
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to – 1.1.  This study did not have summary data using PCS or MCS.  SF-36 does not have 
a single measure of overall HRQOL. 
Summarizing these finding suggest that African American population had a lower 
mean than the European American population as seen in the negative SMD effect size.  
While this is insufficient to answer the overall research question definitively, and is open 
to the charge of comparing different levels of HRQOL, the direction of the data found 
provides an indication that there was a difference between African American and 
European American women that that could be considered moderate (d = -0.68 (Figure 
A10) and d = -0.43(Figure A11).  
Analysis 
Reports that Met Criteria 
During the analysis the failure to find reports that provided statistical comparison 
of HRQOL between African Americans and European Americans necessitated an 
examination of the reports that otherwise met the criteria.  The original plan for the 
analysis was to transform the information from the top level of the quality of life 
instruments into an effect size, compare instruments and then compare the results of the 
instruments.  That was not possible with the lack of comparative data that were available.  
The reports for the different instruments have been grouped for separate analysis and 
reporting.   
Descriptors of Sample 
Of the 22 studies that remained after the coding process, six were dissertations or 
theses.  Table A.5 in Appendix A has details of the dissertations that exited coding. 
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The remaining 16 reports were retrieved from nine different journals published by 
six different publishing imprints (see table A.6 for details).  The 31 rejected reports that 
were commercially published were from 21 different journals and 13 different publishers.  
Publication bias is well known in the area of the publication of significant findings being 
more likely and impacting meta-analysis (Cooper et al., 2009; Lipsey & Wilson, 2001).  
Deviations from the Exclusion Criteria in Accepted Reports 
Two reports of the same study were included in the list (Ashing-Giwa et al., 1999; 
Ashing-Giwa, 1999a).  Each contains a component of the necessary information.  Some 
authors chose to publish multiple reports of the same study providing different pieces of 
information in the reports, and often citing the other work (Lipsey & Wilson, 2001).  
These two reports were an example where neither contains all the information that would 
support a meta-analysis.  Calculation of SMD effect size was possible in this study. 
One study (Ahles et al., 2005) includes 3 male BCS (.7% of study population) and 
another (Dow et al., 1996) includes a single male BCS (.3% of the study population).  
Neither of these studies provides separate data for the male participants.  Both of these 
studies used the QOL-CS instrument.  Only three studies used that instrument, so the 
analysis with and without the male breast cancer studies was not possible. 
One study (Dhingra, 2002) has a mean time from diagnosis of 4.2 years.  It 
included only statistics for the higher level SF36 (MCS) and (PCS).  Two other of the 
studies only included those higher level components (Carpenter, Ganz, & Bernstein, 
2009; Casso et al., 2004). 
143 
 
 
Race as a Variable in the Coded Reports 
Slightly more than half of the studies identified the breakdown of the participant’s 
racial and ethnic background.  Twelve studies (13 reports) gave clear breakdown of 
participants, the overall African American participation in these studies was 8.12% 
(n=472), the European American Participation 87% (n=5061), other 4.8% (n=280), 
including two studies that were African American only studies (n=124). Table A.7 in 
Appendix A shows the breakdown of participant numbers in these reports.  A further nine 
studies did not provide a complete or identifiable racial background for participants (n= 
2527).  Table A.8 in Appendix A provides details of these studies.  
Measures Used in the Coded Reports 
There were six different measures of quality of life used in the studies that exited 
the coding process.  A list of which studies used which instruments can be found in Table 
A9 in Appendix A.  
Only one study allowed the calculation of SMD effect size.  However as Lipsey & 
Wilson (2001, p. 38) point out, while it is not often done, a one variable meta-analysis 
using central tendency descriptive statistics is both possible and productive.  The findings 
must involve the same variable, operationalized in the same way, so that numerical 
values have comparable meaning, and that a statistic is used for comparison that allows 
the determination of the standard error (Lipsey & Wilson, 2001).  A separate analysis of 
the data available from the different instruments was carried out using the arithmetic 
mean as the effect size.  Some studies where the mean was available or could be 
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calculated but where the standard deviation was not available cannot be included in this 
analysis.   
Further analysis was possible only with the QLI-CVIII, QOL-CS, and MOS SF-
36 Instruments using the means of the studies.  The three reports (Ashing-Giwa et al., 
1999; Ashing-Giwa, 1999a; Casso et al., 2004) that used the CARES-SF also included 
usage of the SF-36.  Two of those reports (Ashing-Giwa et al., 1999; Ashing-Giwa, 
1999a) were for the same study and do not report mean and standard deviation.  A 
separate analysis of the Cares-SF was not possible. 
The most informative results from the analysis come from the data in the studies 
that used the SF-36 instrument.  Two factors contribute to this, the availability of 
population norms and the number of studies that were done using the instrument.  
Additionally the SF-36 subscales allowed for an investigation of differences across the 
HRQOL spectrum.  However, the SF-36 does not provide an overall measure of HRQOL.  
The (PCS) and (MCS) were the highest level of summary available.  Comparison of this 
instrument with others was impossible in a meta-analysis but allows comparison between 
studies to be effectively completed. 
Description of Analysis Process 
All analysis was done using the meta- analysis calculator described by Neyeloff, 
Fuchs, & Moreira (2012) as an add-on to Excel 2010. 
Comparisons between means in the analysis use the effect size as a measure of the 
difference as the data were meaningful and consistent operationally in each analysis.  
SMD (Cohen’s d) is a scale free measure that allows comparison between groups 
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(Valentine & Cooper, 2003).  Interpretation of the effect size was based on the guidance 
provided by Cohen (1988) of d =0.20 as small, d =0.5 as medium and d =0.8 as large.   
Effect sizes for analysis were calculated using an online calculator from the 
Campbell collaboration (D. B. Wilson, n.d.) and checked with the calculator at University 
of Colorado, Colorado Springs, (n.d.). 
In all cases based on the Q value of the analysis, a random effects model was 
appropriate as p for the Q statistic in the fixed effect model was significant with  = .05.  
Thus, the true effect sizes of the studies can be concluded to vary.  In most of the 
analysis, I
2
 was small i.e. < 20 so that the observed variance in the effect sizes can be 
considered random (Borenstein et al., 2009). 
MOS SF-36 
In a study of quality of life measurement, Garratt et al. (2002) found that the SF-
36 was the most evaluated HRQOL measure across numerous patient populations.  This 
instrument was used in the largest number of studies in the sample that exited coding (13 
studies, 12 reports), most of which reported data on the combined participant sample 
without racial breakdown.  One report (Bloom, Stewart, Oakley-Girvan, Banks, & 
Shema, 2012) reported on two studies of the same population.  
The availability of population norms meant that for the overall population of long-
term BCS (including both African American and European American participants as well 
as those unidentified or identified as other) some indication can be seen in comparison to 
the US population.  In both of the summary scales there was no notable effect size 
observed, nor were the actual differences in the summary mean indicative of observable 
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differences in the economic, social or clinical domains of the population.  In the SF-36 
subscales for the combined population a slightly negative effect size and lower summary 
means were observed compared to the population norm in the Physical scales. An 
approximately equivalent summary and individual mean for the General Health and 
Vitality scales was observed, as were means generally higher than the population norm 
for Social, Emotional Role and Mental Health scales.  None of the outcomes would be 
expected to be observable in the economic, social or clinical dimensions. 
Insufficient data meant that it was not possible to draw a conclusion as to the 
impact of race on the scoring across the subscales with only one study (Chen, 2005) 
having data sufficient to calculate the SMD effect sizes on the summary scales.  This 
study suggests African American participants overall had a lower HRQOL than European 
American participants. 
SF-36 Instrument 
The instrument has been used in both healthy and clinical populations and in cross 
sectional and longitudinal studies (Zebrack, 2004).  It is a standardized, general measure 
of health status with normative data available and has been used in oncology populations 
including breast cancer (Zebrack, 2004).  The SF-36 has a 0.78 or greater test retest 
validity and an internal consistency that varies between 0.78 and 0.93.  It is sensitive to 
changes in function over time and can distinguish differences in clinical status, age and 
race (Zebrack, 2004). 
The questionnaire measures quality of life across eight health domains that are 
both physically and emotionally based.  The domains are physical functioning (PF) role 
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limitations due to physical health (RP), bodily pain (BP), general health (GH), Vitality 
(VT), Social Functioning (SF), role limitations due to emotional functioning (RE), and 
mental health or emotional well-being (MH).  A single item identifies perceived changes 
in health (Ware, 2003).  A 5 point difference is considered clinically meaningful in the 
domain scores (Ware et al., 1993).  
Two summary scores are generated from these eight domains the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS) that account 
for more than 80% of the variance in the subscales (Ware & Kosinski, 2001).  The PCS 
and MCS were developed using norm based scoring with a mean of 50 and a standard 
deviation of 10 (Ware & Kosinski, 2001). 
While several studies have been done to assess the Minimal Clinically Important 
Differences (MCID) to be able to interpret the SF-36 subscale scores for a clinical 
population (Keurentjes, Tol, Fiocco, Schoones, & Nelissen, 2012; Wyrwich et al., 2004; 
Wyrwich, Tierney, Babu, Kroenke, & Wolinsky, 2005), the consensus appears that the 
MCID is relatively illness specific.  So for example asthma and chronic obstructive 
pulmonary disease (COPD) have similar MCID (Wyrwich et al., 2005) for the SF-36, 
MCID for cardiac issues (Wyrwich et al., 2004) or hip replacement surgery (Keurentjes 
et al., 2012) were quite different.  MCID where available were only related to sub scores 
of the SF-36 and no reference could be identified for BCS, or for the summary scales of 
the SF-36.  
A report on the effect size in SF-36 usage in studies (Lincoln, 2000) looked at 
change in percentile rank of the quality of life of the study population in comparison to 
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the population norms for the US.  Lincoln (2000) used only what were considered high 
quality studies, where methodology included randomization and control groups.  A 
change in the PCS or MCS scores of 5 points or an effect size of 0.5 would have social, 
clinical and economic implications (Lincoln, 2000).  No breast cancer or general cancer 
studies were included in this report.  While a change of 5 points in the mean for the SF-
36 cannot be considered conclusive, I used it as a benchmark that would indicate more 
attention should be paid to the results. 
Demographic Information from the Studies that Used SF-36 
Table 13 
Racial Identification of Participants in Studies Including the SF-36 
 
 
 
 
Title Initial Author 
Date 
Pub. 
total 
subjects 
 African 
American  
subjects 
European 
American 
subjects 
Other 
subjects 
Quality of life of younger 
breast cancer survivors: 
persistence of problems and 
sense of well-being. 
Bloom 2012 312 18 227 67 
Complementary and alternative 
therapies among very long-
term breast cancer survivors 
Carpenter 2009 371 
  
335 36 
Quality of life of 5-10 year 
breast cancer survivors 
diagnosed between age 40 and 
49. 
Casso 2004 216 
  
200 16 
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Title Initial Author 
Date 
Pub. 
total 
subjects 
 African 
American  
subjects 
European 
American 
subjects 
Other 
subjects 
Long-term quality of life 
assessment in post-menopausal 
women with primary breast 
cancer 
Chen 2005 2115 92 1972 51  
Functional Impairment and the 
Economic Consequences of 
Female Breast Cancer 
Chirikos 2002 105       
Health-related quality of life, 
age, and comorbidity in breast 
cancer survivors 1 to 12 years 
post-treatment. 
Dhingra 2002 257       
Breast cancer in younger 
women: reproductive and late 
health effects of treatment. 
Ganz 2003 577 67 405 105 
Surviving cancer: A 
comparison of 5-year disease-
free breast cancer survivors 
with healthy women. 
Helgeson 2005 267   251 16 
Associations between lifestyle 
factors and quality of life 
among older long-term breast, 
prostate, and colorectal cancer 
survivors. 
Mosher 2009 321       
Social capital, social support, 
and quality of life among long-
term breast cancer survivors. 
Petersen, D. 2008 387   284 103 
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Twelve studies passed through the coding that used the SF-36 instrument as the 
measure of HRQOL.  In these studies, 989 participants or 18.3% were not identified by 
racial or ethnic background.  The studies included 198 African American participants or 
4.5% of the participants in this group, and 343 or 7.8% were non-African American and 
non-European American.  The remaining participants were 3879 or 87.8% were 
identified as European American. 
Title Initial Author 
Date 
Pub. 
total 
subjects 
 African 
American  
subjects 
European 
American 
subjects 
Other 
subjects 
Relationship of Optimism-
Pessimism and Health-Related 
Quality of Life in Breast 
Cancer Survivors. 
Petersen, L.R. 2008 255       
Long-term survivorship in 
breast cancer: Quality of life at 
five years and beyond 
Trimble 1997 226 21 205   
  Total participants 5409 198 3879 343 
 Identified by race 4430 4.5% 87.8% 7.8% 
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Physical Component Summary Score Analysis 
PCS SF-36
Study
Sample 
Size
Mean (95% CI)
Bloom (10) 2012 312 49.24 (48.13-50.35)
Bloom (5) 2012 312 50.78 (49.79-51.77)
Casso 2004 216 48.89 (47.49-50.29)
Chirikos 2002 105 49.9 (47.99-51.81)
Dhingra  2002 257 48.81 (47.5-50.12)
Ganz 2003 577 50.2 (49.42-50.98)
Mosher 2009 321 44.8 (43.8-45.8)
Petersen, D.  2008 387 49.17 (48.2-50.14)
Petersen, L.R. 2008 255 39.72 (38.23-41.21)
Trimble ALL 1997 172 46.2 (44.53-47.87)
Summary 47.78 (45.9-49.67)
Boehmer 2012 438 37.82 (36.49-39.15)
Carpenter 2009 371 52.67
Chen AA 2005 105 46.30
Chen EA 2005 3224 50.10
Helgeson 2005 267 53.60
Trimble AA  1997 21 45.6 (41.02-50.18)
Trimble EA 1997 205 45.8 (44.2-47.4)
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Figure 9. Forest plot of PCS scores on studies that use the MOS 36 (all versions). 
Note: Studies in red were not included in the analysis but are plotted to indicate how they 
relate to the studies that are included 
 
PCS has a mean of 50 and a standard deviation of 10.  US population norms for 
PCS; M=49.12 SD 10.45 were available from 1998 for female only populations (SF-
36.org, n.d.).  An effect size of d = -0.039 did not reach the criteria of small in comparing 
this population to the general female norm.  As this difference equates to less than 2 
points difference in the mean there would be no indication that this difference would be 
socially, economically or clinically obvious. 
Several studies using the SF-36 could not be included in the analysis but were 
included in the plot for comparison purposes.  One study reported PCS and MCS but only 
reported means without standard deviations or other statistics that could be used to 
calculate confidence intervals (Carpenter et al., 2009).  Two studies reported full statistics 
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for the eight domains but did not report PCS and MCS (Chen, 2005; Helgeson & Tomich, 
2005).  While those can be calculated using the PCS/MCS (Quality Metric, n.d.) 
confidence intervals cannot be calculated for these statistics.  One study (Trimble, 1997), 
reported the African American and European American participants separately.  These 
studies were reported on the forest plots that follow with a single point rather than with 
the confidence intervals, with the associated marker on the chart in red. 
The lowest score of the studies included in the meta- analysis (Petersen et al., 
2008) has an effect size difference from the summary of all included studies of d = -0.16 
which falls short of the threshold for a small effect.   
Seven of the studies had means above the summary mean.  The effect size from 
the lowest (Petersen et al., 2008) to the highest (Bloom et al., 2012) study was d= -0.998 
was large.  The two studies had some different characteristics that may explain this 
difference.  The lowest mean of the group (L. R. Petersen et al., 2008) drew from a 
population who had completed the Minnesota Multiphasic Personality Inventory (MMPI) 
“to address diagnostic or management dilemmas faced by physicians because of the 
suspected intermingling of physiologic and psychological factors” (L. R. Petersen et al., 
2008, p. 19).  Without further information, it was not possible to draw conclusions as to 
the impact of the difference in participants, but it should be noted that there may be other 
factors that impacted the low outlier.  The highest scoring cohort (Bloom et al., 2012) 
were tested 5 years later, and an effect size d = -0.099 showed a slight increase in PCS 
across the cohort amounting to less than two  points of difference and therefore unlikely 
to be clinically, socially or economically impactful. 
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Of the studies that were not included in the meta-analysis but added for 
comparison purposes, three had means lower than the summary mean, all less than two 
points lower than the summary mean.  Both of the small African American samples were 
lower than the summary mean.  Both samples from one of the dissertations included for 
comparison (Trimble, 1997), were lower than the sample mean.  While the large 
European American sample (Chen, 2005) was more than 3 points above the sample 
mean, with a difference of more than 3.8 points between the African American and 
European American samples. 
While population norms were available, not all of the studies used the same 
population normative standards.  Seven of the studies (Bloom et al., 2012; Ganz, 
Greendale, Petersen, Kahn, & Bower, 2003; Mosher et al., 2009; D. Petersen, 2008; L. R. 
Petersen et al., 2008; Trimble, 1997) used the 1990 norms.  In three studies (Casso et al., 
2004; Chirikos, Russell-Jacobs, & Jacobsen, 2002; Dhingra, 2002) the norm used could 
not be determined. 
As this is norm based scoring a second analysis was run on only the studies 
normed using 1990 data.  The following figure 10 presents that analysis.  No comparison 
studies were included as it could not be determined which norms were used. 
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PCS SF-36 1990 normed data only
Study
Sample 
Size
Mean (95% CI)
Bloom (10) 2012 312 49.24(48.13-50.35)
Bloom (5) 2012 312 50.78(49.79-51.77)
Ganz 2003 577 50.2(49.42-50.98)
Mosher 2009 321 44.8(43.8-45.8)
Petersen, D.  2008 387 49.17(48.2-50.14)
Petersen, L.R. 2008 255 39.72(38.23-41.21)
Trimble ALL 1997 172 46.2(44.53-47.87)
Summary 47.2(43.67-49.72) 0
1
2
3
4
5
6
7
37 42 47 52
 
 
Figure 10. 1990 normed studies in for PCS.   
 
The summary mean of this analysis was slightly lower than the full analysis 
above.  Compared to the population mean of 50 (female only norms for 1990 were not 
found, SF-36.org, n.d.), the SMD effect size of d = 0.064 and 2.8 points difference in the 
mean would not be expected to have measurable social, economic or clinical impact.  
Removing the studies that were normed to other standards did not change the overall 
conclusion that the difference between summary mean and the population mean norm 
would not be sufficient to suggest that there would be social, clinical or economic impact.  
The PCS data for the overall population of studies, the SMD effect size between 
the summary mean and the population norm is less than the cutoff point to be considered 
a small effect.  The difference between studies was large and suggests that the use of the 
random effects model in the analysis was appropriate. 
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Mental Component Summary Score Analysis 
MCS SF-36
Study
Sample 
Size
Mean (95% CI)
Bloom (10) 2012 312 51.96(50.85-53.07)
Bloom (5) 2012 312 51.09(50.1-52.08)
Casso 2004 216 46.62(45.22-48.02)
Chirikos 2002 105 50.7(48.79-52.61)
Dhingra  2002 257 47.58(46.27-48.89)
Ganz 2003 577 49.4(48.62-50.18)
Mosher 2009 321 56.4(55.4-57.4)
Petersen, D.  2008 387 52.44(51.47-53.41)
Petersen, L.R. 2008 255 50.75(49.26-52.24)
Trimble ALL 1997 172 51.7(50.03-53.37)
Summary 50.88(49.27-51.93)
Boehmer 2012 438 50.6(49.66-51.54)
Carpenter 2009 371 49.79
Chen AA 2005 105 53
Chen EA 2005 3224 54.5
Helgeson 2005 267 52.8
Trimble AA  1997 21 51.4(46.82-55.98)
Trimble EA 1997 205 54.6(53-56.2)
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Figure 11. Forest plot of MCS scores on studies that use the MOS 36 (all versions). 
Note: Studies in red were not included in the analysis but are plotted to indicate how they 
relate to the studies that are included 
 
MCS has a mean of 50 and a standard deviation of 10 for the total US population 
in 1998.  Using US population norms for MCS female only populations (1998) (SF-
36.org n.d.) MCS has a mean of 50 and a Standard deviation of 10 for the total US 
population in 1998.  Norm for MCS was 48.96 SD 10.67.  An effect size of d = 0.055 
suggests that there was a slightly higher assessment from the long-term breast cancer 
population that from the female population in general but that this effect would not even 
be considered as small.  As this difference equates to a 1.92 point difference in the 
means, there would be no indication that this difference would be socially, economically 
or clinically obvious. 
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The effect size from the lowest (Casso et al., 2004) to the highest (Mosher et al., 
2009) study was d = 1.16 was large.  This effect size translates to a 9.78 point difference 
in the means of the two studies and would suggest an overall difference that should be 
perceptible on a social, economic or clinical level.  
Five of the ten included studies had means lower than the summary mean.  All but 
two of the studies had means higher than the normed sample.  Of the studies that were not 
included in the meta-analysis but added for comparison purposes, only one had a mean 
lower than the summary mean.  Both African American samples (Chen, 2005; Trimble, 
1997) were higher than the summary mean, but the difference was less than 3 points.  
Both of the European American samples (Chen, 2005; Trimble, 1997) were more than 3.5 
points above the sample mean.  In both studies, the African American samples had a 
lower MCS than the European American samples, although the difference would not 
likely have been noticeable, in a social, economic or clinical perspective. 
MCS SF-36 1990 normed data only
Study
Sample 
Size
Mean (95% CI)
Bloom (10) 2012 312 51.96(50.85-53.07)
Bloom (5) 2012 312 51.09(50.1-52.08)
Ganz 2003 577 49.4(48.62-50.18)
Mosher 2009 321 56.4(55.4-57.4)
Petersen, L.R. 2008 255 50.75(49.26-52.24)
Petersen,D.  2008 387 52.44(51.47-53.41)
Trimble ALL 1997 172 51.7(50.02-53.37)
Summary 51.97(50.31-54.77) 0
1
2
3
4
5
6
7
48 50 52 54 56 58
 
 
Figure 12. MCS study data for 1990 normed studies only. 
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As with the PCS a separate analysis was done with only those studies normed for 
the 1990 US population data (SF-36.org, n.d.).  The previous Figure (12) is a forest plot 
of that analysis.  The summary mean of this analysis was slightly higher than the full 
analysis above.  However compared to the population mean of 50 (female only norms for 
1990 were not found, SF-36.org, n.d.), the SMD effect size of d = 0.0595 was less than a 
two point difference with no observable effect in the population expected from that 
difference.  Removing the studies that were normed to other standards did not change the 
overall conclusion that while there was a small difference between summary mean and 
the population mean norm, the difference would not be sufficient to suggest that there 
would be social, clinical or economic impact that could be measured. 
There was a 7 point difference between the lowest mean and the highest in the 
studies.  They were the only studies that fall outside the confidence interval of the 
summary mean and would be considered outliers.  There was not enough information 
available in the studies to do a moderator analysis so that it was difficult to assess if this 
can be attributed to study characteristics or to population characteristics.  A 7 point 
difference in quality of life would suggest differences that were observable.  All others 
studies would not be expected to have observable impacts. 
The MCS data for the overall population of studies, the SMD effect size between 
the summary mean and the population norm was less than the cutoff point to be 
considered a small effect.  The difference between studies was large and suggests that the 
use of the random effects model in the analysis was appropriate. 
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Use of the Random Effects Model in the Analysis of the Component Scales 
Q was significant in the fixed effects model at p = 0.05 for all these analyses 
causing a rejection the null hypothesis of homogeneity and confirming that the variability 
across studies was more than would be expected from sampling error alone. The choice 
of the Random Effects model was appropriate for both of these distributions of effects.  I
2
 
was negative in all analysis and therefore was set to 0 for the random effects model 
suggesting no inconsistency in the Random Effects model. 
MOS SF-36 Subscales 
Nine studies had data that enabled the analysis of the summary mean for the 
subscales of the SF-36.  The following studies were included in the subscale analysis. 
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Table 14 
Studies Included in the SF-36 Subscale Analysis 
 
The following chart compares the means for the subscales in the meta- analysis of 
the studies with that of the population norms.  These population norms are for the total 
Study Title First author 
Date 
Pub. 
Quality of life of younger breast cancer survivors: persistence of problems 
and sense of well-being. 
Bloom 2012 
Long-term quality of life assessment in post-menopausal women with 
primary breast cancer 
Chen 2005 
Functional Impairment and the Economic Consequences of Female Breast 
Cancer 
Chirikos 2008 
Breast cancer in younger women: reproductive and late health effects of 
treatment. 
Ganz 2003 
Surviving cancer: A comparison of 5-year disease-free breast cancer 
survivors with healthy women. 
Helgeson 2005 
Associations between lifestyle factors and quality of life among older long-
term breast, prostate, and colorectal cancer survivors. 
Mosher 2009 
Social capital, social support, and quality of life among long-term breast 
cancer survivors. 
Petersen, D. 2008 
Relationship of Optimism-Pessimism and Health-Related Quality of Life in 
Breast Cancer Survivors. 
Petersen, L.R. 2008 
Long-term survivorship in breast cancer: Quality of life at five years and 
beyond 
Trimble 1997 
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US population for 1990(Quality Metric, n.d.), the SMD effect sizes were calculated using 
the online calculator available from the Campbell Collaboration website (D. B. Wilson, 
n.d.). The differences were summarized in Fig 13 that follows. 
In the chart, the effect size follows the subscale name and the absolute difference 
in mean between the subscale summary score and the population mean is in brackets 
following that.  No SMD effect size reaches the criteria for small.  From this analysis the 
subscale means would not be expected to have any discernable social, economic, or 
clinical difference for long-term BCS from the general population.  Detailed data on the 
subscale analysis is provided in Appendix A. 
Two absolute mean differences in the (PF) and (PR) scales were just over the 5 
point threshold of what might be observable.  The trend that in the Physical subscales the 
study population scores slightly lower and the Mental subscales the study population 
scores slightly higher can be observed, but the differences were small. 
 
Figure 13. Summary analysis subscale means and 95% CI intervals compared to population norms for 
studies that used SF-36.  Norm =1990 US general population. 
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Overall Observations of the SF-36 Data 
As the analysis done on the studies used a meaningful statistic, the dispersion of 
studies around the summary mean and in comparison to the population norms provided 
insight into how wide the differences were in the studies.  One study (L. R. Petersen et 
al., 2008) consistently reported the lowest means on the subscales except for the Physical 
Functioning (PF) and Physical Role (RP) subscales.  This study did not appear to be an 
outlier in the MCS analysis but did report the lowest study mean on the PCS.  This 
difference reflects that the PCS was not just developed from the two physical scales but 
also includes input from other scales (Ware & Kosinski, 2001).  The summary scales do 
not always give a clear indication of the source of variation using this instrument.  
As there was not always a clear relationship between results on subscales and 
results on the summary scales the subscale scores can be informative.  The European 
American population in Chen’s (2005) study consistently has either the highest or second 
highest mean across six of the eight subscales (RP, BP, V, SF, RE, MH) but did not stand 
out in the analysis of either the MCS and PCS.  Conversely Mosher et al. (2009) shows 
up as a high outlier in three subscales (SF, RE, MH) and both of the MCS analysis. 
There was however a consistency with a slightly lower analysis mean compared 
to the female population norm for PCS, and lower PF, PR, and BP assessments from the 
long-term BCS.  Likewise, an indication of better than the norm status on the MCS was 
consistent with the analysis means for the V, SF, RE, and MH subscales where the study 
means were equivalent or higher than the population norm. 
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While the summary of the studies included did not show a difference from the 
population norms.  Individual studies do show differences where the difference in the 
mean was greater than what might be expected to be observable in clinical, economic or 
social observations.  
QOL-CS Studies 
The QOL-CS Instrument 
This instrument is modeled after work done at the City of Hope National medical 
Center (Dow et al., 1996).  The QOL-CS is a 41 item self-report instrument that assesses 
the physical, psychological, social and spiritual domains of quality of life using an 11 
point scale with 0 being the worst possible outcome and 10 the best possible (Ahles et al., 
2005).  Test related reliability for the overall tool is reported between r = 0.81 and 0.90 
(Zebrack, 2004, p. 247) and retest reliability for each scale is reported as Physical (r = 
0.88), Psychological (r = 0.88), Social (r = 0.81), and spiritual (r = .90) (Dow et al., 
1996).  Cronbach’s alpha for the entire QOL-CS was reported between r = 0.71 and 0.93 
(Zebrack, 2004, p. 247) and internal consistency for the subscales were Physical (r=0.77) 
Psychological (r= 0.89), Social (r = 0.81), and Spiritual (r= 0.71) (Dow et al., 1996, p. 
266).  These indicate satisfactory reliability (Cimprich et al., 2002, p. 87). 
Survivor scores were observed to be higher than those with active disease 
(Zebrack, 2004, p. 247).  The instrument was designed specifically to measure quality of 
life in cancer survivors and covers psychosocial issues that are relevant to survivorship.  
While it is useful in identifying survivor issues it does not currently support longitudinal 
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changes across the cancer trajectory starting with active treatment phases, nor does it 
allow comparison to normal populations (Zebrack, 2004). 
Table 15 
Studies Using QOL-CS 
Title 
Initial 
Author 
Date 
Pub. 
total 
subjects 
 African 
American 
subjects  
European 
American 
subjects 
Other 
subjects 
Quality of life of long-term 
survivors of breast cancer 
and lymphoma treated with 
standard-dose chemotherapy 
or local therapy.  Ahles 2005 549     21 men 
Age at Diagnosis and 
Quality of Life in Breast 
Cancer Survivors. Cimprich 2002 105 9 96 0 
An evaluation of the quality 
of life among long-term 
survivors of breast cancer. Dow 1996 294   93 
7 other 1 
male 
 
Demographics in the QOL-CS studies. None of the studies that used the QOL- 
CS (Table 15) to measure HRQOL reported results for racial categories separately, and 
they were not consistent in how they reported racial and ethnic differences.  Cimprich et 
al., (2002) reported 96 white and nine non-white.  The other two studies (Ahles et al., 
2005; Dow et al., 1996) do not provide a breakdown of African American participants. 
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There were 22 male breast cancer patients included in the samples for two of the 
studies.  The Ahles study (Ahles et al., 2005) included 50 patients or less than 10% who 
were greater than stage 2.  The overall mean time since diagnosis was 10.3 years plus or 
minus 5.3 years.  So it was possible that some participants were less than5 years since 
diagnosis but that was not identified.  The Ahles study (Ahles et al., 2005) mean and SD 
were calculated from the different group data presented.  As this study also included 
Lymphedema patients and a comparison between patients treated with chemotherapy and 
those treated only with local interventions, and or tamoxifen, long-term breast cancer 
groups were combined to calculate the overall data for the study.  The Dow study (Dow 
et al., 1996) compared patients who had survived greater than 5 years and less than 5 
years.  This study includes data from the long-term survivors.  Dow et al., (1996) also 
used the FACT- G as an instrument in the study.  This analysis did not find sufficient 
studies to do a separate analysis on the FACT- G. A qualitative comparison provided that 
the FACT- G was consistent with the QOL-CS and that Physical subscales were more 
likely to be scored higher than the Psychological subscale, and that the social and 
spiritual subscales fell between them. While interesting, this comparison added little to 
the analysis.  Dow et al., (1996) found that time since diagnosis improves overall quality 
of life in the population studied.  Cimprich et al., (2002) focused on the differences in age 
at diagnosis and found that it was a significant predictor of quality of life, but also that 
longer survival times indicated improved quality of life. 
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QOL-CS studies
Study
Sample 
Size
Mean (95% CI)
Ahles, 2005 172 7.29(7.21-7.37)
Cimprich, 2002 577 7.34(7.32-7.36)
Dow, 1996 321 6.51(6.36-6.66)
Summary 7.06(3.69-10.43) 0
1
2
3
6 7 8  
 
Figure 14. Analysis of studies using QOL- CS as study instrument. 
 
Analysis of studies that used the QOL-CS. The small number of studies that 
used this measure, and the lack of population norms make interpretation of the data 
problematic.  It was difficult to put the studies into context.  It can be noted that the 
summary mean was above the midpoint of the instrument.   
QLI-CVIII Studies 
The QLI-CVIII instrument.  
The QLI-CVIII was developed based on a model of HRQOL that takes into 
account both the assessment of an item and its relevance to the life of the person 
responding (Ferrans et al., 2005). Quality of life scores have been shown to differentiate 
between different symptom level in areas of pain, depression and coping with stress (Lee, 
1997).  The Cronbach’s alpha of 0.95 for the total instrument suggesting high consistency 
within the instrument (Lee, 1997) with BCS (Leak et al., 2008) and a range from  =  
0.85-0.98 across studies (Keating, 2007).  The instrument has four domains confirmed by 
factor analysis and representing 91% of the variance (Keating, 2007) Health and 
functioning, psychological/ spiritual, social and economic, and family (Leak et al., 2008).  
It is scored in a likert type scale where 1 = very dissatisfied to 6 = very satisfied (Leak et 
166 
 
 
al., 2008).  Higher scores represent better quality of life (Keating, 2007).  One higher 
order factor representing overall quality of life was identified (Keating, 2007). 
Table 16 
Studies Using the QLI-CVII Instrument 
 
Title 
Initial 
Author Date Pub. 
total 
subjects 
African 
American 
subjects  
European 
American 
subjects 
Other 
subjects 
Social support, God locus of 
health control, and quality of 
life among African 
American breast cancer 
survivors Huff   2012 94 94 0 0 
Describing psychosocial risk 
factors in breast cancer 
diagnosis and survivorship Keating  2007 102 0 102   
Symptom distress, 
spirituality, and quality of 
life in African American 
breast cancer survivors. Leak 2008 30 30     
Quality of life and breast 
cancer survivors. 
Psychosocial and treatment 
issues. Lee 1997 100 3 88 9 
Totals   326 127 190 9 
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Demographics of the studies using the QLI-CVIII. Two of the studies that used 
the QLI-CVIII were totally African American in participation.  One was only European 
American and one had 3% of the participants identified as African American.  
Huff (2013) did not identify the staging of the cancer diagnosis of the population 
used.  The mean time since diagnosis was 82.80 months which met the acceptance 
criteria, but only 46.7% of the population was greater than 60 months into their cancer 
trajectory.  Huff (2013) found that social support was a predictor of quality of life and 
that those who lived in the suburbs had a higher quality of life than those who lived in 
either city or rural settings.  This study was totally based on an African American 
Population as was the study that investigated how demographic characteristics, symptom 
distress and spirituality related to quality of life (Leak et al., 2008).  It found a 
statistically significant relationship between spirituality and higher quality of life (p<.05) 
and an inverse correlation between higher severe symptom distress and quality of life 
(p<.05).  The mean time since diagnosis was 5.6 years, and no significant relationships 
were found of demographic characteristics and quality of life in this population.  The 
samples size of this study was small, and there was no analysis of the impact of years 
since diagnosis on quality of life.  
A relationship between time since diagnosis and quality of life was found in a 
study focused on how social support impacted quality of life (Lee, 1997).  This study was 
primarily 88% European American with a mean time since surgery of 14 years, with 
more than 40% of the participants having a time since surgery of greater than 13 years.  
In a study of psychological risks in breast cancer survival Keating, (2007) using a 
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European American only population found a moderate to good quality of life in a 
relatively small sample.  This study found a significant negative correlation with 
depression. 
QLI-CVIII studies
Study
Sample 
Size
Mean (95% CI)
Huff,2012 94 21.5(20.49-22.51)
Keating ,2007 102 23.86(22.93-24.79)
Leak,2008 30 26.6(25.56-27.64)
Lee,1997 100 30.71(29.86-31.56)
Summary 226 25.67(22.3-29.04) 0
1
2
3
4
20 25 30
 
 
Figure 15. Analysis of studies using QLI-CVIII as study instrument. 
 
Analysis of the QLI-CVIII data. Two studies primarily of African American 
participants and two of European American participants, using the same operational 
definition of the concept allowed for comparison by deriving summary means from the 
two like studies. These were then a SMD based on dissimilar n was calculated.  
 The grand mean of n = 124 African American participants (Huff, 2013; Leak et 
al., 2008) M=0 22.75 SD=0 5.07 and for the n = 202 primarily European American 
participants (Keating, 2007; Lee, 1997) was M =0 27.25 SD =5.68.  Giving a SMD of d = 
0.8247 with 95% Confidence Interval (CI) of -1.0571 to -0.5923 v = 0.0141.  This effect 
size would be considered large and would be expected to be observable in any of the 
social, economic or clinical contexts.  The sample size of this comparison was small and 
alone would not be particularly useful as an overview of the impact.   
Conclusion 
The results of the analysis of the 22 studies in the final study population suggest 
that overall long-term survivors of early-stage breast cancer when all racial backgrounds 
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were included do not differ from the general population in a way sufficient to assume 
there would be any noticeable difference in their assessment of their HRQOL in social, 
clinical or economic dimensions. 
For the small sample of data where African American and European American 
women could be compared, a difference in effect size that ranged from medium to large 
suggest that African American women may have assessed their survival at a lower level 
than European American women.  That this outcome may be subsumed in most reports 
because of the lower participation of African American women in studies, or the failure 
to report data separately for races as the difference did not reach significance in a 
particular study.  In the small number of studies where data could be compared, the 
percentage of African American participants was higher than the overall study population 
and higher than the percentage of African American women reported in the overall breast 
cancer survival population (Susan G. Komen Circle of Promise, 2009). 
Data available was insufficient to assess if different instruments had an effect on 
the outcome.  Only one instrument had sufficient data to examine the components for the 
overall sample including all races, which showed no appreciable difference from the 
population norms.  Only one study had data to allow the calculation of the effect size for 
the difference between African American and European American women, so analysis 
was not able to be conducted at the subscale level.  The small number of studies in both 
the QOL-CS and QLI-CVIII study populations as well as the lack of population norms 
available meant that few conclusions could be drawn about the usefulness of those 
instruments in this study.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
Overview 
Why the Study Was Done 
A large and growing number of women survive early-stage breast cancer for more 
than 5 years (American Cancer Society, 2011).  About 12% of those women were of 
African American racial designation (Susan G. Komen Circle of Promise, 2009).  Long-
term breast cancer survival may have additional impacts than those noted in short-term 
survival.  Some of these differences can be captured using HRQOL as the outcome 
measure (Lipscomb, Gotay, & Snyder, 2004b). 
The impacts of long-term survival may be different because of racial 
identification or because it is a proxy for other cultural or socioeconomic factors that lead 
to a different experience of chronic illnesses such as breast cancer (Vin-Raviv et al., 
2013).  In addition, there may be disparities in the treatment of patients of different racial 
identification that show up in long-term impacts (Bradley et al., 2001; Dignam, 2000; Li 
& Malone, 2003). 
The review of the literature presented in Chapter 2 provided contradictory 
evidence of a difference between African American and European American long-term 
BCS, especially when the domains of HRQOL were examined.  An understanding of if 
there was a difference, how big it was, and where it was most visible would allow more 
effective research into the problem and provide direction for changing the way that 
women of different races were treated after a breast cancer diagnosis. 
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How the Study Was Done 
A meta-analytic approach was chosen to allow the extensive literature on breast 
cancer survival to be identified and selected for analysis to determine if there were data 
available to determine if there was a difference between African American and European 
American long-term BCS (Chalmers, 2007; Cooper et al., 2009). 
Electronic searches of databases returned 59 reports, dissertations, and articles 
that met the predetermined criteria and that were entered into the coding phase of meta-
analysis.  Of those 59 documents, 22 studies were identified that could theoretically 
match predetermined criteria.  A meta-analysis requires that at least two studies would be 
available for comparison (Lipsey & Wilson, 2001).  Unfortunately, during the search it 
was identified that only one study, reported in two different reports, (Ashing-Giwa et al., 
1999; Ashing-Giwa, 1999a) provided the data for comparison of African American and 
European American BCS on the dependent variable of this study, HRQOL.  While SMD 
was the effect size that was planned to be used for this study, there were no data to 
calculate it as a comparison between African American and European American women 
for most studies.  While it is not often done, it was possible to do a meta-analysis on the 
mean of studies (Lipsey & Wilson, 2001) and consequently, the studies were coded to 
identify where possible comparisons for the total population of BCS could be compared 
across HRQOL instruments. 
Studies that fell into groups that used the same instrument were compared using 
meta-analytic techniques.  By using the mean as the effect size statistic for those 
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techniques, it was possible to find summary data that were both meaningful and usable 
when I could compare them to population norms. 
The Questions Asked 
The primary question pertained to the difference, if any, between the way African 
American and European American long-term BCS perceive their survival as measured by 
HRQOL.  In addition, there were several questions related to testing moderating 
variables, socioeconomic factors, age, or the instrument used.  I hoped that the various 
domains of HRQOL including at least physical, mental, social, and perhaps spiritual, 
could be differentiated and could be seen to impact the perception of long-term survival. 
The Findings 
Only one study reported in two different reports, provided data at the level of 
overall HRQOL that allowed a SMD to be calculated between African American and 
European American participants (Ashing-Giwa et al., 1999; Ashing-Giwa, 1999a).  
African Americans, when compared to European Americans, showed a negative SMD 
effect size that fell in the moderate to large range.  There were not enough data to 
calculate the effect size for multiple studies. 
An analysis of HRQOL as operationalized in MOS SF-36 was conducted on 13 
studies that used that instrument.  The SF-36 is a standardized, general measure of health 
status with normative data available from the United States population, but not for 
different racial backgrounds, and it has been used in oncology populations including 
breast cancer (Zebrack, 2004).  SMD no greater than d = 0.07 (i.e. no greater probability 
than chance) were found between the total population of long-term breast cancer patients 
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(including both African American and European American participants) and SF-36 
population norms (1990).  These findings were for the summary scales of the SF-36, 
(PCS and MCS) and the subscales that report on the separate dimensions of HRQOL.  
It was not possible to draw conclusion as to the impact of race on the scoring 
across the subscales.  Only one study (Chen, 2005) reported subscale data using the SF-
36 for African American (n = 101) and European American women (n = 3,150) 
separately.  This dissertation was a study of women 5 years post breast cancer from 
registry data; it included both Canadian and U.S. participants, but only the U.S. data were 
analyzed for my study in keeping with the criteria set for inclusion.  African American 
women scored lower on all subscales with an effect size in the low to moderate range.   
The small number of studies that used either the QOL-CS or the QLI-CVIII 
instruments did not allow further analysis of the studies that used those instruments. Lack 
of population norms available for those instruments meant that no further interpretation 
was possible. 
The percentage of African American participants was lower in the 22 studies in 
the analysis phase than in the BCS population in general.  Nine studies did not report 
racial breakup of participants and few reported the data for African American and 
European American populations separately.   
The Interpretation of Findings 
The primary interest of this research was to understand if there was a difference 
between African American women and European American women in how they 
perceived survival from breast cancer.  The criterion for inclusion was that the women 
174 
 
 
had to have been diagnosed with early-stage breast cancer and be at least 5 years post 
diagnosis.  The outcome measure was operationalized to be a standard measure of 
HRQOL. 
Forty studies were found where the population was consistent with the criteria and 
of these, only one allowed for the calculation of SMD between the HRQOL measure for 
African American and European American BCS (Ashing-Giwa et al., 1999; Ashing-
Giwa, 1999a).  Other studies allowed for the calculation of the effect size for a 
component of the SF-36 instrument.  These studies were at either the summary level of 
the PCS and the MCS, the two summary scales of the SF-36 (Trimble, 1997) or at the 
subscale level for the eight different subscales that make up the SF36 (Chen, 2005).  An 
effect size using four studies that used the QLI-CV III was calculated. Two of the studies 
had n = 124 African American only participants (Huff, 2013; Leak et al., 2008) and two 
had n = 202 primarily European American participants (Keating, 2007; Lee, 1997). The 
SMD statistic produced a large effect size (Cohen, 1988) and would be expected to be 
observable in any of the social, economic or clinical contexts. 
 The outcome of this study was that there was no possibility of conducting a valid 
meta-analysis. Studies where the statistic could be calculated gave a medium to large 
effect size suggesting that there would have been an observably lower quality of life for 
long-term African American BCS that for their European American counterparts. 
As an alternative analysis approach and to attempt to see if the data found would 
suggest other avenues of research, an analysis using meta-analytic techniques was done 
using the mean and standard deviation statistics that were provided for the overall 
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population samples in 22 studies.  These studies did not provide data to analyze racial 
differences. A comparison of long-term breast cancer patients of all races with the overall 
population norms would indicate if the research showed lower HRQOL across the BCS 
population or if only the case in the small number of studies that showed a difference in 
the African American population. 
Only one instrument had population norms for a racially integrated population.  
The SF- 36 was the most used instrument in the studies found (13 studies) and provided 
population norms against which to compare the summary findings.  Other instrument 
groupings could not be compared in this way.  The findings for the SF-36, total 
participant population suggested that there would be no observable difference between 
the long-term breast cancer participants and the general US population in HRQOL in the 
clinical, economic or social dimensions. 
The review of the literature before the meta-analysis was attempted suggested that 
there would be differences between the populations and that at least on some HRQOL 
dimensions there would be effect size differences that were observable (Giedzinska et al., 
2004; Paskett et al., 2008).  Differences seen in the literature between African American 
and European American BCS included their coping strategies, treatment methods, and 
life impact (Ashing-Giwa, Padilla, Tejero, Kraemer, et al., 2004).  Other differences 
including physical functioning (Bowen et al., 2007; Deimling et al., 2003; Paskett et al., 
2008), emotional functioning (Ashing-Giwa et al., 2007; Bowen et al., 2007; Giedzinska 
et al., 2004) and social functioning (Bourjolly et al., 1999) were observed. 
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During the coding phase reports that used nonstandard instruments or where only 
one study used an instrument were excluded if a SMD could not be calculated.  Two 
reports of the same study (Mishel et al., 2005; Porter et al., 2006) that had interesting 
information as to the survival of African American and European American women and 
the differences observed, used a quality of life measure that was focused on mood states 
as their primary measure.  They were the only studies that used that measure so even at 
the lowest level comparison of grouping studies by instrument there was no statistical 
comparison that I could make.  In these studies approximately 29% of participants were 
African American (n = 149 from a study total of n = 509 participants). The studies used 
the data from an intervention to support develop a causality model for negative mood 
states.  Data were not provided in either report of the different scores for African 
American and European American women and the only comment was "There was no 
significant change on the total POMS or any of the subscales” (Mishel et al., 2005, p. 
973). 
While most of the findings of these two studies suggest that there were 
similarities between African American and European American long-term survivors. The 
analysis of the antecedents for negative mood state suggests that there were differences 
especially related to physical health problems. The authors suggest these issues may be 
reflective not only of a greater burden carried by African American women but also of 
difficulties dealing with the health system (Porter et al., 2006).  For European American 
women greater distress over symptoms that continue from breast cancer treatment were 
more indicative of negative mood states (Porter et al., 2006).  No differences between 
177 
 
 
groups were noted in the effects of religious participation or social support. Using 
cognitive reframing was much more important in the African American participants in 
ameliorating negative emotions. According to the authors this finding is related to the 
identified propensity (Bower et al., 2005) of African American women to be able to find 
meaning in adversity (Porter et al., 2006). 
From the literature review and from the studies that did not report statistically 
usable data there were indications of a difference in the experience of women of different 
races in long-term survival.  The failure of this meta- analysis means that the support for 
the differences found in the literature was limited. Where the effect sizes could be 
calculated the findings suggest that differences between African American and European 
American long-term breast cancers survivors were observable in clinical, social and 
economic dimensions.  What was most surprising was that when the general participant 
population was compared to the general US population there were no differences, yet 
where there was the possibility of comparison of African American and European 
American survivors there was a distinct and noticeable difference with a large effect size.   
The secondary questions of the moderating effect of SES and age on the results 
could not be answered due to lack of data to answer the primary question.  While data 
were available to analyze the sub domains of HRQOL in the SF-36 no difference from 
population norms was apparent when the participant population in total was compared to 
the US population norms for the total population.  It was impossible to compare different 
instruments to see if there was an effect size variation for different instruments in the 
same population.  None of the secondary questions proposed were able to be addressed. 
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Implications of the Findings  
While many researchers included African American women in their populations, 
there was almost no reporting of results separately.  It is possible that no difference was 
found so none was reported, although noting the lack of difference would be appropriate.  
Some difference would have been predicted based on both qualitative and quantitative 
findings and literature that did not constrain the population to long-term survival 
(Ashing-Giwa, Padilla, Tejero, Kraemer, et al., 2004, Bourjolly, et al, 1999; Bowen et al., 
2007; Deimling, et al., 2003; Paskett et al., 2008).  There were reports where small but 
clinically observable differences between African Americans and European Americans 
were noted (Paskett et al., 2008; Ye et al., 2012).  
Studies that did not report differences sometimes commented on the difference in 
quality of life for different racial backgrounds.  Ganz (2003 p4190) said “better quality of 
life was significantly associated with being African American” as compared to European 
American.  Chen(2005), who did report different statistics with a negative and medium to 
large effect size, noted that African American women were more likely to have physical, 
physical role and mental health impacts on quality of life that were clinically different to 
European American women.  Trimble (1997) who again reported differences with effect 
sizes in the moderate range commented that race did not impact quality of life.  
In a retrospective study based around a clinical trial of Letrozole in long-term 
early-stage breast cancer patients (Moy et al., 2006) it was noted (p. 1640) that the action 
of the drug was different in minorities in that it did not promote disease free survival.  
This action was thought to be related to how the drug acts on genetic patterns that were 
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observed in different minority populations.  This hypothesis supports the need for 
research that distinguishes the differences for minority women and reports the data to 
allow treatment and care decisions to be made based on the needs of the women involved.  
Moy identified these differences, but the published paper did not report results by race 
just for minority women in total.   
Even if no differences were observed between African American and European 
American women in survival research, because there were a number of contradictory 
findings in the area, having access to the data would allow meta-analysis.  An attempt 
was made to contact 47 report authors where data appeared to have been collected, but 
not reported, or where the reporting was only at the highest population level.  Two 
authors responded positively but were unable to provide data. 
The proportion of African Americans in the study population was relatively small, 
so it was possible that that the researchers did not consider it important to report the 
results separately.  I am not the first to note the small number of African American 
participants in breast cancer research studies.  Ashing-Giwa and Ganz (1997) executed a 
qualitative study of African American women and breast cancer.  This study was in 
response to their observation that the numbers of minority women included in breast 
cancer survival studies was too small to be able to draw conclusions (Ashing-Giwa & 
Ganz, 1997).  Twelve studies of the 22 reported racial breakdown with African 
American’s accounting for 8.12% of the study population, if the two African American 
only studies are removed the African American participant percentage falls to 6.12% or 
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about half of the 12% calculated in the total survivor population.  It was easy to see why 
results would get lost in the much larger European American numbers. 
Publication bias is always an issue that must be considered in a meta-analysis 
(Lipsey & Wilson, 2001) and the failure to find suitable studies must be considered 
potentially as symptom of publication bias where no statistically significant findings were 
being published (Ellis, 2010) or as  a reflection of the state of minority research in 
psychology (Hartmann et al., 2013).  The publication of material that focused awareness 
on health disparities between European Americans and American Ethnic Minorities by 
the Department of Health and Human Services in 2001 and a change to APA guidelines 
in 2003 emphasized the need for psychological research with ethnic minorities. These 
publications might have been expected to prompt a change in the focus on ethnic 
minorities (Hartmann et al., 2013).  Of the nine reports that did not identify their 
participant by race seven were older than 2003 and one of those was the dissertation.  
Conversely 12 did identify racial background of participants, and seven were newer than 
2003, and 3 of those were dissertations.  
The source of the reports for this analysis does reflect one trend that Hartmann et 
al., (2013) pointed out; the greater publication of psychologically oriented minority 
focused research in health and medical journals.  All of the non-dissertation reports of 
studies were published in what could arguably be considered medical and health journals 
see Appendix A for details.  Finally, the lack of separate reporting may be directed from 
editorial policy dictated by the same subtle bias or simply based on required reporting 
approaches and space requirements.  Without input from researchers and editors it was 
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impossible to know but opens up and interesting research question as to why the data 
were not reported separately. 
The small numbers of African American participants is not a new issue in Cancer 
related research although it was obvious in this study.  Attempts to develop a culturally 
appropriate and sensitive recruitment strategy (Ashing-Giwa, 1999b) met with limited 
success.  An attempt to develop minority focused research design (Ashing-Giwa, 2005a) 
was more successful (Ashing-Giwa, Padilla, Tejero, & Kim, 2004). This study introduced 
a non-standard set of HRQOL instruments and failed to report statistics that could be 
combined in this meta-analysis. 
Initial concern over the inclusion of research of different quality (DeCoster, 2004; 
Ellis, 2010; Lipsey & Wilson, 2001) proved to be relatively irrelevant to this study as 
there was not enough research to conduct the meta-analysis.  Studies were coded by type 
of research conducted and showed that the quality of research did not matter; the data 
were not reported in a way that could enable the analysis. 
Implications for Social Change 
In might be expected with a failure of the research to come to definitive 
conclusions that there would be little support for the social change agenda, in fact, the 
failure reinforces the need for greater knowledge about the long-term consequences of 
breast cancer for African American women.  That there was so little separate reporting of 
findings in the studies and that the participation rates were so small in the studies that 
were found means that studies that were based primarily on the European American 
population should not be generalized to the African American population automatically.  
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Even though on comparison the differences between the total participant population and 
the total norm population did not show effect sizes big enough to be observed, the small 
amount of data from multiple sources suggests that there was a difference, and it still 
needs to be examined and defined. 
Calls of researchers for higher participation from minorities, especially African 
Americans in biopsychosocial research (Ashing-Giwa, Padilla, Tejero, & Kim, 2004; 
Ashing-Giwa, 2005a; Hartmann et al., 2013) are more important than ever as the makeup 
of the US population changes (Hartmann et al., 2013).  It is also more relevant as 
research emphasizes that race can have impacts in the type of treatment and the social 
and psychological impact of chronic disease (Krieger & Sidney, 1996).  Even though it 
proved impossible to integrate the current research, there were enough indications from 
what was found to provide support for further inquiry and for continued focus on 
changing the way participants are recruited into studies to ensure appropriate minority 
involvement. 
Recommendations for Action 
It was disappointing and frustrating that after an extensive search, and despite the 
amount of research being conducted, and the intersection of two hot topics, Breast Cancer 
Survival and Minority experience of illness, I was forced to admit that the quality of 
research was questionable.  Some of the most published researchers failed to report 
statistics on dispersion in their findings.  Other researchers adjusted their data without a 
clear indication of the manipulations they had executed. In reality these actions suited the 
purposes of the study, report or journal, but made inclusion of the data into a meta-
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analysis, or replication of the work unlikely.  The failure to report minority statistics, 
even when reporting that there were minority participants in the study, and in some cases 
noting differences in text, provided an object lesson in good reporting practices.  
It was hard to make a failure into a call for change.  But I believe that this requires 
just that.  The findings of this research would have been important if the summary 
showed a difference between the African American survivors and the European 
American survivors. It would have been important if no difference was apparent.  It was 
just as important that identification of the issues with the data as well the need for further 
diligence in recruitment of participants and the reporting of findings be highlighted and 
published.   
Recommendations for Further Study 
The primary question of the dissertation requires further investigation.  Finding 
out if there is a difference in HRQOL for African American and European American 
long-term BCS needs to be done on a large enough and geographically diverse enough 
participant base, with an oversampling of African American participants to try to 
determine a detailed enough answer to support action.  Likewise, information on age and 
SES to enable the examination of these moderators is still required. 
Many authors in this area have mentioned the importance of not only looking at 
overall HRQOL but also of understanding the how the underlying domains were 
distinguished (Cella et al., 1993; Chalmers, 2007; Osoba et al., 1997; Ringdal & 
Ringdal, 1993; Schag et al., 1991).  This lower level of data of physical, psychological, 
social and spiritual domains also needs to be examined.   
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The proliferation of instruments in measuring HRQOL, and the differing 
operational definitions of the concepts embodied in the instruments (Lipscomb et al., 
2004b; Zebrack, 2004) made the combination of data from different studies difficult.  
Meta-analysis requires that the effects being combined arguably represent the same 
concept (Cooper et al., 2009; Lipsey & Wilson, 2001).  Little work was found that 
compares the instruments, and few of the instruments had norms available for BCS and 
matched populations.  This valuable way of looking at the experience of women would 
be more powerful when the kind of information available about more established 
measurement approaches is available. 
There is an opportunity to use evolving technology in support of developing 
information from data.  The development of databases of research data that would allow 
the integration across published and unpublished data opens up the possibility for 
research to be consolidated more easily.  This kind of database would provide the 
opportunity for more effective synthesis and analysis using techniques of data-mining 
and data- analytics that were beyond the scope of this dissertation and not possible 
without a repository of data.   
A cost/benefit analysis of initiating a curated or non-curated Database for the 
housing of research data in this area needs to be examined.  Databases and data sets 
already exist for research (University of Illinois, 2013) and the “value of curated 
databases lies in the organisation, the annotation and the quality of the data they contain” 
(Buneman, 2009 abstract).  Non-curated databases are becoming more possible and are 
less expensive to maintain, but may allow the issue of non-availability of data, except in 
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summarized or otherwise manipulated forms, to be overcome (Cannon, Howell, Goddard, 
& De Schutter, 2002). 
There is a further need to explore how to increase minority involvement in 
research.  An exploration of the use of social media may provide access to previously 
under-represented minority participants.  Where computers may not have reached into 
minority populations, cell phones and social media may have greater reach (Chou, Hunt, 
Beckjord, Moser, & Hesse, 2009). 
In Conclusion 
Reflection on the Process 
While it is more likely that a qualitative researcher will include their reflections 
on the process of the dissertation, this has been a journey.  I made progress through 
Chalmers’ article on SIDS deaths (Chalmers, 2007) and other medical problems hidden 
by the proliferation of research and unearthed by meta-analysis that provided the insight 
into the power of integrating research from many studies.  The path was illuminated by 
Krieger’s understanding of race and its impacts on health and well-being in the United 
States (Kreiger, 1990), which opened up my understanding of the importance of race on 
the perception of mental and physical health.  This was a journey from frustration with 
the approaches to reporting of research and the inclusion or lack of inclusion and 
distinction among participants, through the newness and therefore lack of rigor in 
HRQOL instrumentation, and the unavailability of raw data.  Even though the meta-
analysis failed, the dissertation added to the knowledge base. This study helped identify 
the bigger problem of how we can integrate the data from the many researchers who are 
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working across the field in such a way as to be able to cross pollinate and inform future 
research. It suggests further work to find a way to make it possible to turn data more 
effectively into information would be useful. 
Conclusion 
The meta-analysis failed through lack of available granular data.  There was 
enough evidence in the literature, from qualitative and quantitative studies and where 
there were enough data to make a comparison, to continue to investigate the difference 
between African American and European American long-term BCS.  This evidence 
supports a continued hypothesis that current data, which do not break out racial or 
socioeconomic differences, mask distinctions that would be visible when examined with 
data of deep enough granularity.  There was evidence of underrepresentation of African 
American women in this research and that even when they were included in the research 
their data were not reported in such a way as to make differences visible.  
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Appendix A: Process Documentation 
This Appendix contains additional information from the search, coding and 
analysis sections of the process followed in this dissertation.  The working of the analysis 
and the development of the forest plots, a spreadsheet of the searches and retrieval from 
each database with the actual syntax used for each data search are separately available on 
request. 
Support Documentation 
Search and Coding Documentation 
The following tables provide further documentation from the process steps 
conducted in the search. 
Table A1 
Search by Step Numbers in Process 
Running total Number Description 
 
8699 Retrieved documents from searches 
4357 4342 Duplicates 
4324 33 Rejected from federal government documents 
4310 14 Not English 
3168 1142 
Wrong stage of cancer, too advanced breast cancer, or related to 
prevention or treatment 
1527 1641 
Drug trials, not breast cancer, not cancer at all, other quality of 
life studies of non-illness populations 
1429 98 Directly related to instruments and validation 
1411 18 Reviews and meta-analysis 
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Running total Number Description 
1373 38 Qualitative studies 
1181 192 Background interest 
  1181 Move to next review process. - read abstracts. 
542 639 rejected on reading abstracts 
213 329 rejected on full text pull 
75 138 
rejected of first coding pass  ( 60 Background interest, 212 meta-
analysis, review, and instrument related, remainder duplicates 
and wrong timeframe) 
 
75 retained in plan 12.3.13 
78 3 added from bibliographies and references 12.3.13 
60 18 
non-standard instruments, population included larger proportion 
of recent survivors than initially identified 
58 2 only one study uses the instrument so comparisons not possible. 
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Table A2 
Code Page 
Column head type values Information 
search sequence N:A 
reference search control.  Sequence number is 
made of combination of search arguments and 
search retrieval source. 
See Search control 
worksheet. 
document status N  
1= returned in search, 2= relevant to study , 3= 
background information, 4= possible study for 
inclusion, 5= study for coding, 6= coded, 7= 
invalid or withdrawn, 8 = examined, not included   
In bib software A Yes/ No   
Full text A Yes/ no   
information type N 
1=Background;2=Empirical 
evidence;3=Both;4=This document was irrelevant 
What type of information 
was contained in this 
document? 
type of evidence N 
1= Descriptive;2= Evaluation of an 
interventions;3=Both;4 = Other 
 If empirical, what type of 
empirical evidence did 
this document contain? 
type of background                             N
1= Descriptions of previous research;2=Issues in 
program implementation;3= Arguments for and/or 
against; 4= Review of previous research; 5= 
methods information 6=Other 
If background, what type 
of background 
information did this 
document contain? 
Record ID N 
Sequential reference number assigned starting with 
1000   
Retrieval Date dd/mm/yy 
Date of retrieval from database 
  
Rejection Reason alpha 
NQ = not quantitative,  T = related to treatment, S= wrong stage of cancer, D = 
not long-term survivors, R = not report of study, P = prevention 
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Table A3 
Final Retrieval of Documents in Last Stage of Coding 
 
 
 
Study ID Title Initial Author 
Date 
Published Journal  
1387 
Quality of life of African-American and white long 
term breast carcinoma survivors. Ashing-Giwa 1999 Cancer 
19 
 Quality of life and psychosocial outcomes in long-
term survivors of breast cancer: A focus on African-
American women Ashing-Giwa 1999 
 Journal of 
Psychosocial 
Oncology 
1522 
Disparities in HRQOL of cancer survivors and non-
cancer managed care enrollees Clauser 2008 
Health Care 
Financing Review 
1966 
Depressive Symptoms and Health-Related Quality of 
Life in Breast Cancer Survivors. Reyes-Gibby 2002 
Journal of Women’s 
Health 
2024 
 Long-term adjustment of survivors of early-stage 
breast carcinoma, 20 years after adjuvant 
chemotherapy Kornblith 2003 Cancer 
2169 
All’s Well That Ends Well? Quality of Life and 
Physical Symptom Clusters in Long-Term Cancer 
Survivors Across Cancer Types. Zucca 2012 
Journal of Pain and 
Symptom 
Management 
1904 
The quality of life of African American women with 
breast cancer. Northouse 1999 
Research in Nursing 
& Health 
1978 
Breast cancer in African American women:  
Validation of a quality of life instrument. Rowley/ 2000 Dissertation 
1040 
Personality, coping, and quality of life in early stage 
breast cancer survivors Caloudas 2011 Dissertation 
1283 Worry of recurrence in breast cancer survivors Rothrock  2003 Dissertation 
2077 
An Exploratory Analysis of Fear of Recurrence 
among African-American Breast Cancer Survivors. Taylor   
International Journal 
of Behavioral 
Medicine 
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Study ID Title Initial Author 
Date 
Published Journal  
2027 
Benefits from an uncertainty management 
intervention for African–American and Caucasian 
older long-term breast cancer survivors. Mishel   Psycho-Oncology 
2031 
Predicting Negative Mood State and Personal Growth 
in African American and White Long-Term Breast 
Cancer Survivors. Porter   
Annals of Behavioral 
Medicine 
2130 
Relationship between quality of life and mood in 
long-term survivors of breast cancer treated with 
mastectomy Weitzner   
 Supportive Care in 
Cancer:  
1148 
Breast cancer survivorship: Contributing factors for 
special populations Jabson   Dissertation 
1692 
Quality of life and lymphedema following breast 
cancer. Heiney   Lymphology 
2035 
Quality of life among older survivors of breast 
cancer.  Sammarco   Cancer Nursing 
2036 
Quality of life of breast cancer survivors: a 
comparative study of age cohorts Sammarco   Cancer Nursing 
1145 
Social support, God locus of health control, and 
quality of life among African American breast cancer 
survivors Huff    Dissertation 
222 
Symptom distress, spirituality, and quality of life in 
African American breast cancer survivors. Leak   Cancer Nursing 
1161 
Describing psychosocial risk factors in breast cancer 
diagnosis and survivorship Keating   Dissertation 
1799 
Quality of life and breast cancer survivors. 
Psychosocial and treatment issues. Lee 1997 Cancer Practice 
1362 
Quality of life of long-term survivors of breast cancer 
and lymphoma treated with standard-dose 
chemotherapy or local therapy.  Ahles 2005 
Journal of Clinical 
Oncology. 
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Study ID Title Initial Author 
Date 
Published Journal  
584 
Age at Diagnosis and Quality of Life in Breast 
Cancer Survivors. Cimprich 2002 Cancer Practice 
1570 
An evaluation of the quality of life among long-term 
survivors of breast cancer. Dow 1996 
Breast cancer 
research and 
treatment 
1446 
Association between current lifestyle behaviors and 
health-related quality of life in breast, colorectal and 
prostate cancer survivors. Blanchard 2004 
Psychology and 
health 
1392 
A cross-cultural validation of patient-reported 
outcomes measures: a study of breast cancers 
survivors. Ashing-Giwa 2013 
Quality of Life 
Research 
163 
Surviving cancer: A comparison of 5-year disease-
free breast cancer survivors with healthy women. Helgeson 2005 Psycho-Oncology.  
277 
Breast cancer survivors' health-related quality of life: 
racial differences and comparisons with noncancer 
controls. Paskett 2008 Cancer 
282 
Relationship of Optimism-Pessimism and Health-
Related Quality of Life in Breast Cancer Survivors. Petersen 2008 
Journal of 
Psychosocial 
oncology 
1052 
Long-term quality of life assessment in post-
menopausal women with primary breast cancer Chen 2005 Dissertation 
1056 
Functional Impairment and the Economic 
Consequences of Female Breast Cancer Chirikos 2002 Women and health 
1328 
Long-term survivorship in breast cancer: Quality of 
life at five years and beyond Trimble 1997 Dissertation 
1364 
Lymphedema and quality of life in breast cancer 
survivors: the Iowa Women's Health Study. Ahmed 2008 
Journal of clinical 
oncology 
1452 
Quality of life of younger breast cancer survivors: 
persistence of problems and sense of well-being. Bloom 2004 Psycho-Oncology 
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Study ID Title Initial Author 
Date 
Published Journal  
1458 
Health-related quality of life in breast cancer 
survivors of different sexual orientations. Boehmer 2012 
Quality of Life 
Research 
1468 
Fatigue in long-term breast carcinoma survivors - A 
longitudinal investigation Bower 2006 Cancer 
1521 
Quality of life for women diagnosed with breast 
carcinoma in situ Claus 2006 
Journal of clinical 
oncology 
1878 
Invariance Testing of the SF-36 Health Survey in 
Women Breast Cancer Survivors: Do Personal and 
Cancer-related Variables Influence the Meaning of 
Quality of Life Items? Mosewich 2013 
Social Indicators 
Research 
2006 
Then and now: quality of life of young breast cancer 
survivors.  Bloom 2012 Psycho-Oncol 2004 
3001 
 Five years later: a cross-sectional comparison of 
breast cancer survivors with healthy women Tomich 2002 Psycho-oncology 
10 
Frequent Search for Sense by Long-Term Breast 
Cancer Survivors Associated with Reduced HRQOL. Andersen 2008 Women & Health 
71 
Complementary and alternative therapies among very 
long-term breast cancer survivors Carpenter 2009 
Breast cancer 
research and 
treatment 
1565 
Health-related quality of life, age, and comorbidity in 
breast cancer survivors 1 to 12 years post-treatment. Dhingra 2002 Dissertation 
1630 
Breast cancer in younger women: reproductive and 
late health effects of treatment. Ganz 2002 
Journal of the 
national cancer 
institute 
1713 
Quality of Life in Long-Term Breast Cancer 
Survivors. Hsu 2013 
J Clin Oncol. 2013 
Aug 26. [Epub ahead 
of print] 
1826 
The roles of herbal remedies in survival and quality 
of life among long-term breast cancer survivors - 
results of a prospective study. Ma 2011 BMC Cancer 
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Study ID Title Initial Author 
Date 
Published Journal  
1879 
Associations between lifestyle factors and quality of 
life among older long-term breast, prostate, and 
colorectal cancer survivors. Mosher 2009 Cancer 
1881 
Clinical outcomes of ethnic minority women in 
MA.17: a trial of letrozole after 5 years of tamoxifen 
in postmenopausal women with early stage breast 
cancer Moy 2006 Annals of Oncology 
1883 
Efficacy, toxicity, and quality of life in older women 
with early-stage breast cancer treated with Letrozole 
or placebo after 5 years of tamoxifen: NCIC CTG 
intergroup trial MA.17. Muss 2008 
Journal of clinical 
oncology 
1935 
Social capital, social support, and quality of life 
among long-term breast cancer survivors. Petersen 2008 
Journal of 
Psychosocial 
Oncology 
2030 
 Functional status of long-term breast cancer 
survivors: demonstrating chronicity Polinsky 1994 
 Health & social 
work 
2117D 
Exercise in breast cancer survivors: Predicting quality 
of life with the cognitive-appraisal model of stress 
and coping. Wagner 2006 Dissertation 
2113 
Health-related quality of life of African American 
breast cancer survivors compared with healthy 
African American women. Von Ah 2012 Cancer Nursing 
143 
Quality of Life in Long-Term, Disease-Free 
Survivors of Breast Cancer: a Follow-up Study. Ganz 2002 
Journal of Clinical 
Oncology 
75 
Quality of life of 5-10 year breast cancer survivors 
diagnosed between age 40 and 49. Casso 2004 
Health & Quality of 
Life Outcomes 
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Study ID   
Title   
Initial Author   
Date Published   
total subjects   
 African 
American 
subjects   
European 
American 
subjects   
Other subject   
 Study date   
Methodology    
geography   
mean time 
since diagnosis   
instrument   
statistics 
reported   
notes on article   
 
Figure A1. Coding form used to collect data. 
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Table A4 
Instruments Used in Rejected Reports 
 
Instrument Number Reports 
EORTC 4 Clauser et al., 2008; Kornblith et al., 2003; Reyes-Gibby et al., 2012; 
Zucca et al., 2012 
FACTB 2 Northouse et al., 1999; Rothrock, 2003; Rowley, 2000; Taylor et al., 2012 
POMS 2 Mishel et al., 2005; Porter et al., 2006 Both reports of the same study 
QLI CV III 3 Sammarco, 2003, 2009; Weitzner, Meyers, Stuebing, & Saleeba, 1997 
QOLBC 2 Heiney et al., 2013; Jabson, 2010 
SF36 14 Ahmed, Prizment, Lazovich, Schmitz, & Folsom, 2008; Ashing-Giwa & 
Rosales, 2013; Blanchard et al., 2004; Bower et al., 2006; Claus, 
Petruzella, Carter, & Kasl, 2006; Ma, Carpenter, Sullivan-Halley, & 
Bernstein, 2011; Mosewich, Hadd, Crocker, & Zumbo, 2013; Moy et al., 
2006; Muss et al., 2008; Paskett et al., 2008; Polinsky, 1994; Tomich & 
Helgeson, 2002; Von Ah et al., 2012; Wagner, 2006 
236 
 
 
Table A5 
Dissertations and Sources that Exited the Coding Process 
Authors 
Pub 
Date Title Source 
Huff   2013 
Social support, God Locus of Health Control, 
and quality of life among African American 
breast cancer survivors 
(D.H.A.). Central 
Michigan University, 
United States -- Michigan. 
Chen.  2005 
Long-term quality of life assessment in post-
menopausal women with primary breast cancer  
(M.Sc.). Queen’s 
University at Kingston 
(Canada), Canada.  
Dhingra    2002 
Health-related quality of life, age, and 
comorbidity in breast cancer survivors 1 to 12 
years post-treatment 
(Ph.D.). Illinois Institute of 
Technology, United States 
-- Illinois. 
Keating    2007 
Describing psychosocial risk factors in breast 
cancer diagnosis and survivorship  
(Ph.D.). Loyola University 
Chicago, United States -- 
Illinois.  
Trimble    1997 
Long-term survivorship in breast cancer: 
Quality of life at five years and beyond  
(Ph.D.). The Ohio State 
University, United States -- 
Ohio.  
Petersen, 
D.  2008 
Social Capital, Social Support and Long-Term 
Quality of Life  
(PhD). University of 
California, Berkley, 
Berkley. 
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Table A6 
Reports that Exited Coding Process with Publication Sources 
 
 
 
 
Authors Pub Date Title Source Publisher 
Dow, K. H., Ferrell, B. R., 
Leigh, S., Ly, J., & 
Gulasekaram, P. 1996 
An evaluation of the quality of life 
among long-term survivors of 
breast cancer. 
Breast Cancer 
Res.and Treat. Springer 
Carpenter, C. L., Ganz, P. A., 
& Bernstein, L. 2009 
Complementary and alternative 
therapies among very long-term 
breast cancer survivors. 
Breast Cancer 
Res.and Treat. Springer 
Leak, A., Hu, J., & King, C. R. 2008 
Symptom Distress, Spirituality, 
and Quality of Life in African 
American Breast Cancer 
Survivors. Cancer Nursing 
Lippincott Williams 
and Wilkins 
Lee, C. O. 1997 
Quality of life and breast cancer 
survivors. Psychosocial and 
treatment issues Cancer Practice Wiley 
Cimprich, B., Ronis, D. L., & 
Martinez-Ramos, G. 2002 
Age at diagnosis and quality of life 
in breast cancer survivors. Cancer Practice Wiley 
Mosher, C. E., Sloane, R., 
Morey, M. C., Snyder, D. C., 
Cohen, H. J., Miller, P. E., & 
Demark-Wahnefried, W. 2009 
Associations between lifestyle 
factors and quality of life among 
older long-term breast, prostate, 
and colorectal cancer survivors. Cancer Wiley 
Ashing-Giwa, K., Ganz, P. A., 
& Petersen, L. 1999 
Quality of life of African-
American and white long term 
breast carcinoma survivors. Cancer Wiley 
Casso, D., Buist, D. S., & 
Taplin, S. 2004 
Quality of life of 5-10 year breast 
cancer survivors diagnosed 
between age 40 and 49. 
Health and quality of 
life Outcomes Biomed central 
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Authors Pub Date Title Source Publisher 
Ahles, T. A., Saykin, A. J., 
Furstenberg, C. T., Cole, B., 
Mott, L. A., Titus-Ernstoff, L., 
… Silberfarb, P. M. 2005 
Quality of life of long-term 
survivors of breast cancer and 
lymphoma treated with standard-
dose chemotherapy or local 
therapy. 
Journal of Clinical 
Oncology 
Am. Soc. Clinical 
Oncology 
Hsu, T., Ennis, M., Hood, N., 
Graham, M., & Goodwin, P. J. 2013 
Quality of life in long-term breast 
cancer survivors. 
Journal of Clinical 
Oncology 
Am. Soc. Clinical 
Oncology 
Ganz, P. A., Greendale, G. A., 
Petersen, L., Kahn, B., & 
Bower, J. E. 2003 
Breast Cancer in Younger 
Women: Reproductive and Late 
Health Effects of Treatment. 
Journal of Clinical 
Oncology 
Am. Soc. Clinical 
Oncology 
Ashing-Giwa, K. 1999 
Quality of life and psychosocial 
outcomes in long-term survivors 
of breast cancer: A focus on 
African-American women. 
Journal of 
Psychosocial 
Oncology 
Taylor and Francis 
Routledge 
Petersen, L. R., Clark, M. M., 
Novotny, P., Kung, S., Sloan, 
J. A., Patten, C. A., … 
Colligan, R. C. 2008 
Relationship of Optimism-
Pessimism and Health-Related 
Quality of Life in Breast Cancer 
Survivors. 
Journal of 
Psychosocial 
Oncology 
Taylor and Francis 
Routledge 
Bloom, J. R., Stewart, S. L., 
Oakley-Girvan, I., Banks, P. J., 
& Shema, S. 2012 
Quality of life of younger breast 
cancer survivors: persistence of 
problems and sense of well-being. Psycho-Oncology Wiley 
Helgeson, V. S., & Tomich, P. 
L. 2005 
Surviving cancer: A comparison of 
5-year disease-free breast cancer 
survivors with healthy women. Psycho-Oncology Wiley 
Chirikos, T. N., Russell-
Jacobs, A., & Jacobsen, P. B. 2002 
Functional Impairment and the 
Economic Consequences of 
Female Breast Cancer. Women & Health 
Taylor and Francis 
Routledge 
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Analysis Support Documentation 
Table A7 
Racial Background of Participants in Studies Included in Analysis 
Initial Author 
Date 
Published 
total 
subjects 
African 
American 
subjects 
European 
American 
subjects 
Other 
subject 
Ashing-Giwa 1999 278 117 161 0 
Bloom 2012 312 18 227 67 
Carpenter 2009 371 0 335 36 
Chen 2005 3329 105 3224   
Cimprich 2002 105 9 96 0 
Ganz 2003 577 67 405 105 
Hsu 2013 285 8 214 63 
Keating 2007 106 0 106   
Lee 1997 100 3 88 9 
Trimble 1997 226 21 205   
 Total   5689 348 5061 280 
 Percentage     6.12% 88.96% 4.92% 
      
Huff  2012 94 94 0 0 
Leak 2008 30 30     
 Total   124 124     
 Grand total   5813 472 5061 280 
 Percentage     8.12% 87.06% 4.82% 
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Table.A8 
Participant Numbers where Breakdown of Racial Background Not Provided 
 
Initial 
Author 
Date 
Published 
Total 
Subjects 
 Comment 
Ahles 2005 425 white only identified 
Casso 2004 216 Caucasian and other 
Chirikos 2008 105 
maximize representation of racial minorities but never 
gives breakdown 
Dhingra 2002 257 no racial identification 
Dow 1996 294 Only identifies Caucasian 
Helgeson 2005 267 92 % were Caucasian 
Mosher 2009 321 Have breakdown of total sample but not BC sample 
Petersen 2008 255 No racial breakdown identified 
Petersen 2008 387 white/ other 
   Total 2527   
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Table A9 
Instruments Used by the Coded Reports 
Instrument Number Citation 
FACT B 1 Caloudas, 2011( not included in analysis) 
QLI-CVIII 4 Huff, 2013; Keating, 2007; Leak, Hu, & King, 2008; Lee, 1997 
QOL CS 3 Ahles et al., 2005; Cimprich, Ronis, & Martinez-Ramos, 2002; Dow et 
al., 1996 
SF 12 1 Boehmer, Glickman, Milton, & Winter, 2012 
SF- 36             
 
 
 
 
 
 
With  
CARES-SF                                                                                   
14 
 
 
 
 
 
 
3 
Bloom et al., 2004; Bloom, Stewart, Oakley-Girvan, Banks, & Shema, 
2012; Carpenter et al., 2009; Chen, 2005; Chirikos, Russell-Jacobs, & 
Jacobsen, 2002; Dhingra, 2002; P A Ganz et al., 2002; Patricia A. 
Ganz, Greendale, Petersen, Kahn, & Bower, 2003; Helgeson & 
Tomich, 2005; Hsu, Ennis, Hood, Graham, & Goodwin, 2013; Mosher 
et al., 2009; D. Petersen, 2008; L. R. Petersen et al., 2008; Trimble, 
1997;                    
                                                                                                               
Ashing-Giwa, Ganz, & Petersen, 1999; Ashing-Giwa, 1999; Casso, 
Buist, & Taplin, 2004 
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Support documentation for SF-36 subscale analysis. The following are the 
forest plots of the analysis of the studies that contain subscale data. Chen (2005) provided 
separate data for African American and European American participants, although the 
African American population sample is small compared to the European American 
participant pool. Bloom (2012) provided data on the same sample in two different time 
periods; 5 and10 years post diagnosis, these studies can be considered as distinct even 
though the same population was studied. All population norms in the following 
discussion were retrieved from SF-36.org (n.d.). 
Physical function SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 87.37(85.35-89.39)
Bloom,2012 (10 Year) 312 86.22(83.84-88.6)
Chen (EA),2005 3144 77.03(76.19-77.87)
Chen(AA),2005 101 65(59.36-70.64)
Chirikos,2002 105 82.6(78.7-86.5)
Ganz,2003 577 84.3(82.69-85.91)
Helgeson,2005 267 84.77(82.3-87.24)
Mosher,2009 321 73.2(70.99-75.41)
Petersen L.R.,2008 255 58.41(54.67-62.15)
Petersen,D.,2008 387 87.23(85.24-89.22)
Trimble,1997 183 75.8(72.29-79.31)
Summary 5964 78.6(77.36-79.85)
Pop Norm 1990 2474 84.5(83.6-85.4) 0
1
2
3
4
5
6
7
8
9
10
11
12
55 60 65 70 75 80 85 90
Physical function subscale
PF Data PF Mean PF Pop Norm
 
 
Figure A2. Physical Function subscale analysis with Population norm for 1990 general population. 
 
The Physical Function subscale of the SF-36 Is composed of 10 items. Low 
functioning on this subscale is defined as “limited a lot in performing all physical 
activities including bathing or dressing” (Ware & Sherbourne, 1992, p. 475). High 
endorsement of this subscale is defined as “Performs all types of Physical activities 
including the most vigorous without limitations due to health” (Ware & Sherbourne, 
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1992, p. 475). The 5.9 point difference between the mean of the analysis and the 
population norm suggested that there was an observable difference in clinical, social or 
economic status of breast cancer patients when compared to the population norm. Three 
studies (Chen, 2005 (EA); Mosher et al., 2009; Trimble, 1997) had differences that 
expected to be observable while most of the other studies were closer to the population 
mean and would not be expected to have observable differences. 
Physical Role SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 82.05(78.36-85.74)
Bloom,2012 (10 Year) 312 80.77(76.91-84.63)
Chen (EA),2005 3142 82.6(81.51-83.69)
Chen(AA),2005 100 72(64.24-79.76)
Chirikos,2002 105 70.2(62.13-78.27)
Ganz,2003 577 79.2(76.35-82.05)
Helgeson,2005 267 81.9(77.83-85.97)
Mosher,2009 321 74.5(70.69-78.31)
Petersen L.R.,2008 255 50.64(45.27-56.01)
Petersen,D.,2008 387 80.33(76.87-83.79)
Trimble,1997 182 68.7(62.85-74.55)
Summary 5960 75.22(70.91-79.54)
Pop Norm 1990 2474 81.2(79.87-82.53) 0
1
2
3
4
5
6
7
8
9
10
11
12
65 70 75 80 85
Physical Role Subscale
PR Data PR Mean PR Pop Norm
 
 
Figure A3. Physical Role subscale analysis with Population norm for 1990 general population. 
 
The Physical Role subscale is drawn from 4 items on the SF36 questionnaire and 
sets out to measure where the respondent’s roles are limited due to the physical impacts 
of their illness. The low end of this subscale is defined as “Problems with work or other 
daily activities as a result of Physical Health” (Ware & Sherbourne, 1992, p. 475) and the 
high end of this spectrum is defined as “No problems with work or other daily activities 
as a result of Physical health, past 4 weeks” (Ware & Sherbourne, 1992, p. 475). The 
difference between the analysis mean and the population norm in this subscale of 5.98 
points suggested an observable difference between the long-term BCS and the general 
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population. Four of the studies (Chen (African American), 2005; Chirikos et al., 2002; 
Mosher et al., 2009; L. R. Petersen et al., 2008; Trimble, 1997) had a mean that was more 
than 5 points different from the norm and would predict observable differences in social, 
economic or clinical functioning. 
Body Pain SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 73.83(71.13-76.53)
Bloom,2012 (10 Year) 312 72.15(69.62-74.68)
Chen (EA),2005 3159 77.16(76.41-77.91)
Chen(AA),2005 101 71.31(66.21-76.41)
Chirikos,2002 105 72.1(66.76-77.44)
Ganz,2003 577 78.4(76.61-80.19)
Helgeson,2005 267 75.62(72.69-78.55)
Mosher,2009 321 70.5(68.13-72.87)
Petersen L.R.,2008 255 64.09(60.68-67.5)
Petersen,D.,2008 387 71.65(69.36-73.94)
Trimble,1997 184 73.4(69.77-77.03)
Summary 5980 72.92(70.57-75.28)
Pop Norm 1990 2474 75.5(74.57-76.43) 0
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Figure A4. Body Pain subscale analysis with Population norm for 1990 general population. 
 
The Body Pain Subscale is drawn from 2 items in the instrument and ranges from 
“ Extreme and frequent interference with normal social activities due to physical and 
emotional problems” to “ performs normal social activities without interference due to 
physical or emotional problems, past 4 weeks” (Ware & Sherbourne, 1992, p. 475). In 
this subscale, the difference between the grand mean and the population norm was less 
than the 5 point threshold where observable differences would be expected. Only one 
study (L. R. Petersen et al., 2008) showed a difference from both the analysis mean and 
the population norms that would suggest observable differences. One study (Ganz et al., 
2003) showed a difference of 5.48 points from the summary mean which may indicate 
observable difference. If the results of the lowest (L. R. Petersen et al., 2008) and highest 
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(Ganz et al., 2003) means in the study sample were compared, observable difference 
between the samples on the body pain spectrum should be expected. 
General Health SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 77.79(75.6-79.98)
Bloom,2012 (10 Year) 312 72.48(70.27-74.69)
Chen (EA),2005 3137 76.62(76-77.24)
Chen(AA),2005 100 69.98(66-73.96)
Chirikos,2002 105 73(68.7-77.3)
Ganz,2003 577 72.1(70.39-73.81)
Helgeson,2005 267 79.03(76.52-81.54)
Mosher,2009 321 73.2(71.44-74.96)
Petersen L.R.,2008 255 60.68(57.92-63.44)
Petersen,D.,2008 387 72.71(70.76-74.66)
Trimble,1997 183 69.2(65.84-72.56)
Summary 5956 72.54(70.01-75.08)
Pop Norm 1990 2474 72.2(70.74-73.66) 0
1
2
3
4
5
6
7
8
9
10
11
12
55 60 65 70 75 80 85
General Health Subscale
GH Data GH Mean GH Pop Norm
 
 
Figure A5. General Health subscale analysis with Population norm for 1990 general population. 
 
General Health perceptions are drawn from 5 questions in the instrument with 
lower scores meaning that the respondent “Believes personal health is poor and likely to 
get worse” and higher scores reflecting that the respondent “Believes personal health is 
excellent” (Ware & Sherbourne, 1992, p. 475). 
This subscale is not used in calculating the summary PCS and MCS measures and 
has been shown to be useful in distinguishing changes in health status in the year 
preceding administration of the instrument. There is support for this category as being 
reliable in interpreting this at a group level with drops in the mean value corresponding to 
self-evaluated declines in health and increases in the mean value corresponding to 
improvements in overall HRQOL (Ware, n.d.) 
In this subscale, the grand mean and the population norm were similar with 0.34 
of a point difference in the means. In this subscale there was both a lower score (L. R. 
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Petersen et al., 2008), where the study mean is 11.86 points lower than the population 
norm, and two higher scores (Bloom et al.( 5+ years), 2012; Helgeson & Tomich, 2005) 
where there is a greater than 5 point difference from the population norm. All of these 
would suggest observable differences between the studies and the population. With the 
spread of 18.4 points from the lowest study mean to the highest, differences in the 
populations from these studies should be obvious. 
Vitality SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 62.96(60.61-65.31)
Bloom,2012 (10 Year) 312 63.41(61.2-65.62)
Chen (EA),2005 3149 65.66(64.97-66.35)
Chen(AA),2005 101 63.04(59.55-66.53)
Chirikos,2002 105 60.5(56.16-64.84)
Ganz,2003 577 58.1(56.32-59.88)
Helgeson,2005 267 64.18(61.67-66.69)
Mosher,2009 321 61.3(59.24-63.36)
Petersen L.R.,2008 255 52.86(50.3-55.42)
Petersen,D.,2008 387 64.46(62.57-66.35)
Trimble,1997 185 59.9(58.44-61.36)
Summary 5971 61.54(59.2-63.89)
Pop Norm 1990 2474 61.1(60.28-61.92) 0
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Figure A6. Vitality subscale analysis with Population norm for 1990 general population. 
  
The Vitality subscale is derived from 4 items in the instrument. The lower score 
for a participant is defined as “Feels tired and worn out all of the time” while high scores 
describe a respondent who “Feels full of pep and energy all of the time, past four weeks” 
(Ware & Sherbourne, 1992, p. 475). 
The population norm and the analysis mean were 0.44 point different. Most of the 
studies were within 5 points difference from the mean with only one (L. R. Petersen et 
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al., 2008) having a greater distance at 8.68 points lower. The distance between the highest 
(Chen (EA), 2005) and lowest (L. R. Petersen et al., 2008) of the studies was 12.8 points. 
Social Function SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 86.66(84.29-89.03)
Bloom,2012 (10 Year) 312 85.7(83.25-88.15)
Chen (EA),2005 3150 91.37(90.77-91.97)
Chen(AA),2005 100 85.38(80.88-89.88)
Chirikos,2002 105 85.7(80.08-91.32)
Ganz,2003 577 83.9(82.12-85.68)
Helgeson,2005 267 89.6(87.23-91.97)
Mosher,2009 321 90.2(88.25-92.15)
Petersen L.R.,2008 255 75.04(71.81-78.27)
Petersen,D.,2008 387 86.27(84.18-88.36)
Trimble,1997 184 85.4(82.16-88.64)
Summary 5970 86.05(83.38-88.72)
Pop Norm 1990 2474 83.6(82.72-84.48) 0
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Figure A7. Social Function subscale analysis with Population norm for 1990 general population. 
 
The Social Function subscale is drawn from 2 questions on the instrument. Lower scores 
reflect “Extreme and frequent interference with normal social activities due to physical 
and emotional problems” while higher scores reflect a respondent who “Performs normal 
social activities without interference due to physical or emotional problems, past four 
weeks” (Ware & Sherbourne, 1992, p. 475). 
The analysis mean in this subscale was higher than the population norm by 2.45 
points that would not be enough to expect observable differences. The lowest scoring 
study (L. R. Petersen et al., 2008) was 16.33 points lower than the highest scoring study 
(Chen (EA), 2005). Both of these studies were greater than5 points different from the 
analysis mean and the population norm, suggesting observable differences in the social, 
continuum described by this subscale. 
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Role Emotional SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 81.41(77.8-85.02)
Bloom,2012 (10 Year) 312 86.65(83-90.3)
Chen (EA),2005 3115 88.93(88-89.86)
Chen(AA),2005 100 75.5(67.89-83.11)
Chirikos,2002 105 84.1(77.54-90.66)
Ganz,2003 577 79.1(76.3-81.9)
Helgeson,2005 267 86.44(83.06-89.82)
Mosher,2009 321 90.8(88.22-93.38)
Petersen L.R.,2008 255 73.27(68.56-77.98)
Petersen,D.,2008 387 85.01(81.85-88.17)
Trimble,1997 183 79.4(74.37-84.43)
Summary 5934 83.18(80.02-86.34)
Pop Norm 1990 2474 81.3(80-82.6) 0
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Figure A8. Role Emotional subscale analysis with Population norm for 1990 general population. 
 
The Role Emotional subscale reflects limitations in role performance due to 
emotional problems. It is drawn from 3 items in the instruments and reflects a spectrum 
from “Problems with work or other daily activities as a result of emotional problems” to 
“No problems with work or other daily activities as a result of emotional problems, past 
four weeks” (Ware & Sherbourne, 1992, p. 475). 
The analysis mean was 1.88 points higher than the population norm for the Role 
emotional subscale. A 17.53 point difference exists between the lowest scoring study (L. 
R. Petersen et al., 2008) and the highest scoring study (Mosher et al., 2009). There was a 
greater dispersal of scores on this subscale with 4 studies below the population norm 
(Chen (African American), 2005; Ganz et al., 2003; L. R. Petersen et al., 2008; Trimble, 
1997) and 4 studies scoring more than 5 points higher than the population norm (Bloom 
et al. (10 year), 2012; Chen (African American), 2005; Helgeson & Tomich, 2005; 
Mosher et al., 2009). 
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Mental Health SF-36 1990 
Study
Sample 
Size
Mean (95% 
CI)
Bloom,2012 ( 5 year) 312 77.72(75.96-79.48)
Bloom,2012 (10 Year) 312 79.01(77.26-80.76)
Chen (EA),2005 3149 81.44(80.93-81.95)
Chen(AA),2005 101 79.9(76.76-83.04)
Chirikos,2002 105 74.3(70.86-77.74)
Ganz,2003 577 74.9(73.44-76.36)
Helgeson,2005 267 78.85(76.99-80.71)
Mosher,2009 321 85.1(83.75-86.45)
Petersen L.R.,2008 255 72.73(70.3-75.16)
Petersen,D.,2008 387 79.79(78.27-81.31)
Trimble,1997 184 76.6(74.04-79.16)
Summary 5970 78.33(76.3-80.36)
Pop Norm 1990 2474 74.8(74.09-75.51) 0
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Figure A9. Mental Health subscale analysis with Population norm for 1990 general population. 
 
The Mental Health subscale is drawn from 5 items in the instrument and reflects 
lower scores that are described as “Feelings of nervousness and depression all of the 
time” to higher scores described as “ Feels peaceful, happy, and calm all of the time, past 
four weeks” (Ware & Sherbourne, 1992, p. 475). 
In this analysis the general population norm was lower than the mean of the 
studies included by 3.53 points, less that would indicate observable real world 
differences. There was a difference between the lowest study mean study (L. R. Petersen 
et al., 2008) and the highest study mean (Mosher et al., 2009) of 12.37 points that would 
suggest that there was an observable difference between these two studies. Only one 
study (Mosher et al., 2009) has a predicted observable difference from the analysis mean 
in a positive direction, while both populations reported in Chen (2005) as well as Mosher 
et al. (2009) show a greater than5 point difference in the mean from the population norm. 
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Only one study (L. R. Petersen et al., 2008) was lower by an amount that would suggest 
observable difference. 
Overall summary effect size, all data. All data that was available to be 
translated into SMD was analyzed using two different groups of studies.  As there is a 
charge that this data could be comparing different levels of information, the outcome 
measure can only be used as an indication 
Summary of effect sizes for African American and European American long term BCS studies
Study
Sample 
Size
Effect size SMD 
(95% CI)
QLI 326 -0.82(-1.06--0.59)
Trimble, 1997 PCS  226 -0.02(-0.47-0.43)
Trimble, 1997 MCS 226 -0.32(-0.77-0.13)
Ashing Giwa, 1999 278 -1.46(-1.75--1.17)
Summary 830 -0.68(-1.19--0.18)
Studies differentiated by color of marker
0
1
2
3
4
-2.00 -1.50 -1.00 -0.50 0.00 0.50 1.00  
Figure A10. Summary SMD: Ashing – Giwa (1999) and Trimble (1997). 
Summary of effect sizes for African American and European American long term BCS studies (2)
Study
Sample 
Size
Effect size SMD 
(95% CI)
QLI 326 -0.82(-1.06--0.59)
Trimble, 1997 PCS  226 -0.02(-0.47-0.43)
Trimble, 1997 MCS 226 -0.32(-0.77-0.13)
Ashing Giwa, 1999 278 -1.46(-1.75--1.17)
Chen,2005:PF 3245 -0.5(-0.7--0.3)
Chen,2005:RF 3242 -0.34(-0.54--0.14)
Chen,2005:BP 3260 -0.27(-0.47--0.07)
Chen,2005:GH 3237 -0.37(-0.57--0.17)
Chen,2005:V 3250 -0.13(-0.33-0.07)
Chen,2005:SF 3250 -0.35(-0.54--0.15)
Chen,2005:ER 3215 -0.5(-0.7--0.3)
Chen,2005:MH 3250 -0.11(-0.3-0.09)
Summary -0.43(-0.62--0.25)
Studies differentiated by color of marker
0
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-2.00 -1.50 -1.00 -0.50 0.00 0.50  
Figure A11. Summary SMD: Ashing – Giwa (1999), Trimble (1997), and Chen (2005). 
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